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ABSTRACT 
Cerebral malaria is one of the complications of the broad clinical syndrome named 
‘severe malaria’. The pathogenesis of cerebral malaria is thought to be due to the 
ability of infected red blood cell (iRBC) to sequester in the blood microvasculature 
of vital organs. Sequestration, resulting from the interaction (often called 
cytoadherence) between parasite proteins expressed on the surface of iRBC such as 
PfEMP-1, and host endothelial cell adhesion molecules such as ICAM-1, CD36 and 
EPCR, can modulate the downstream effects of several biological processes in the 
endothelial cells such as EC activation, intracellular signalling, endothelial cell 
permeability and endothelial apoptosis. 
The aim of this thesis is to gain a better understanding of how the P. falciparum 
parasite can modulate the gene expression of the host endothelial cells response to 
cytoadherence using the RNA-seq technique. We used an in vitro co-culture model 
of IT4var14 strain with HBMEC in the presence of 10ng/ml TNF. RNA-seq analysis 
of HBMEC transcriptome following co-culture showed significant differential 
regulation of genes which defined gene ontologies such as ‘immune system’ at 2 
hours, ‘immune response’, ‘arachidonic acid’, ‘positive and negative apoptotic 
pathways’ at 6 hours, and ‘immune response’ and ‘cell cycle pathways’ at 20 hours 
of co-incubation. However, another co-culture model using IT4var37 isolate with 
HBMEC in the presence of TNF found that exposure of HBMEC to iRBC expressed 
genes in brain EC often in opposite levels compared to the IT4var14 strain under the 
same condition. These findings emphasize the ability of different PfEMP-1 variants 
from the same genetic background (IT4) to modulate different gene expression in 
host cells, and also the potential ability of the malaria parasite to use PfEMP-1 var 
gene switching technique to protect itself from the host defensive system.  
We conducted further co-culture experiments to assess the ability of IT4var14 
parasite to modulate the transcriptional levels of different endothelial cells (HDMEC 
and HBMEC) that differentially express ICAM-1 and CD36 receptors; we 
demonstrated that there are similarities and differences in gene expression between 
TNF-stimulated HDMEC and HBMEC exposed to IT4var14 strain, which might be 
due to ICAM-1 expression in both ECs but the lack of CD36 on HBMEC, leading to 
the transduction of different signalling pathways in HDMEC and HBMEC. The 
ability of TNF stimulation in modulating the expression of genes in HBMEC 
exposed to IT4var14 parasite isolate, and uninfected erythrocytes on endothelium has 
also been examined in this study. It was found that the TNF plays a role in mediating 
the gene expression in human brain EC incubated with IT4var14 strain and 
uninfected RBC, this might be due to stimulation of TNF to HBMEC to induce 
expression of ICAM-1. These results are presented and discussed in the thesis with 
an aim to better understanding of the CM syndrome and the potential to lead to the 
discovery and development of new therapies for cerebral malaria. 
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1. GENERAL INTRODUCTION 
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1.1 Overview: 
Malaria is an ancient vector-borne infectious disease transmitted via female 
Anopheles mosquitos and is caused by protozoa of the genus Plasmodium. It is one 
of the main tropical diseases distributed across many parts of the world. It remains 
one of the leading causes of morbidity and mortality in tropical areas especially in 
countries with limited resources (Bruce-Chwatt, 1987, Murray et al., 2012, Guerin et 
al., 2002). 
Human malaria can be caused by various Plasmodium species including Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale curtisi and 
Plasmodium ovale wallikeri (Sutherland et al., 2010) and, lastly, Plasmodium 
knowlesi that has been recently found to infect humans, particularly in Malaysia 
(William et al., 2013). 
This chapter reviews knowledge about malaria disease, parasite life cycle, clinical 
manifestation of malaria and malaria pathogenesis. 
1.2 Malaria as a disease: 
1.2.1 Malaria history: 
Historically, malaria disease has been noted for more than 4000 years. It was initially 
described in ancient Chinese medical document by Nei Ching from around 2700 BC. 
The disease was widely recognized by the Greeks in the 400 BC where Hippocrates 
wrote about the characteristic symptoms of malaria  (Cox, 2010). The word malaria 
derives from the Italian “mal ’ aria” which means “bad air”; However, this was 
controversial until significant developments in research on malaria that allowed the 
identification of the main causative agent and the transmission vector at the end of 
the 19th century.  In 1880, a French army surgeon called Charles Laveran discovered 
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the malaria parasites, whereas the initial evidence that mosquitos transferred 
Plasmodium parasite to humans was identified by Ronald Ross in 1897 (Cox, 2010). 
1.2.2 Malaria epidemiology: 
In 2013, an estimated 3.3 billion people around the world were at risk of malaria 
infection (WHO, 2014), with varying percentages of at risk populations between 
countries (Figure 1.1). The latest report from the World Health Organization (WHO) 
estimated number of worldwide malaria cases at 214 million and estimated malaria 
death numbers at 438.000 people (WHO, 2015). This represents a 37% reduction in 
malaria reported cases and a 60% reduction in mortality rate since 2000, due to 
widespread malaria eradication programmes. Most of the malaria cases and deaths 
take place in African regions with an average of 88% and 90% respectively, and 
more than two-thirds of these cases occur in children under five years old (WHO, 
2015). The vast majority of morbidity and mortality for malaria globally is linked to 
P. falciparum, but mainly in tropical and subtropical areas in Africa (Snow et al., 
2005). 
 
Figure 1.1: Global population at risk of malaria infection, 2013. 
Global map shows classification of countries by percentages of population at risk of malaria 
infection in 2013 (Adapted from WHO, 2014). 
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1.2.3 Malaria control and prevention 
There are several approaches that can be used to control and prevent distribution of 
malaria disease that include transmission interruption, vector control, treatment and 
vaccines (Chambers, 2012). To reduce the transmission of malaria disease, 
insecticide spraying and treated bed nets are largely used as vector control techniques 
that preventing bites from mosquitos. Although these techniques are reliable and 
have some effectiveness, mosquitos may develop resistance against insecticide and 
bed nets must to be replaced regularly (Liu, 2015). Artemisinin-based combination 
therapies (ACTs) are a standard treatment for the clinical malaria cases, which has an 
enhanced effect on reducing severe malaria (SM) and death (Dondorp et al., 2010). 
Of these strategies, the most successful approach has been the insecticide-treated bed 
nets with 68% decline in cases between 2000 and 2015 (Bhatt et al., 2015).  
Implementation of insecticide spraying and ACT at a larger scale and continued use 
of insecticide-treated bed nets will be required to further reduce malaria prevalence. 
However, there is an increase in threats of using these programmes with the 
emergence of insecticide resistance  (Ranson and Lissenden, 2016) and growing 
resistance against the artemisinin in South East Asia (Fairhurst, 2015). New 
insecticides and drugs are required but new strategies such as the development of 
effective vaccines will be required to induce the likelihood of malaria control and 
elimination (Hemingway et al., 2016). 
1.3 Plasmodium falciparum life cycle: 
The malaria parasite has a complex life cycle requiring two hosts (mosquito and 
human) (Figure 1.2). In the female Anopheles mosquitos, sexual reproduction of the 
parasite takes place, while asexual replication occurs in human host. Infection of the 
malaria begins when an infected mosquito vector injects sporozoites which are stored 
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in its salivary glands into the skin of the human host during feeding. Then, 
sporozoites migrate via blood vessels to the liver where they mature within the 
hepatic cells over a short period around (5-14 days) including multiple rounds of 
asexual multiplication to produce thousands of merozoites (Hansen et al., 2014). 
Merozoites are released after rupturing the hepatocyte in vesicles termed merosomes 
(Sturm et al., 2006), which protect merozoites until they reach into bloodstream 
(Baer et al., 2007). 
In the bloodstream, within seconds of releasing merozoites, they invade the 
erythrocytes in a complex process involving multiple parasite-host protein 
interactions that can be divided into four stages: primary attachment and 
reorientation, formation of irreversible attachment tight junction, merozoite invasion 
by an actin-myosin motor and completion by resealing of the RBC membrane and 
shedding of merozoite surface proteins (Beeson et al., 2016). Within the erythrocyte, 
the parasite starts an asexual intra-erythrocytic development cycle within the 
parasitophorous vacuole (PV) involving an early ring trophozoite, late trophozoite, 
developing schizont and developed schizont stages (Delves et al., 2012). Rupture of 
the infected red blood cell (iRBC) and release of merozoites takes place in 
synchronisation after every 24 hours for P. knowlesi, 48 hours for P. falciparum, P. 
vivax and P. ovale, and 72 hours for P. malariae, and contributes to inflammatory 
response and clinical signs and symptoms observed (White et al., 2014). However, a 
small proportion of iRBC differentiate into male and female gametocytes that 
circulate in the bloodstream.  
The mechanism of development of the parasite into gametocytes remains not clear, 
but may involve parasite density (Liu et al., 2011). During the blood feed, the 
gametocytes move to the mosquito midgut where iRBCs are digested and 
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gametocytes released, and sexual development occurs. Both male and female 
gametes are fertilized to form diploid zygotes that then develop into motile forms 
called ookinetes, which then travel into the mosquito midgut epithelial wall and 
differentiate into oocysts which produce thousands of sporozoites (Miller et al., 
2013). Once the oocysts rupture, sporozoites are released and invaded the mosquito 
body cavity and migrate to the salivary glands where they reside until the mosquito 
takes a human blood meal. This completes the transmission cycle of the malaria 
parasite to the next human host (Smith et al., 2014). 
 
Figure 1.2: The life cycle of P. falciparum in mosquito and human. 
Life cycle stages in the mosquito and human hosts. See text above for a detailed description. 
Figure adapted from (Cowman et al., 2012).  
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1.4 Clinical manifestations of malaria: 
Individuals infected by malaria have a range of clinical outcomes. In an area of 
exposure to malaria infection, in early life, it starts usually with severe 
manifestations; around 10% of children develop severe malaria symptoms with 
different pathological impacts. Then, immunity is developed to severe symptoms in 
those individuals and they suffer only from uncomplicated malaria (UM), which is 
also referred to as mild malaria, particularly in areas with highly endemic such as 
Sub-Saharan Africa. As immunity develops further, clinical disease is rarely seen and 
cases are referred to as asymptomatic. 
1.4.1 Uncomplicated malaria: 
Generally, UM is characterised with several signs range from headaches, fatigue, 
muscle aches and abdominal discomfort, followed by vomiting, nausea orthostatic 
hypotension (White et al., 2014). 
1.4.2 Severe malaria: 
The vast majority of severe malaria cases caused by P. falciparum are associated 
with age dependent symptoms, particularly in high-transmission areas. SM in 
children consists three overlapping syndromes: severe malarial anaemia, metabolic 
acidosis/ respiratory distress and cerebral malaria (CM). In adults, in addition to CM 
and acidosis, acute pulmonary oedema, jaundice and acute renal injury are also 
classified as most common features of SM (White et al., 2014).  
1.4.2.1 Severe anaemia: 
Malaria is considered as one of the major cause of severe anaemia in young children, 
especially in areas with high transmission where repeat infection often occurs. 
Patients with severe anaemia are defined as haemoglobin concentration < 5 g/dl of 
blood in the presence of P. falciparum parasitaemia (Calis et al., 2008). Severe 
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malarial anaemia results from several ways; destruction of infected erythrocytes to 
release new generations of merozoites, lysis of uninfected erythrocytes by unknown 
mechanisms and minimised erythrocyte production. These are often followed by 
fever, and the typical description of fever is linked to the parasite cycle (White et al., 
2014).  
1.4.2.2 Acidosis and hypoglycaemia: 
Metabolic acidosis is one of the lethal symptoms associated with severe malaria. In 
severe malaria patients, acidotic breathing usually is considered as a bad prognosis 
indicator for the disease, and is thought to be caused by the accumulation of lactic 
acid. Usually, lactic acidosis is linked to hypoglycaemia, especially in pregnant 
women and children (White et al., 2014). 
1.4.2.3 Cerebral malaria: 
One of the complications of severe malaria is cerebral malaria. It is defined as a 
coma, P. falciparum parasitaemia and Blantyre coma score ≤ 2 in children with the 
absence of other causes of coma (Molyneux et al., 1989). However, ruling out other 
causes of coma could be difficult and a study by Taylor and her colleagues 
demonstrated that in 23% of patients with a clinical definition of CM, the main 
reason of death was not CM (Taylor et al., 2004). 
Coma is the hallmark of CM. It suddenly develops following seizures, and 
consciousness is usually very rapidly regained (within 24-48h) among children in 
malaria endemic areas of Sub-Saharan Africa (Idro et al., 2005). Systemic features 
reported among children with CM include hyponatremia (>50%), severe anaemia 
(20-50%), hypoglycaemia (30%), jaundice (8%) and metabolic acidosis exhibited as 
respiratory distress (English et al., 1996, English et al., 1997, English et al., 1998, 
Molyneux et al., 1989). Neurological deficits are another complication that affected 
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6-29% of children with CM at the time of discharge (Idro et al., 2004). One of the 
most common complications of CM in children is retinopathy. It occurred in >60% 
of children with CM and has three major characteristic features: retinal whitening, 
retinal vessel discoloration to white or pink-orange (Beare et al., 2004) and retinal 
haemorrhages (Olumese et al., 1997). 
Endothelial activation is well characterised by expression of several adhesion 
molecules on the vessel surface such as intercellular adhesion molecule 1 (ICAM-1), 
vascular cell adhesion molecule 1 (VCAM-1), E-selectin and P-selectin (Armah et 
al., 2005b), breakdown of endothelial cells tight-junctional proteins (TJPs) (Pino et 
al., 2005) and by a variety of other biomarkers like angiopoitin-1 (Ang-1), soluble 
cell adhesion molecules (sCAMs), vascular endothelial growth factor (VEGF) 
(Turner et al., 1998) and endothelial micro particles (Schindler et al., 2014). 
Blood brain barrier (BBB) is defined as a physiological barrier which separates the 
cerebrospinal fluid (CSF) and the brain tissue from the blood circulation and has a 
vital role in brain function (Persidsky et al., 2006). Breakdown of this barrier is 
commonly associated with the central nervous system diseases. In CM, there were 
evidences that support the disruption of BBB due to sequestration of parasites in the 
brain microvascular endothelial cells, leading to upregulation of ICAM-1 receptor 
and reduction in cell junction proteins such as ZO-1, occluding and vinculin (Medana 
and Turner, 2006, Brown et al., 2001a). 
Nitric oxide (NO) is considered as a natural gaseous molecule which may be 
involved in CM pathogenesis. During CM, several studies hypothesized that 
upregulated inducible NOS (iNOS) activity by inflammatory cytokines leading to 
increase NO production kills the malaria parasites as a part of innate immunity 
(Cramer et al., 2005, Pino et al., 2004). On the other hand, NO might diffuse across 
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the BBB into tissue of brain and kill neurons (Brown, 2001). Furthermore, it can also 
dysregulate the DNA gene expression of neurons and be responsible for reversible 
coma in patients with CM (Pacher et al., 2007). 
The platelets play an important role in the pathogenesis of CM. An autopsy study by 
Grau et al. showed that platelet accumulation is observed at the site of parasite 
sequestration (Grau et al., 2003). Release of transforming growth factor- β (TGF- β) 
from α-granules of platelets in the brain microvascular cells is suggested to be one of 
the factors that mediates platelet-induced apoptosis of the brain endothelial cells 
(Wassmer et al., 2006c). Moreover, in an in vitro parasite co-culture study, iRBC 
incubated with platelets and tumour necrosis factor alpha (TNFα) cytokine had been 
shown to induce gene expression changes involved in inflammation and apoptosis in 
human brain microvascular endothelial cells (HBMEC) (Barbier et al., 2011). 
Several reports have indicated the existence of high levels of pro-inflammatory 
cytokines in human CM for over two decades (Grau et al., 1989, Kern et al., 1989), 
and confirmed by different groups (Riley et al., 2010), however; other investigators 
suggested that there is no association between the severity of the disease and the pro-
inflammatory cytokines effects (Conroy et al., 2010). Pro-inflammatory cytokines 
such as TNFα and interleukin 1 β (IL-1β) have been identified as potential mediators 
of CM disease (Miranda et al., 2013). 
1.5 Malaria pathogenesis: 
1.5.1.1.1 P. falciparum cytoadherence: 
Infected red blood cells at trophozoite and schizont stages disappear from the 
peripheral circulation and adhere to other cells via specific parasite ligand and host-
cell receptor interactions that result in sequestration of the parasite (Rowe et al., 
2009). The parasites sequester in microvascular beds of various vital tissues and 
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organs such as placenta, subcutaneous tissue, kidney, lungs, liver and the brain, 
which avoids removal by the spleen (Buffet et al., 2011). Sequestration of iRBC is a 
result of cytoadherence of iRBC to the endothelial cells (ECs) which line the blood 
vessels. ECs express several receptors on their surfaces. Some of these receptors 
increase their expression in response to stimulation by inflammatory cytokines such 
as TNFα, which is known to be up-regulated in malaria (Chakravorty et al., 2008) 
and plays a vital role in severe malaria disease (Taylor et al., 2013, Manning et al., 
2012). Several reports have showed that ECs receptors serve as ligands for iRBC 
adhesion (Figure 1.3). Adhesion of iRBC to EC receptors can be mediated by P. 
falciparum erythrocyte membrane protein 1 (PfEMP-1), which is a protein displayed 
on the iRBC surface and responsible for the adhesion to various host cells (Pasternak 
and Dzikowski, 2009). More details regarding some of the ECs receptors involved in 
cytoadherence, PfEMP-1 and the impact of the cytoadherence on ECs are described 
briefly in sections below. 
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Figure 1.3: Summary of the human receptors that interact with the Plasmodium 
falciparum-infected erythrocyte. 
 
1.5.1.2  Host adhesion receptors: 
The most common EC receptors that have been reported to mediate the sequestration 
of iRBC are CD36 (Barnwell et al., 1989, Oquendo et al., 1989), ICAM-1 (Berendt 
et al., 1989), endothelial protein C receptor (EPCR) (Turner et al., 2013), platelet EC 
adhesion molecule 1)/CD31 (PECAM-1) (Rowe et al., 2009), and chondroitin 
sulphate A (CSA) (Walter et al., 1982). In addition, there are more than ten other 
molecules have been identified as receptors play role in the cytoadhesion. 
1.5.1.2.1 CD36: 
CD36 is an integral protein expressed on a cell surface of a variety of host cells 
including endothelial, epithelial cells, monocytes, macrophages and platelets (Rowe 
et al., 2009). CD36 is involved in the regulation of membrane transport systems, 
platelet adhesion (McGilvray et al., 2000) and immune responses in humans 
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(Febbraio et al., 2001, Greenwalt et al., 1992). It has been revealed that CD36 is a 
common receptor that binds to most patient isolates (Chakravorty et al., 2008). 
However, there is no particular role for CD36 in the pathogenesis of the malaria 
(Rowe et al., 2009). Some studies carried out in Africa showed no difference in the 
ability of CD36-binding between parasite strains from patients with severe and 
uncomplicated malaria (Newbold et al., 1997, Rogerson et al., 1999). On the other 
hand, other evidence demonstrated that it is more associated to uncomplicated 
malaria strains (Ochola et al., 2011). In contrast, a study conducted on patients from 
Benin showed that CD36 bind to isolates from CM patients more than UM isolates 
(Almelli et al., 2014). A study by Wassmer and colleagues found that platelet-
expressed CD36 could act as a bridge mediating binding of endothelial cells lacking 
in CD36 (such as in the brain) to iRBC (Wassmer et al., 2004). 
1.5.1.2.2 ICAM-1: 
ICAM-1 is an another commonly used receptor, which is expressed on endothelial 
cells and leukocytes (Rowe et al., 2009). The key role of ICAM-1 on ECs is allowing 
transmigration of the leukocyte from blood circulation to the target tissues in 
inflammatory sites induced by cytokine activation. This is mediated by the adhesion 
to specific leukocyte receptors such as macrophage-1 antigen (Mac-1) or leukocyte 
function-associated antigen (LFA-1). Also, ICAM-1 can mediate the adhesion to 
pathogenic organisms, such as human rhinoviruses (HRVs) (Staunton et al., 1989, 
Greve et al., 1989), and Plasmodium falciparum infected erythrocytes (Berendt et al., 
1989). Involvement of ICAM-1 in the pathogenesis of malaria remains unclear. 
However, there are several evidences supporting the involvement of ICAM-1 in 
severe malaria diseases, specifically CM. Post-mortem studies demonstrated induced 
sequestration of the parasite in the brain of SM patients, who also showed increased 
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in expression of ICAM-1 (Turner et al., 1994). Additionally, in vitro studies have 
also shown the ability of ICAM-1 to adhere to different isolates from CM patients 
(Newbold et al., 1997, Ochola et al., 2011). ICAM-1 expression levels on various 
types of ECs can be stimulated by inflammatory cytokines, including IL-1β and 
TNFα which are over-stimulated during malaria infection (Chakravorty et al., 2008). 
Moreover, the expression levels of ICAM-1 can be also activated directly by iRBC 
(Tripathi et al., 2006, Viebig et al., 2005b). 
1.5.1.2.3 EPCR: 
The expression of EPCR in microvascular endothelial of several organs involving 
brain is quite low (Moxon et al., 2013). EPCR has many functions including anti-
inflammatory responses via modifying the response of the signalling receptor 
protease-activated receptor 1 (PAR1) to thrombin, it also acts as a receptor for 
protein C in the process of producing activated protein C, which regulates 
coagulopathy protection, as well as it works to adhere the monocyte Mac-1 
(CD11b/CD18) to vascular EC. This interaction might play a role in associating 
vascular inflammation and coagulation in acute vascular inflammatory disease (Fink 
et al., 2013). As both ICAM-1 and EPCR have the ability to bind to Mac-1 and 
PfEMP-1, it was suggested that similarities might exist between Mac-1 and PfEMP-1 
surfaces (Aird et al., 2014). 
Two different studies conducted in CM showed the role of EPCR in the disease. 
Moxon and his colleagues demonstrated in their research that the EPCR had a role in 
children with cerebral malaria. The study found that loss of EPCR co-localized with 
sequestered iRBC at endothelial sites in the brains of children dying from CM 
(Moxon et al., 2013). They also revealed that levels of soluble EPCR in CSF in 
children with CM were high; however, the level in the plasma was not altered 
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compared to other malaria complications, which suggests that loss of EPCR linked 
cerebral coagulation and inflammation to parasite sequestration. Another study by 
Turner et al examined the binding of EPCR to particular PfEMP-1 variants that have 
been associated with SM (Turner et al., 2013). It was found that adherence of the 
ECs of several organs, including brain to DC8 containing PfEMP-1 was mediated by 
EPCR. The finding of this study was confirmed by examined the binding of parasites 
isolated from patients with severe malaria to EPCR, which was higher compared to 
the parasites isolated from patients with uncomplicated malaria. 
1.5.1.2.4 PECAM-1: 
This receptor is expressed widely on platelets, ECs, granulocytes and monocytes. It 
was reported that around 50% of malaria isolates from Kenya bound to PECAM-1 
but there was no significant correlation between PECAM-1 and SM. Moreover, 
studies carried out in Africa showed no protection role for PECAM-1 against SM 
(Heddini et al., 2001). In contrast, expression of this receptor increased the risk of 
CM in Thailand (Rowe et al., 2009). Binding of PECAM-1 to PfEMP-1 containing 
DC5 was assigned, and associated with SM in children from Tanzania, although the 
sample numbers were limited. Thus, it was suggested that SM can be mediated by 
DC5-PfEMP-1 expressing parasites (Berger et al., 2013). 
1.5.1.2.5 CSA: 
Accumulation of P. falciparum iRBCs and monocytes in the placenta is known as a 
specific characteristic of pregnancy associated malaria (PAM) (Walter et al., 1982). 
Sequestration of iRBC in the human placenta is mediated by CSA (Duffy and Fried, 
2003) and var2CSA PfEMP-1 members (Viebig et al., 2005a, Avril et al., 2006, Bir 
et al., 2006, Buffet et al., 1999, Salanti et al., 2003). Then, antibodies that recognize 
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placental iRBCs develop and associate with protection against PAM in the 
subsequent pregnancies (Duffy and Fried, 2003, Staalsoe et al., 2001).  
1.5.1.2.6 Other cytoadherence receptors: 
Other EC receptors that have been implicated in cytoadherence of iRBC include: 
Thrombospondin (TSP) (Rowe et al., 2009), VCAM-1 (Ockenhouse et al., 1992b), 
neural cell adhesion molecule (NCAM) (Pouvelle et al., 2007), E-selectin (Schofield 
et al., 1996), P-selectin (Yipp et al., 2007) integrin αvβ3 (Siano et al., 1998) and 
fibronectin (Eda and Sherman, 2004). However, the role of these receptors (and 
others) in the pathogenesis of malaria is unknown (Rowe et al., 2009).  
1.5.1.3  PfEMP-1: 
P. falciparum causes more mortality and morbidity than any of the other species, and 
this might be associated with the expression of PfEMP-1. PfEMP-1 is a variable 
protein with high molecular weight (200 to 350 kDa) (Aley et al., 1986) which is 
displayed on the surface of the iRBC and localized to structures known as knobs. The 
knob is visible on the iRBC surface from about 16-18 hours after invasion at the 
same time as sequestration takes place (Gardner et al., 1996). The presence of knobs 
is an important factor for optimal display of PfEMP-1 for cell-cell interactions (Rug 
et al., 2006, Horrocks et al., 2005). PfEMP-1 is implicated in cytoadherence to many 
adhesion receptors on the host endothelial cells. This protein is encoded by 50-60 
different var genes per parasite genome of which only one var gene is expressed in a 
parasite at any particular time (Kirchgatter and Del Portillo, 2005). The majority of 
these var genes are located in subtelomeric regions of all 14 parasite chromosomes 
(Gardner et al., 2002). 
 P. falciparum uses a mechanism to evade from the host immune system, this is 
called an antigenic variation, which is defined as “the changes of the molecules of 
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the parasites exposed to the immune system over the course of an infection” (Deitsch 
et al., 2009). In this case, only a single gene is expressed while all the other genes are 
silenced; in other meaning, antigenic variation involves switching expression to an 
alternative var gene, resulting in transcription of an antigenically distinct PfEMP-1 
protein (Chakravorty et al., 2008, Smith et al., 2001). Switching takes place at an 
average of up to 2% per generation (Roberts et al., 1992), although this average 
differs between parasite variants (Horrocks et al., 2002). 
The ability of parasites to interact with host cells and to mediate sequestration in 
several tissues can be determined by the variation in different PfEMP-1 proteins 
(Montgomery et al., 2007). PfEMP-1 is structured from one domain in the 
intracellular exon, and multi-domains in the extracellular exon composed of Duffy 
binding like domains (DBLα) and cysteine-rich interdomain region (CIDRα) as the 
head structure, and followed by different numbers and classifications of DBL and 
CIDR domains (Gardner et al., 2002, Smith, 2014) (Figure 1.4). Many adhesive 
properties have been mapped to DBLs such as DBLβ type domain which is known, 
in some cases, to mediate binding to ICAM-1 (Springer et al., 2004), DBLα type 
which can mediate rosetting, a process of interacting with uninfected erythrocytes via 
complement receptor 1 (CR1) (Rowe et al., 1997), and CIDRα type domain which is 
responsible for binding to CD36 receptor (Miller et al., 2002) and EPCR (Turner et 
al., 2013). 
 
Figure 1.4: Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-1) 
structure.  
	
18 
The figure shows the typical arrangement of PfEMP-1 protein domains. The figure modified 
from (Smith, 2014).  
 
1.5.1.4 Effects of cytoadherence on endothelial cells: 
1.5.1.4.1 Direct activation of ECs: 
Many studies on post-mortem tissue have showed alteration of the EC in malaria 
associated with cytoadherence. Up-regulation of ICAM-1 and E-selectin adhesion 
receptors in cerebral micro-vessels has supported the view of endothelial stimulation 
in fatal malaria (Turner et al., 1994), also a subsequent study that showed a positive 
association between malaria disease severity and increase of ICAM-1, VCAM-1, P-
selectin and E-selectin, indicating widespread systemic activation of EC (Garcia et 
al., 1999).  
Studies on post-mortem brain tissue have also demonstrated evidence of BBB 
disruption. Haemorrhages are seen in most cases, but they are small and not usually 
correlated with necrosis. Thus, it is supported that the processes regulating the 
integrity of BBB are altered, leading to accumulation of fluids and some plasma 
proteins into brain parenchyma and perivascular space, and contributing to cerebral 
oedema which can lead to death (Newton et al., 1998, Adams et al., 2002). However, 
it is also clear that the amount of vessel leakage is small and this supports the role of 
sequestered parasite as a major contributor to brain swelling. Recently, in vitro 
evidence suggests that the EC is activated during the malaria infection via β-catenin, 
which is released from ruptured iRBC and this can lead to alterations in EC junctions 
in HBMEC, leading to induced the permeability of the endothelial barrier (Gallego-
Delgado et al., 2016).  
The last decade has seen interest in investigating how the parasite sequestration can 
modulate the phenotype and function of EC directly. Several groups are focusing on 
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investigating the changes in EC that follow interaction with iRBC, using in vitro co-
culture systems. It has become apparent that the alterations induced by iRBC, while 
they can increase the EC permeability, at the same time, they can protect EC from 
generalized cell death. Although malaria infection has been closely linked to 
widespread EC activation, this phase involves several changes seen in ECs, including 
functional changes and signal transduction. A number of in vitro studies have 
showed over-expression of adhesion receptor (ICAM-1) (Viebig et al., 2005b, 
Tripathi et al., 2006). However, this response was specific to conditions of the 
cultures, source of the EC and also presence of TNF. In contrast to Viebig et al, 
Chakravorty and colleagues did not observe any increase of ICAM-1 expression by 
iRBC as there was a critical requirement for levels of TNF (Chakravorty et al., 
2007).  This was also seen in a different study showing direct activation of brain EC 
but not human umbilical vein endothelial cells (HUVEC) by iRBC (Tripathi et al., 
2006). Although different types of ECs might respond differentially, the observation 
in all these studies is the ability of iRBC to induce alterations to ECs. 
1.5.1.4.2 Intracellular signalling: 
EC surface-adhesion receptors usually work as mediators of cell-cell adhesion but, in 
addition to this, they can also mediate intracellular signalling in EC. Two common 
cytoadhesion receptors in EC are ICAM-1 and CD36. Several studies have revealed 
that the interaction between CD36 and PfEMP-1 can mediate extracellular-signal-
regulated kinase1/2 (ERK1/2) phosphorylation in ECs. Furthermore, it was 
demonstrated that ERK1/2 activation was essential in supporting adhesion of iRBC 
via an ecto-alkaline phosphatase that dephosphorylates CD36 and then induces the 
CD36 binding affinity (Ho et al., 2005, Yipp et al., 2003). Indeed, a randomized 
20 
clinical study showed reduction of iRBC sequestration in patients with UM by using 
the alkaline phosphatase inhibitor, levamisole (Dondorp et al., 2007).  
Similarly, it has been established that the interaction between iRBC and ICAM-1 can 
lead to intracellular signalling in ECs, particularly in leucocyte adhesion in 
inflammation. Activation of mitogen-activated protein kinases (MAPKs) following 
adhesion of surface ICAM-1 can lead to multiple functional and phenotypic changes, 
involving tyrosine phosphorylation of cytoskeletal proteins, such as paxillin, focal 
adhesion kinase (FAK) and p130Cas (CAS), resulting in rearrangement of 
cytoskeletal mediated by Rho activation (Etienne et al., 1998), modulation of tight 
protein junctions, movement of neutrophils towards junctions for transendothelial 
migration, over-expression of VCAM-1, mediated by activator protein 1 (AP1) and 
ERK1 (Lawson et al., 1999). There is evidence to suggest that intracellular domain 
of ICAM-1 is essential for T lymphocyte mediating signalling and migration 
following ICAM-1 adhesion (Greenwood et al., 2003). ICAM-1 signalling is 
complex and involves activities such as transcription factor activation MAPK, 
protein expression, oxidative stress via stimulation of xanthine oxidase, cytokine 
production and subsequent reactive oxygen species (ROS) production (Wang and 
Doerschuk, 2000). ICAM-1 adhesion was also shown to induce the expression of 
ICAM-1 and affect the ligation of leucocytes (Clayton et al., 1998). Moreover, the 
interaction between ECs and iRBC can lead to stimulation of p38 MAPKs and 
ERK1/2, c-Jun N-terminal kinase (JNK) in ECs, which was dependent on the avidity 
of the adhesion between ICAM-1 and PfEMP-1 (Jenkins et al., 2007), and, in another 
study, it showed over-expression of ICAM-1 on HUVEC following adhesion with 
iRBC in the presence of TNF (Chakravorty et al., 2007) (Figure 1.5). Tripathi and 
colleagues observed nuclear translocation of the transcription factor nuclear factor 
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κB (NF-κB) as part of the intracellular signalling cascade that results in over-
expression of ICAM-1, following adhesion with iRBC (Tripathi et al., 2006). 
Interestingly, they also observed reduction in ICAM-1 expression using ROS 
inhibitors. 
 
Figure 1.5: Summary of intracellular signalling pathways results from 
interaction iRBC to ECs. 
The figure shows the intracellular signalling pathways activated in response to interaction 
iRBC vascular ECs via CD36 and ICAM-1. Figure adapted from (Chakravorty et al., 2007). 
 
1.5.1.4.3 Indirect activation of ECs: 
Although evidence supports a direct interaction between iRBC and ECs in the 
modulation of endothelium, the parasite produces proteins which can adhere to ECs 
or macrophages to initiate process of signalling cascades that can modulate these 
cells without direct interaction. For instance, the parasite-derived factor P. 
falciparum glycosylphosphatidylinositol (PfGPI) which is released during rupture of 
the mature schizont, can increase release of TNF from macrophages (Lu et al., 2006). 
P. falciparum merozoite proteins were also demonstrated to increase disruption of 
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endothelial barriers in a Src-family kinase-dependent manner, but not intact iRBC 
(Gillrie et al., 2007). A further mechanism for modulation of the ECs was identified 
by Treeratanapiboon and colleagues, in which endothelial permeability was induced 
following exposure to peripheral blood mononuclear cells (PBMCs) which were 
previously exposed to P. falciparum proteins (Treeratanapiboon et al., 2005). 
1.5.1.4.4 Modulation of endothelial permeability: 
Sequestration of iRBC in cerebral and pulmonary microvascular endothelial cells can 
be implicated in the development of two of the major symptoms of SM; CM and 
pulmonary oedema respectively. Breakdown of EC TJPs such as ZO-1, vinculin and 
occludin which maintain the integrity of vascular endothelial, was observed by 
analysis of the immunohistochemistry in vessels containing sequestered iRBC in 
post-mortem tissue from Malawian children and Vietnamese adults with CM (Brown 
et al., 2001a, Brown et al., 1999a). A study in Thailand, demonstrated a reduction in 
the expression of the TJPs vinculin, ZO-1 and occludin when iRBC isolated from 
CM patients were incubated with ECs (Susomboon et al., 2006). 
In vitro studies have also shown an induction in the permeability of brain and lung 
ECs mediated by interaction with iRBC. Resistance of the BBB was significantly 
decreased by up to 70% following exposure to intact iRBC and also contact with 
iRBC-derived soluble factors from the culture supernatant, prepared by precipitation 
with around 40% ammonium sulphate (Tripathi et al., 2007). Further study using 
lung ECs also showed induced endothelial permeability following contact to iRBC 
(Pino et al., 2003, Essone et al., 2017). Reductions in the resistance of the EC have 
also been observed in platelet-mediated cytoadherence (Wassmer et al., 2006b). 
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1.5.1.4.5 Modulation of endothelial apoptosis: 
Apoptosis is a complex biological process of cell death, and this process could be 
mediated by several stimuli, including cytokines, hormones, growth factors, viral or 
bacterial infection and immune responses (Thompson, 1995). Several in vitro studies 
have suggested that EC apoptosis is increased by sequestered iRBC in HBMEC. 
Although caspase 3 activity, which is an apoptosis marker, has been showed in 40% 
of CM patients, there was no evidence of particular damage in CM brain (Medana 
and Turner, 2006). Thus, EC apoptosis is not a specific feature of CM and could not 
be attributed an essential role in the BBB disruption. Similarly, pulmonary oedema 
may result from iRBC -induced lung capillaries permeability, and is considered to be 
a common feature of SM (Maguire et al., 2005), but it is not thought to be associated 
with host apoptosis.  
The basis of malaria pathophysiology remains unclear, and there is considerable 
variance in the evidence for iRBC mediated cell death in vascular ECs (Figure 1.6). 
Some evidences suggested that there is a direct induction of apoptosis by iRBC, 
mediated through activation of caspase 3. On the other hand, other evidence has 
suggested that vascular endothelial apoptosis is an indirect process of oxidative stress 
due to iRBC -increased generation of ROS. Indeed, some studies used superoxide 
dismutase or other antioxidants which have shown protection of ECs in the presence 
of physical interaction with iRBC (Pino et al., 2003, Taoufiq et al., 2006). Other 
studies have revealed an increase of EC apoptosis following contact with iRBC. For 
example, apoptosis was increased in ECs when co-incubated with neutrophils in the 
presence of sera from malaria patients, which was mediated by products of 
neutrophil secretion (Hemmer et al., 2005).  
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Figure 1.6: Effects of the iRBC cytoadherence to vascular endothelial cells. 
The figure demonstrates the direct and indirect effects of interaction iRBC to ECs that can 
mediate endothelial dysfunction and survival. Figure adapted from (Chakravorty et al., 
2007). 
 
1.5.1.4.6 Modulation of the endothelial inflammatory response: 
The interaction between ECs and iRBC leads to endothelial activation and induce a 
range of inflammatory cytokines. Indeed, there are many evidences observing 
induction of pro-inflammatory cytokines such as TNF (Kwiatkowski et al., 1990), 
IL-1β, interleukin-8 (IL-8) (Burgmann et al., 1995), interferon γ (IFNγ) and IL-6 in 
serum levels of SM patients. Moreover, TNF, TGF-β and IL-1β have been shown in 
post-mortem brain tissue in human CM (Brown et al., 1999a). A study by Clark and 
colleagues on post-mortem tissue from children with CM with no pathological 
diagnosis except malaria, showed high expression level of haem oxygenase-1 (HO-
1), an inflammatory mediator, in liver, lung and brain tissues, suggesting widespread 
systemic inflammation (Clark et al., 2003). Endothelial vesiculation and the 
generation of microparticles are considered to be an additional result of EC 
activation in CM disease. These can contact other host cells, such as platelets and 
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leucocytes, to increase cytokine release, thus maintaining an inflammatory 
environment (Coltel et al., 2006).  
There is a belief that inflammatory response being increased in the host following an 
infection with malaria is a key factor in mediating malaria pathogenesis (Clark et al., 
2006). It is possible that systemic activation plays an important role in malaria 
pathology, as demonstrated by a study using a synthetic transcriptional inhibitor of 
TNF which demonstrated inhibition of ICAM-1 expression and also inhibition of 
iRBC interaction to HBMEC (Wassmer et al., 2006a). However, localized 
cytoadhesion between ECs and iRBC might also contribute directly to malaria 
disease, specifically during the early stages of malaria infection.  
1.5.1.4.7 Modulation of endothelial survival: 
Microarray analysis study of transcriptional changes in HUVEC following co-culture 
with iRBC in the presence of TNF by Chakravorty and colleagues have showed 
modulation of multiple genes that can mediate cell survival (Chakravorty et al., 
2007). This involves up-regulation of uncoupling protein 3 (UCP3), which detoxifies 
ROS to protect ECs from oxidative stress (Cannon et al., 2006), and down-regulation 
of caspase 3 expression, which is a late stage marker of apoptosis.  The protection of 
the ECs might be a mechanism to protect the P. falciparum parasite and enhance 
survival of the transmissible phenotypes. Thus, it is possible that, the adhesion of 
iRBC to ECs can suppress several genes that are mediating apoptosis and up-regulate 
genes that have a role in protection and survival of the ECs, in addition to inducing 
damage. 
1.6 Thesis objectives: 
In the last two decades, several studies have been conducted to understand malaria 
pathogenesis. Better understanding of this syndrome might lead to the discovery and 
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development of new therapies for SM. To do that, it is important to understand how 
the P. falciparum is modulating the host response to infection. This thesis aims to: 
• Determine the transcriptional response to iRBC adhesion to brain endothelial 
cells in co-culture at 2, 6 and 20 hours. 
• Compare this profile between two different PfEMP-1 variants, ITvar14 
(upsB) and ITvar37 (upsC). 
• Identify differences in the transcriptional response to cytoadherence in brain 
(HBMEC) and dermal (HDMEC) endothelial cells. 
• Examine the role of the uninfected erythrocyte and systemic TNF in 
endothelial modulation during cytoadherence. 
These were mainly achieved using the RNA-seq technique. Summary of experiments 
in this thesis can be seen in Figure 1.7. 
 
Figure 1.7: Summary of experiments in this study. 
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CHAPTER 2 
2.  MATERIALS AND METHODS 
  
28 
2.1 Malaria parasite culture: 
Lab adapted IT4var14 (A4) (Ockenhouse et al., 1992a) and IT4var37 (4E12) (Janes 
et al., 2011) P. falciparum isolates were used in this study. These isolates were gift 
from Prof Alister Craig (Liverpool School of Tropical Medicine, UK) and Prof 
Joseph Smith (University of Washington, USA). They were grown and maintained in 
culture with some modification as described previously by Trager and Jensen (Trager 
and Jensen, 1976), with some modifications. The parasites were cultured at 1% 
haematocrit in O+ human erythrocytes and grown at 37°C in complete RPMI 1640 
medium (supplemented with 10% human serum, 37.5 mM 4-(2-hydroxyethyl)-1-
piperazine ethane sulfonic acid (HEPES), 6 mM NaOH, 7 mM D-glucose, 25 mg/ml 
gentamicin sulfate, 2 mM L-glutamine) and at a pH of 7.2 in a plastic tissue culture 
flask which was filled with a gas mixture of 96% nitrogen, 3% carbon dioxide, and 
1% oxygen prior to sealing. 
2.1.1 Growth and washing media preparation: 
For washing and growing the parasite, the materials below were mixed with the 
particular quantities and filtered in a laminar flow hood under aseptic conditions. 
2.1.1.1 Washing medium: 
• 500 ml of RPMI (R0883, Sigma, USA) stored at 4°C.  
• 18.75 ml of HEPES Buffer (1 M, H0887, Sigma) stored at 4°C. 
• 5 ml of 20% Glucose solution (7 mM, Sigma powder) kept at room 
temperature. 
• 5 ml of L- Glutamine solution (200 mM, G7513, Sigma) stored at -20°C.  
• 3 ml 1 M of Sodium Hydroxide solution kept at room temperature. 
•  1.25 ml Gentamicin Sulphate solution to give 25 ng/µl (10 mg, G1272, 
Sigma) stored at 4°C. 
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2.1.1.2 Growth medium: 
Only 100 ml of the mixture was used as parasite washing medium (incomplete 
medium) and stored at 4°C. 45 ml of human pooled serum was added to the 
remaining mixture then filtered and stored at 4°C as growth medium (complete 
medium). In parasite culture, all solutions must be warmed in an incubator or water 
bath at 37°C prior to use. 
2.1.1.3 Human pooled serum: 
Blood bags were collected from the Royal Hospital (Liverpool, UK) in non-
anticoagulant blood collection bags and stored overnight at 4°C. Then, they were 
centrifuged for 20 minutes at 3000 rpm. After that, the serum was carefully taken, 
mixed and stored in 45 ml aliquots at -20°C. 
2.1.2 Red Blood cells separation: 
Non-red blood cells components were taken and removed from the whole blood prior 
to using it in culture of the parasite. First of all, 12.5 ml of Histopaque (10771, 
Sigma) was put in four 50 ml Falcon tubes (BD Falcon Conical Tube, BD 
Biosciences, UK). 25 ml of parasite washing medium was added to 25 ml of whole 
blood cells and mixed well in another 50 ml Falcon tube. After that, 12.5 ml of the 
mixture of blood was added to the four tubes containing Histopaque dropwise. The 
solutions were centrifuged for 15 minutes at 3000 rpm and the supernatants were 
aspirated prior to adding about 3 volumes of the washing medium. These were mixed 
and centrifuged again for 5 minutes at 3000 rpm. The supernatants were removed 
and the pellets of the RBC were re-suspended in an equal volume of washing 
medium and stored at 4°C. The RBCs have a haematocrit of about 50% and are 
known as washed RBC (wRBC). 
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2.1.3 Parasites thawing: 
An appropriate volume of growth media, washing media, 12% NaCl, 1.8% NaCl and 
0.9% with 0.2% glucose were warmed at 37°C prior to use. According to LSTM 
policy, the parasite vial was removed carefully from liquid nitrogen following the 
code of practice. The stabilate was rapidly warmed at 37°C prior to transferring it 
into a 50 ml Falcon tube. Relying on the pellet volume, one-fifth of its volume of 
12% NaCl was added slowly dropwise and mixed gently with the pellet. Simply, 200 
µl of 12% NaCl was added if the pellet was 1000 µl, then incubated for 5 minutes at 
room temperature. This was followed by the addition of five volumes of 1.8% NaCl 
to the pellet volume dropwise and incubation at room temperature for 5 minutes. 
Thereafter, five volumes of 0.9% NaCl containing 0.2% glucose was added dropwise 
and incubated at room temperature for 5 minutes. The mixture was centrifuged for 5 
minutes at 1800 rpm. The supernatant was aspirated and the pellet was washed with 
washing medium and centrifuged for 5 minutes at 1800 rpm. The pellet then was re-
suspended in an appropriate volume of complete medium, transferred to T25 cm2 
culture flask (BD Falcon, USA), gassed for 30 seconds and incubated in a 37°C 
incubator.  
2.1.4 Evaluating parasite growth and maintenance of continuous culture: 
The parasitemia was evaluated by using Giemsa thin smear and according to the 
results, an appropriate volume of wRBC was added. It was assessed by making a 
Giemsa thin smear which was then examined under a light microscope. 500 RBCs 
were counted; the number and stages of any iRBCs were recorded. The smears of 
cultures were obtained by taking a drop from parasite culture, spreading it smoothly 
on a labelled glass slid and air-dried at room temperature. The smear was fixed for 
few seconds with absolute methanol prior staining with 10X diluted Giemsa (stock of 
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the Giemsa stain solution was diluted with 10% of phosphate-buffered water [4 mM 
KH2PO4 and 20 mM Na2HPO4 at pH 7.2]) for approximately 20 minutes at room 
temperature. After that, the stain was washed off with tap water and the slide air-
dried prior to examining it under a binocular light microscope by using (100x) oil 
immersion objective lens. 
Most parasite cultures were adjusted at 1% haematocrit and 1% parasitemia. The 
formula that was used to adjust the parasitemia for continuous culturing was as 
follows: P1 V1 = P2 V2, where P1 is the counted parasitemia for the evaluated culture, 
V1 is the evaluated culture volume, P2 is the required parasitemia to continue 
culturing the parasite, which is commonly 1-1.5%, and V2 is the required volume of 
parasite culture to maintain the growth of the parasite at given the parasitemia. To 
keep the haematocrit at 1%, 10 µl of packed RBCs (100%) was required for 1 ml of 
parasite culture. But, because the wRBC stock was diluted to 50%, the volume is 
doubled. A coulter counter was used to assess the haematocrit of the parasite culture 
and wRBC. 
2.1.5 Parasites synchronisation: 
2.1.5.1 Plasmion flotation: 
The parasite culture was transferred to a 50 ml Falcon tube and centrifuged for 5 
minutes at 1800 rpm, then the supernatant discarded. The pellet was re-suspended in 
washing medium in 1.5X of pellet volume, and transferred into a 15 ml Falcon tube 
(BD Falcon Conical Tube, BD Biosciences, UK). Thereafter, the suspension was 
mixed with Plasmion in 2.5X of pellet volume and allowed to settle at 37°C for 20 - 
30 minutes. In the top layer of the suspension, the trophozoite stage knobby iRBCs 
might be seen. This layer was transferred carefully to a new 15 ml Falcon tube. The 
tube after that was centrifuged for 5 minutes at 1800 rpm and the supernatant 
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removed. The pellet was re-suspended gently in 10 ml washing media and 
centrifuged for 5 minutes at 1800 rpm. Then, the supernatant was discarded and a 
thin smear of the pellet was prepared prior adding the appropriate volume of growth 
medium and fresh wRBC, and gassed as described earlier. Greater than 50% of 
iRBCs at mature stages were usually seen in the smear after this procedure. This kind 
of selection was performed routinely to make sure that knobby populations were kept 
for adhesion and co-culturing assays as described earlier by (Jensen, 1978). 
2.1.5.2 Sorbitol: 
Occasionally, parasite culture was synchronised by 5% of D-sorbitol (S3889, Sigma) 
which acts to lyse the iRBCs with mature stages of trophozoites (Lambros and 
Vanderberg, 1979). It was used when the parasite culture contained higher 
trophozoite parasitemia. The parasite culture was centrifuged at 1800 rpm for 5 
minutes and pelleted, then treated with 10X of 5% D-sorbitol for 20 minutes at 37°C. 
After that, it was centrifuged for 5 minutes at 1800 rpm, the supernatant discarded 
and the pellet washed with 10 ml of incomplete medium. The pellet then was re-
suspended in an appropriate volume of complete medium, transferred to a new 
culture flask, gassed and incubated at 37°C. The 5% of D-sorbitol was prepared as 
the following: 25 g of D-sorbitol (Sigma Co, UK) was dissolved in 500 ml of 
distilled water, the solution filtered and kept at 4°C. 
2.1.6 Selection of IT4var14 parasite on BC6 antibody: 
The selection of IT4var14 isolate from other var genes was performed using BC6 
monoclonal antibody (mAb) (Oxford University) that specifically recognises 
IT4var14 (Smith et al., 1995). 50 µl of Protein G Dynabeads (10003D, Invitrogen) 
were purified on the magnet and washed 3 times with 500 µl of 1% BSA/PBS 
(A8327, 30% Bovine Serum Albumin and D8537, Dulbecco’s phosphate buffer 
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saline, Sigma), then re-suspended in 366 µl of 1% BSA/PBS and 34 µl of BC6 
original stock 235 µg/ml. The mixture was rotated at 15 rpm for 60 minutes at room 
temperature, thereafter washed 3 times with 500 µl of 1% BSA/PBS and re-
suspended in 200 µl 1% BSA/PBS. Parasite culture was enriched for trophozoites 
stages by using plasmion as described above. The iRBC were re-suspended in 200 µl 
1% BSA/PBS and incubated with BC6 labelled Dynabeads suspension, and rotated at 
15 rpm at room temperature for 45 minutes then washed 3 times with 500 µl of 1% 
BSA/PBS very gently to remove unbound parasites. iRBCs were re-suspended in 
appropriate volume of growth media with fresh washed red blood cells and cultured 
as standard.  
Parasites selected on BC6 were cryopreserved to provide sufficient material for 
adhesion and co-culturing assays using the same populations. This was made to 
minimize the impact of antigenic switching. Usually, the parasite was used in 
binding and co-culturing assays for up to 3 weeks post-selection. 
2.1.7 Cryopreservation of parasites: 
The parasite culture of around 5-8% parasitemia at ring stage was pelleted and 
cryopreserved by re-suspending in a glycerolyte freezing medium. Cryopreservation 
was performed according to the following calculation: 3X of the pellet volume was 
re-suspended in 5X volumes of the cryopreservation solution. Two steps were carried 
to add the cryopreservation media; first, the pellet was re-suspended with one-fifth 
volume of the required cryopreservation media dropwise then allowed to stand at 
room temperature for 5 minutes. Second, the remaining volume of the 
cryopreservation media was gently added and mixed completely prior transferring to 
properly labelled cryovials. Keeping the cryovials in a rack and covering with tissues 
to allow freezing at -80°C slowly for overnight. On the day after, Vials were 
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transferred to liquid nitrogen cryostorage. An example is given below for the 
calculation of cryopreservation: if the pellet was 1000 µl, then 1666 µl of the 
cryosolution was required. (1666 µl / 5) = 333 µl, this volume was considered as first 
volume that was suspended with the pellet. Thereafter, (1666-333) = 1333 µl, this 
remaining volume was the second re-suspension. 
2.2 Endothelial Cells culturing: 
HBMEC passage 3 (P3) (ACBRI 376) were obtained from Cell Systems (USA). 
Human dermal microvascular endothelial cells (HDMEC) (C-12210) were obtained 
from Promocell in 1ml of cryopreserved cells at (P1). 
2.2.1 Endothelial medium preparation: 
HBMEC and HDMEC medium were cultured in Endothelial Cell Growth Medium 
MV (ready-to-use) (C-22020) that was supplemented with Endothelial Cell Growth 
Medium MV SupplementMix (C-39225). To store and re-use the medium, it was 
kept at 4°C and aliquots were warmed in a water bath prior to use. 
2.2.2 ECs thawing: 
Sterile filtered plastic tissue culture flask (T25 cm2) (BD Falcon, USA) was coated 
with 2 ml of 1% of Gelatin solution (G1393, type B, 2% in H2O, Sigma) for around 
1 hour in a humidified tissue culture incubator at 37°C and 5% carbon dioxide (CO2), 
then the solution was aspirated. Cryopreserved cells were warmed at 37°C prior to 
transferring the cells into the coated flask containing 5 ml of warmed endothelial 
medium, and allowed to attach at 37°C, 5% CO2 incubator for 2-3 hours. After that, 
the endothelial medium was replaced by the same amount of warmed medium and 
incubated for 48 hours. Cells were examined for confluence and medium was 
replaced every 48 hours. According to the standard protocol and manufacturer’s 
instructions, once the cells are confluent (80-90%), sub-culturing must be carried out. 
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2.2.3 ECs sub-culturing: 
Sub-culturing of the ECs was done by Promocell detech kit (C-41220) which 
contains HEPES-buffered Balanced Salt Solution (HEPES-BSS), Trypsin/EDTA 
solution and Trypsin Neutralization Solution (TNS). These solutions were aliquoted 
and warmed at 37°C before using. Medium was aspirated from the flask prior to 
adding 1.5 ml of HEPES-BSS to wash off the remaining medium. HEPES-BSS then 
was aspirated before detaching the cells by 1.5 ml of trypsin. The detached cells were 
observed by an inverted microscope. Thereafter, similar amount of TNS was 
immediately added as soon as the cells have been detached to minimise the possible 
impact of trypsin. The mixture was transferred into 15 ml Falcon tube and 
centrifuged for 3 minutes at 300 xg. The cells after that were gently re-suspended 
into warmed fresh medium and distributed into three T25 cm2 gelatin coated filtered 
tissue culture flasks. At this stage, the cells were considered at the next passage (P4) 
and expanded until P5 and then cryopreserved for assays at P6, P7 and P8.  
2.2.4 ECs cryopreservation: 
For cryopreservation, cells were detached as described for sub-culturing but then 
they were re-suspended at 5-7.5 X105 cells/ml in promocell Cryo-SFM (C-29910) 
instead of suspension in media. The Vials were gradually frozen at -20°C for few 
minutes to -80°C overnight, prior to storing them in the liquid nitrogen cryostore.  
2.3 Detection of selected IT4var14 parasite on BC6 antibody by flow 
cytometry: 
Fluorescence-activated cell sorting (FACS) was used to evaluate the IT4var14 
parasite that was selected on BC6 mAb. Parasites were cultured and maintained 
following standard laboratory conditions. Mature pigmented trophozoites, at 3-8% 
parasitemia and a haematocrit of 1-2%, were enriched using plasmion floatation. In 
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terms of the plasmion flotation, the parasites were transferred to 50 ml falcon tube 
and centrifuged at 1800 rpm for 5 minutes. The pellets were suspended with 1250 µl 
warmed plasmion as (500 µl pellets × 2.5 plasmion solution) and 750 µl incomplete 
parasite culture media (YM) as (500 µl pellets × 1.5 YM) then incubated at 37°C for 
20 minutes. After incubation, the supernatant was aspirated into a new 15 ml falcon 
tube then centrifuged at 1800 rpm for 5 minutes. The pellets were washed with 5 ml 
YM and centrifuged again at 1800 rpm for 5 minutes, 10 µl of enriched pellets 
(containing 50-60% of trophozoites-stage iRBCs, at 20% haematocrit) was re-
suspended with 100 µl of 1% BSA/PBS in two 1.5 ml eppendorf tubes. The 
eppendorf tubes were centrifuged at 2500 rpm for 2 minutes, one of them was re-
suspended with mAb BC6 diluted 1:10 in 1% BSA/PBS (8.5 µl of mAb BC6 + 91.5 
µl of BPS) and the other re-suspended with 100 µl of 1% BSA/PBS as control 
sample, then they were incubated for 30-60 minutes in 37°C incubator.  
In the meantime, the compatible secondary detecting antibody (goat anti-mouse IgM 
antibodies-APC conjugated (Southern Biotech, 1020-11L, 0.5 mg) was prepared as 
1:100 (Ab: 1% BSA/PBS) (2 µl of APC + 200 µl of 1% BSA/PBS + 0.2 µl of 
Ethidium Bromide to stain the nuclei). After incubation, the tubes were centrifuged 
at 2500 rpm for 2 minutes then washed with 100 µl of 1% BSA/PBS and centrifuged 
at 2500 rpm for 2 minutes. The cells were re-suspended with 100 µl of the prepared 
secondary antibody and incubated at 37°C for 60 minutes in darkness. Tubes were 
centrifuged at 2500 rpm for 2 minutes then washed with 100 µl of 1% BSA/PBS and 
centrifuged again at 2500 rpm for 2 minutes to remove excess antibody. Cells were 
re-suspended in small glass tube containing 500 µl cell wash (FACS buffer) and 
analysed by using a Bickton-Dickinson FACSCalibur flow cytometer (BD LSR11). 
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Data were obtained by using FACSCalibur flow cytometer, then FlowJo software 
(TriStar, San Carlos, CA, USA) was used to collect and analyse 50.000 events. 
BC6, a monoclonal antibody that recognise the surface of live iRBCs infected with 
IT4var14 P. falciparum strain, was included in the experiments as a positive control. 
Negative controls include the fluorescent reactivity of iRBCs with either an 
irrelevant mouse IgM or with secondary antibody and Ethidium bromide stain alone. 
2.4 Mycoplasma detection test: 
Mycoplasmas are small parasitic bacteria and considered as famous cell culture 
contaminants and could have deep impacts on host cell biology for survival (Rottem, 
2003) and dysregulate host gene expression (Hopfe et al., 2013). Preventing 
contamination by mycoplasma is difficult for many reasons. Firstly, mycoplasma 
cells are small in diameter (0.3-0.8 µm) (Razin, 2006), and have the ability to escape 
through standard filtration membranes. Secondly, mycoplasmas are resistant to most 
commonly used antibiotics because they lack cell walls (Olarerin-George and 
Hogenesch, 2015). Thirdly, mycoplasmas have the ability to reach to high 
concentration in infected cells media without leaving turbidity (Young et al., 2010). 
Lastly, although the essential source of mycoplasma contamination is possibly other 
cell cultures, lab personnel are considered to be a likely source of contamination as 
well (Drexler and Uphoff, 2002). 
The parasite strains, ECs cultures, washed blood cells and parasite culture media 
were regularly monitored for mycoplasma contamination using the Universal 
Mycoplasma Detection Kit (ATCC® 30-1012K™). 
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2.5 Detection of microvascular endothelial receptors by flow 
cytometry: 
Endothelial cells were grown in 12-well plates until they become confluent at 37°C 
in a 5% CO2 incubator. Cells in six wells were then, stimulated with 10ng/ml TNF 
overnight. The ECs were washed with 500 µl HEPES buffer, trypsinized with 500 µl 
of trypsin and neutralised with 500 µl of TNS. Cells were transferred to 1.5 ml 
eppendorf tubes and centrifuged at 5000 rpm for 5 minutes then the pellets were 
washed with 500 µl of 1% BSA/PBS and centrifuged at 5000 rpm for 5 minutes prior 
to adding conjugated monoclonal antibody APC- mouse anti human ICAM-1, FITC 
mouse anti human CD31, FITC mouse anti human CD36 and APC- mouse anti 
human-EPCR for both stimulated and non-stimulated cells as (10 µl of each antibody 
+ 490 µl of 1% BSA/PBS in each eppendorf tube) (BD Biosciences Ltd). They were 
incubated for 60 minutes at 37°C in the dark. In parallel, isotype matched antibodies 
were used as a control for non-specific labelling (BD Biosciences Ltd). The cells 
were centrifuged at 5000 rpm for 5 minutes then washed with 500 µl of 1% 
BSA/PBS prior transferring to small glass tube that contained 500 µl of FACS 
buffer. The receptors expression levels were analysed by using a Bickton-Dickinson 
FACSCalibur flow cytometer. 
2.6 Static Protein Adhesion assays:  
Static protein-binding assays were performed as described previously (Patil et al., 
2011). Two 60 mm Plastic petri dishes (Falcon code 1007; Becton Dickinson, 
Oxford, UK) were spotted with 2 µl of ICAM-1 and CD36 proteins at concentration 
of 50 µg/ml in triplicate in a radial pattern and incubated in a humidified chamber for 
a maximum of two hours at 37°C, to permit the proteins to adsorb to the surface, 
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after which the proteins spots were aspirated off using a fine tip, and the plates were 
blocked with 1% BSA/PBS overnight at 4°C. The plastic petri dishes were warmed 
at 37°C for one hour prior to the assay. In the meanwhile, the parasites from cultures 
containing mostly mature trophozoites were prepared at 3% parasitemia and 1% 
haematocrit in sterile binding buffer (RPMI 1640 R4130 (Sigma, Dorset, UK) in 1l 
distilled H2O with HEPES, glutamine and 2% glucose at pH 7.2). The blocking 
buffer was discarded from the plates, and 1.25 ml of the parasite suspension was 
incubated in each plate at 37°C for 60 minutes with gentle rotation of the plates, to 
re-suspend the parasites, every 10 minutes. The dishes were carefully washed with 
binding buffer medium (4-6 washes) until almost no background was seen, and then 
the adherent cells were fixed in 1% glutaraldehyde in PBS for one hour. The plates 
were stained with 10% Giemsa for about 20-30 minutes, rinsed with water and dried 
overnight. 
Six images of each spot were captured under x200 magnification by using software 
HC Image (Sewickley, USA). The images were analysed by Image-Pro version 7 
(Rockville MD, USA). Binding for each protein was expressed as the mean number 
of the bound iRBC per mm2 in all spots for that protein in at least three independent 
experiments. 
2.7 Preparation of endothelial cells for co-culturing: 
ECs between passages 4-8 were used in the experiments. Methodologies of the 
endothelial cell culture have been described in detail above. When cells reached to 
80-90% confluence, half of the EC flasks were stimulated with the addition of 
10ng/ml TNF overnight. 
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2.8 Preparation of malaria parasites for co-culture: 
P. falciparum strains were cultured as described above. Parasites were cultured until 
they reached 5-8% parasitemia (trophozoite or schizont stages), and then they were 
enriched by using plasmion in order to obtain 50-60% parasitemia. 
2.9 Co-culture of ECs with malaria parasite: 
The concentrated parasites were re-suspended in EC medium to a parasitemia of 50% 
and 1% haematocrit. Endothelial medium was removed from EC flasks and the cells 
then were re-suspended with 5 ml of parasites suspension for 0, 2, 6 and 20 hours at 
37°C, in a 5% CO2 incubator. In the control group, uninfected red blood cells were 
re-suspended in 5 ml endothelial cell medium to obtain 1% haematocrit and applied 
onto EC monolayers for 0, 2, 6 and 20 hours at 37°C, 5% CO2 in a humidified 
incubator. At each time point, the co-culture medium was aspirated from each flask 
and the cells were washed 1X with EC medium to remove unbound parasites or 
uninfected RBC. 1.5 ml of EC medium was added to each flask prior harvesting the 
cells by cell-scraper. The cells were then transferred to 1.5 ml labelled sterile 
eppendorf tubes. 
2.9.1 RNA extraction from co-culture assays: 
In this study, extraction and purification of high quality RNA free from any other 
contaminants was an impotent step. The RNA was extracted from each co-cultured 
flask according to the RNeasy Mini Kit (Qiagen, 74104) protocol instructions.  
Samples were centrifuged at 13.000 rpm for 1 minute and the supernatant discarded. 
350 µl of buffer RTL was added to the pellet and homogenized for 1 minute with 
vortex. Then, 350 µl of 70% ethanol was added to the homogenate and transferred to 
RNeasy mini spin column in 2 ml collection tube. After that, the tube was 
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centrifuged at 8000 xg for 15 seconds and the flow-through removed. 700 µl of RW1 
buffer was added to the spin column, centrifuged for 15 seconds at 8000 xg and the 
filtrate discarded. 500 µl of buffer RPE was added to the column, and then 
centrifuged at 8000 xg for 15 seconds and the flow-through discarded. This step was 
repeated but with centrifugation 2 minutes instead of 15 seconds. The RNeasy spin 
column was placed in a new 2 ml collection tube and centrifuged at full speed for 1 
minute to dry the membrane. The column was then placed in a new 1.5 ml collection 
tube and 50 µl of RNase-free water was directly added and centrifuged for 1 minute 
at 8000 xg to elute the RNA. This step was repeated using another 50 µl RNase-free 
water. The RNA sample was stored at -80°C. High precautions were taken to avoid 
any RNase contamination when preparing and handling the RNA. 
2.9.2 Quality assessment of RNA samples: 
The quality of the RNA samples was assessed using an Agilent 2100 Bioanalyzer 
(RNA 6000 Nano Kit, 5067-1511, Agilent technologies) and following its protocol 
instructions. The Agilent Bioanalyzer 2100 separates the RNA according to their 
sizes and quantifies each molecule. The RNA quality test was repeated twice to 
ensure the RNA products were at high quality. 2100 Expert software (Syngene, 
Cambridge, UK) was used to analyse the outputs. RNA integrity number (RIN) 
which reflects degradation level of RNA samples was the very important outcome 
value of the software (Schroeder et al., 2006). 
2.9.3 RNA sequencing: 
RNA samples were sent to King Abdullah University for Science and Technology 
(KAUST) (Kingdom of Saudi Arabia) for mRNA deep sequencing. Agilent 2100 
Bioanalyzer was used to check the quality of RNA samples and only samples with 
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RIN of greater than 7 were used for sequencing. The raw sequencing data was 
received by FTP transfer in FASTQ format. 
2.9.4 Bioinformatics for RNA sequencing data: 
Although the next generation sequencing (NGS) machines generated the great 
amount of data, the correct interpretation of data using bioinformatics tools is 
critical. The machines of NGS can amplify and sequence a fragment of DNA on a 
fixed spot, thus photos with high-resolution could be taken to record changes in 
colour of a spot after each pyro-sequencing round. Hence, raw reads of sequencing 
output might be considered as images instead of readable text files. Manufacturers 
always supply software that acts as sequencing platforms to transfer these images 
into sequencing data. Thus, the starting point of most bioinformatics analysis is the 
sequence reads. 
2.9.4.1 Quality assessment of raw sequencing reads:  
The quality control of the raw sequencing data is the first step. The high-throughput 
NGS machine produces the RNA-seq data. These data contain millions of short reads 
and their quality control are complicated. FastQC (Andrews) software is a quality 
control tool for high throughput sequence data. It is easy to use, allows checking of 
the quality of reads and includes several useful statistics describing the quality of 
data: Total Number of Sequences contained in the results of sequencing, Per Base 
Sequence Quality, Per Sequence Quality Score, Per Base Sequence Content, Per 
Sequence GC Content and Sequence Length Distribution.  
The most important quality indicator is the Total Number of Sequence, reads with 
few numbers in the results of RNA sequencing causes lack of detection of genes that 
have lower expression, thereby reducing the integrity of transcriptome. Per Base 
Sequence Quality detects the fraction of bases with low quality at each read position 
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and represents the accuracy of the reads. Per Base Quality Score exhibits the subset 
of reads that have universally low-quality values and a general loss of quality within 
the sequencing run. Per Base Sequence Content demonstrates base content of each 
sequence position of all sequences, irregular distribution of content means the library 
of sequencing is not random. There were two possibilities for this; either containing 
sequences with over representation or biased fragmentation that may happen when 
the library was generated using hexamer random priming (Hansen et al., 2010). Per 
Sequence GC Content measures the content of the GC across the whole length of 
each read in random library. Unusual shaped distribution indicates a problem with 
the library because of specific contaminantion, such as adapter dimer. Sequence 
Length Distribution displays if all sequences are the same length.  
2.9.4.2 Mapping of RNA sequencing reads: 
In the last decade, several mapping software tools had been developed to map short 
sequences to human reference genome. ELAND (Cox, 2007) and Maq (Li et al., 
2008a) were the earliest aligners. Although they had advantages, they were slow and 
require more memory compared to aligners using Burrows-Wheeler transformation, 
Bowtie and BWA (Li and Durbin, 2009).  
In this study, the sequences were aligned to UCSC Homo sapiens reference genome 
hg38 using TopHat v2.1.0 (Trapnell et al., 2009), which is integrated with Bowtie 
v2.2.6.0 (Langmead et al., 2009). TopHat eliminates a few number of reads based on 
quality scoring of each read and thereafter maps the reads to a provided human 
reference genome. The pre-built UCSC homo sapiens hg38 bowtie index was 
downloaded from the UCSC Genome Browser site 
(http://hgdownload.soe.ucsc.edu/downloads.html#human). Less than 40 alignments 
per read, with up to 2 mismatches per alignment were used as the TopHat default 
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settings. TopHat builds its database in a two-round mapping procedure. First, it tries 
to map sequences to the human reference genome and identifies potential splice 
junctions from the initial mapping. Second, it maps the sequences that were not 
aligned to the first round to the junctions of the exons. 
2.9.4.3 Quality assessment of sequence alignment: 
Quality of the sequence alignment to human reference genome for each sample was 
assessed by Samtools-flagstat (Li et al., 2009), which collects statistics about 
sequence reads based on their sequence alignment map (SAM) flags. 
2.9.4.4 Identification of gene expression changes: 
After mapping sequences to the human reference genome, many analyses could be 
carried out with existing software. In theory, the number of sequences aligned to a 
gene is proportional to the gene abundance. Software uses counts of reads mapped to 
each gene as a starting point to identify differentially expressed genes. Cuffdiff 
software (Trapnell et al., 2012) was used to determine differential expression of 
genes between Control and examined groups. The expression of those genes was 
reported in Fragments Per Kilobase of exon per Million fragments mapped (FPKM) 
(Mortazavi et al., 2008). A strict criterial was used to select differentially expressed 
genes: normalized expression >1 FPKM, Log2FC (log2 fold change) >1 (up-
regulated) or Log2FC <-1 (down-regulated), P-value <0.05 and FDR (false discovery 
rate) <0.05 (calculated as described (Subramanian et al., 2005)) as threshold to 
control the number of false positives. Analysis of the Cuffdiff were performed by 
using the human reference genome comparing the examined samples to the control 
samples. For those analyses, the biological replicates were pooled together.  
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2.9.4.5 Visualization of different expression genes: 
Gene expression analysis is considered one of the most popular analysis in the 
biomedical science field. In the last decade, high-throughput genomics have been 
developed until the introduction of RNA sequencing. With regard to the RNA-seq as 
a high-throughput gene expression profiling assay, the heatmap is one of the most 
popular methods of presenting the data of gene expression (Zhao et al., 2014). R 
software has been used as a tool to generate the heatmap function (Eisen et al., 
1998). This hierarchical clustering method was used to identify genes with high and 
low expression over different time points.  
2.9.4.6 Functional and pathway analysis of differentially expressed genes: 
Lists of differently expressed genes are often the results from the RNA sequencing. 
To extend these into the underlying biology requires functional and pathway 
analysis. Several databases and software of gene functions have been developed for 
this purpose, covering simple to more advanced pathway approaches (Khatri et al., 
2012). These usually depend on existing knowledge and their protein products. 
Several tools commonly used include the Database for Annotation Visualization and 
Integrated Discovery (DAVID) (Huang da et al., 2009) and Reactome pathway 
database v56 (Fabregat et al., 2016). DAVID was used under default setting to 
identify genes types that were differentially expressed. It has the ability to cluster 
genes into similar groups and functions, using data such as Gene Ontology (GO) 
term categories (biological process, molecular function and cellular component). 
Genes with more/less than 1 log2 fold change of expression were uploaded to the 
applications. 
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CHAPTER 3 
3. GLOBAL TRANSCRIPTIONAL PROFILES OF HUMAN 
BRAIN MICROVASCULAR ENDOTHELIAL CELL 
RESPONSES TO MALARIA PARASITE 
INTERACTIONS 
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3.1 Introduction: 
Cerebral malaria is considered as a part of severe complicated malaria, with mortality 
rate in adults from 15% in southeast Asia (Dondorp et al., 2005) to 8.5% in African 
children (Dondorp et al., 2010). The standard clinical definition of CM is a diffuse 
encephalopathy that is characterized by seizures and loss of consciousness (coma) 
(Newton et al., 2000). The clinical manifestations of CM differ from adults and 
children, and the causes of these differences are still not entirely clear but might be 
associated with age and immunity of patients (Olliaro, 2008). 
Cerebral malaria is a complicated clinical syndrome. Starting from infection by the 
Plasmodium falciparum parasite, then followed by parasite asexual multiplication 
and cytoadherence in brain endothelial microcapillaries. Cytoadhesion of iRBC on 
microvessels is a form of sequestration that has important roles in CM pathogenesis, 
either; directly by blockage microvessels that supply nutrients and oxygen to the 
brain, therefore causing blood flow obstruction resulting in tissue hypoxia and 
avoidance of splenic clearance; or indirectly by coagulation defects, inflammation 
mediation and endothelium dysfunction (Storm and Craig, 2014). Binding of iRBC 
multiple human brain receptors such as ICAM-1 (Berendt et al., 1989) and EPCR 
(Turner et al., 2013) is mediated by a specific parasite surface molecule (PfEMP-1). 
There are several key events following sequestration of iRBC on brain endothelial 
cells that can play roles in CM pathogenesis. These include endothelial cell 
activation (Kim et al., 2011), breakdown BBB (Medana and Turner, 2006), oxidative 
stress (Percario et al., 2012), platelet activation and apoptosis (van der Heyde et al., 
2006), and neuroinflammation (Miranda et al., 2013) (Figure 3.1). 
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Figure 3.1: Mechanisms of CM pathogenesis. 
a)  P. falciparum infected erythrocyte (pRBCs) sequestration, b) Blood brain barrier 
disruption, c) Endothelial cell activation, d) Platelet activation, e) Endothelial cell apoptosis 
and f) Decreased NO bioavailability. Grey boxes represent molecules with changed levels 
(induce shown by upward arrow; reduce shown by downward arrow) as an outcome of each 
mechanism. This figure is adapted from (Hora et al., 2016). 
 
In recent years, several applications have been developed to study the gene 
expression and regulation of the genome such as microarray and RNA sequencing. 
Although microarray is reliable and sometimes more cost effective than RNA-seq, it 
suffers from number of limitations, such as limited detection range (Wang et al., 
2009), relatively low resolution and high background noise (Casneuf et al., 2007). 
RNA-seq measures the expression of the gene in a more sensitive manner and can 
also measure other aspects of RNA molecules, including splicing patterns (Pan et al., 
2008, Sultan et al., 2008), changes of expression of individual transcript variants 
(Trapnell et al., 2010), allelic specific expression (Heap et al., 2010), sequencing 
variants (Barbazuk et al., 2007, Medvedev et al., 2009, Montgomery et al., 2010, Li 
et al., 2011), RNA editing events (Picardi et al., 2010, Peng et al., 2012) and accurate 
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transcription start site (TSS) mapping (Sultan et al., 2008). Moreover, RNA-seq can 
detect 25% more genes than the microarray does (Sultan et al., 2008). 
In the last two decades, several cerebral malarial studies have investigated the 
mechanisms of the pathogenesis using cDNA microarray technology, most of them 
concentrating on the role of the malaria parasite in the disease (Claessens et al., 2012, 
Subudhi et al., 2015b, Goel et al., 2014, Subudhi et al., 2015a). However, limited 
studies have focused on responses of the host cells to the malaria parasite interactions 
in CM disease (Chakravorty et al., 2007, Barbier et al., 2011). Up to now, there has 
no RNA sequencing study carried out to investigate the response of HBMEC to the 
malaria iRBC co-adhesion interaction. 
The aim of this chapter is to investigate the ability of the IT4var14 parasite variant to 
modulate gene expression in HBMEC in the presence of the inflammatory cytokine 
TNFα, at different time points in a co-culture system, using the RNA sequencing 
technology. Gene functional analysis and pathways analysis were also investigated 
under the same conditions. 
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3.2 Methods: 
3.2.1 Parasite culture: 
IT4var14 lab isolate was cultured as described in the general methods chapter using 
standard culturing techniques in O+ human erythrocytes at 1% haematocrit (Trager 
and Jensen, 1976).  
3.2.2 ECs culture: 
HBMEC was cultured in endothelial cells culture media in a humidified tissue 
culture incubator at 37°C and 5% CO2 as explained in the general methods chapter.  
3.2.3 Detection of mycoplasma infection in parasite isolate and HBMEC: 
Mycoplasma infection was examined in IT4var14 parasite and HBMEC as described 
in the general methods chapter. 
3.2.4 Characterization of the IT4var14 malaria parasite and HBMEC: 
FACS was used to detect the population representation of the IT4var14 parasite 
culture, which selected on BC6 mAb. Also, it was used to confirm the expression of 
ICAM-1, EPCR and CD31 protein receptors in the presence and absence of TNFα on 
HBMEC. Static protein adhesion assays were performed to assess the binding of 
iRBC to ICAM-1 and CD36 proteins. All these procedures were described in the 
general methods chapter. 
3.2.5 Co-culture ECs with malaria parasite: 
HBMEC were co-cultured with the IT4var14 parasite in the presence of TNFα 
stimulation at 0, 2, 6 and 20 hours in a humidified incubator at 37°C, 5% CO2 as 
described in the general method chapter.  
3.2.5.1 RNA extraction and quality control: 
As described in the general methods chapter, RNA from each co-cultured flask was 
extracted and purified from any other contaminations. Quality of the RNA samples 
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then was assessed using an Agilent Bioanalyzer 2100. 
3.2.5.2 Overview of the workflow for RNAseq data analysis: 
Although there are several freely available software packages used for the analysis of 
RNA-seq, selection of software of the bioinformatics workflow is critical and the 
choice depends on the aim of the analysis. For our RNA sequencing study, the 
purpose was to reveal differences of gene transcription levels of the TNFα activated 
HBMEC after incubation with the IT4var14 P. falciparum strain at 2, 6 and 20 hours. 
As described in the general methods chapter, the software tools which were used in 
our pipeline are demonstrated in Figure 3.2.  
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Figure 3.2: The workflow of the RNAseq analysis and software. 
FastQC was used to check the quality of the fastq files. Quality of the filtered sequences 
were then mapped to UCSC Homo sapiens reference genome hg38 with TopHat2. Samtools 
was used to examine the quality of the alignments. Cuffdiff was used to quantify 
differentially expressed transcripts. Gene functional analysis was investigated using the 
DAVID tool. Reactome was also used to test the gene pathway analysis. Genes with 
differential expression levels at 2, 6 and 20 hours of incubation compared to 0 hour of iRBC 
with TNFα activated HBMEC were visualized using Heatmap. 
 
 
3.2.5.3 Reverse transcription of mRNA (cDNA synthesis): 
Prior to cDNA synthesis, each RNA sample was checked using an Agilent 2100 
Bioanalyzer as described in the general methods chapter to ensure each sample had 
an accurate concentration measurement. cDNA synthesis was performed using RT2 
first strand kit (QIAGEN Cat #330401) according to the manufacturer’s instructions. 
It was carried out in 20 µl of reaction volume which is appropriate for 25 ng-5 µg of 
total RNA. In a sterile 0.5 ml eppendorf tube, 2 µl buffer GE was mixed with 0.6 µg 
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RNA, RNase-free water to give a final volume of 10 µl of genomic DNA elimination 
mix. This was heated for 5 minutes at 42°C, and then immediately placed on ice for 
at least 1 minute. A reverse-transcription mix was then prepared to add to each tube 
containing 4 µl 5x buffer BC3, 1 µl control P2, 2 µl RE3 Reverse Transcriptase Mix 
and 3 µl RNase-free water. 10 µl of the reverse-transcription mix was added to each 
tube containing 10 µl genomic DNA elimination mix, mixed gently and incubated for 
exactly 15 minutes at 42°C. Then the reaction was inactivated immediately by 
heating at 95°C for 5 minutes and 91 µl RNase-free water added to each reaction 
tube. 
3.2.5.4 Primer design for q-RT-PCR validated genes: 
The following genes were selected to validate the RNA-seq results at 6 hour of 
incubation IT4var14 parasite with HBMEC/TNF (Table 3.1). The primers were 
requested from Sigma-Aldrich company at 100 micro molar (µM), then diluted to a 
concentration of 0.5 µM by nuclease-free distilled water (Sigma Cat #W4502) prior 
to use in qRT-PCR reactions. 
Table 3.1: Primer sequences table. 
Gene name Forward primer sequence Reverse primer sequence Primer publication 
LAMC2 ACATTCCTGCCTCAGACCAC TCCCTTGTCAGTTGCTCCAT (Zhang et al., 2014) 
PLA2G4A CGTGATGTGCCTGTGGTAGC TCTGGAAAATCAGGGTGAGAATAC (Bickford et al., 2013) 
VCAM-1 CATGGAATTCGAACCCAAACA GGCTGACCAAGACGGTTGTATC (Koo et al., 2003) 
ID2 TCAGCCTGCATCACCAGAGA CTGCAAGGACAGGATGCTGATA (Khan et al., 2011) 
NFKBIA ACAGAGGACGAGCTGCCCTA CCTTTGCGCTCATAACGTCA (van der Pouw Kraan et al., 2014) 
HBA2 CCGGTCAACTTCAAGCTCCT CGGGCAGGAGGAACGGCT (Qadah et al., 2015) 
AQP1 TGGACACCTCCTGGCTATTG GGGCCAGGATGAAGTCGTAG (Motulsky et al., 2014) 
GAPDH 
TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG (Minsky and Roeder, 
2015) 
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3.2.5.5 Real-Time PCR: 
All pipette tips used in the qRT-PCR were DNase, RNase free, sterile filter tips and 
work was performed on a clean bench. Q-RT-PCR reactions were set up by mixing 1 
µl cDNA template and 7.5 µl of nuclease-free distilled water (Sigma Cat #W4502), 
12.5 µl 2x RT2 SYBR Green Mastermix (QIAGEN Cat #330500), 2 µl forward 
primer and 2 µl reverse primer with a final concentration 0.5 µM and in a final 
volume of 25 µl for each reaction. qRT-PCR reactions were mixed by vortexing prior 
to loading in a Mx3000P 96-well PCR plate (Agilent Technologies Cat #401334) and 
sealed with optical caps (Agilent Technologies Cat #401425). The plate was then run 
on a Stratagene Mx3005P device (Agilent Technologies, Santa Clara, California, 
U.S.A). The following cycling parameters in the Mx3005P software were applied: 
95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute.  
3.2.5.6  Interpreting qRT-PCR results: 
The expression of the gene of interest was calculated using the comparative Ct 
method for relative measurement of gene expression. The mean of the replicate 
sample outputs was calculated as a first stage; then for the second stage, the ∆Ct 
value was calculated by subtracting the Ct value of the target gene from the reference 
gene as shown in this equation below: 
∆Ct= Ct target gene – Ct housekeeping gene
For the third stage, the ∆∆Ct value was calculated by subtracting ∆Ct of the 
stimulated samples from the basal samples as exhibited below: 
∆∆Ct=∆Ct stimulated samples - ∆Ct basal samples 
Finally, the range in fold expression was calculated as following: 2-(∆∆Ct). 
GAPDH was used in this study as a housekeeping gene.  
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3.3 Results: 
3.3.1 Detection of mycoplasma infection in parasite isolate and HBMEC: 
Harvesting the parasite and EC free from the mycoplasma infection was the first 
challenge in this study. The IT4var14 parasite and HBMEC cultures were tested and 
showed no mycoplasma contamination (Appendix 1). 
3.3.2 Characterisation of the IT4var14 malaria parasite and HBMEC: 
3.3.2.1 Static adhesion of IT4var14 parasite on ICAM-1 and CD36 proteins: 
Based on the level of binding to ICAM-1 and CD36, IT4var14 was characterised as a 
good binder for both proteins in agreement with a previous study (Madkhali et al., 
2014) (Appendix 2). 
3.3.2.2 Detection of HBMEC receptor expression: 
The expression of the endothelial cell markers CD31, ICAM-1 and EPCR, with and 
without TNFα stimulation, were confirmed using FACS (Figure 3.3). ICAM-1 
expression was higher with TNFα stimulation. However, with TNFα activation, 
EPCR was slightly reduced. These results are consistent with previous studies 
(Madkhali et al., 2014). 
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Figure 3.3: Detection of HBMEC receptor expression. 
FACS analysis of ICAM-1, EPCR and CD31 expression on HBMEC without (left panel) and 
with (right panel) TNF stimulation. Stimulation was for 24 hrs using 10 ng/ml TNF. ICAM-
1, EPCR and an endothelial marker (CD31) are shown at the upper, the middle and the 
bottom panels respectively. 
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3.3.3 Quality control of RNA samples: 
In order to identify transcriptional changes within TNFα-stimulated HBMEC as a 
result of interaction with erythrocytes infected with the IT4var14 parasite, three 
independent co-culture experiments were carried out at 0,2,6 and 20 hours, and the 
RNA was isolated. An Agilent 2100 Bioanalyzer was used to determine the quality 
of the RNA samples. This machine measures the quality of the RNA using RIN, 
which compares the intensities of the 18S and 28S ribosomal RNA (rRNA). Samples 
with RIN of higher than 7 are deemed to be of minimal degradation and good 
quality. In this study, all the samples showed the RIN more than 7 (Table 3.2). 
Table 3.2: RIN calculated by Agilent 2100 Bioanalyzer. 
First Experiment 
Sample 
number Description of sample RIN 
RNA Conc 
(ng/µl) 
1 Parasite co-cultured with HBMEC at 0 hour (TNF +ve) 9.7 106 
2 Parasite co-cultured with HBMEC at 2 hours (TNF +ve) 10 163 
3 Parasite co-cultured with HBMEC at 6 hours (TNF +ve) 10 273 
4 Parasite co-cultured with HBMEC at 20 hours (TNF +ve) 10 209 
Second Experiment 
Sample 
number Description of sample RIN 
RNA Conc 
(ng/µl) 
5 Parasite co-cultured with HBMEC at 0 hour (TNF +ve) 9.9 124 
6 Parasite co-cultured with HBMEC at 2 hours (TNF +ve) 10 149 
7 Parasite co-cultured with HBMEC at 6 hours (TNF +ve) 10 246 
8 Parasite co-cultured with HBMEC at 20 hours (TNF +ve) 10 143 
Third Experiment 
Sample 
number Description of sample RIN 
RNA Conc 
(ng/µl) 
9 Parasite co-cultured with HBMEC at 0 hour (TNF +ve) 10 277 
10 Parasite co-cultured with HBMEC at 2 hours (TNF +ve) 9.6 396 
11 Parasite co-cultured with HBMEC at 6 hours (TNF +ve) 8.8 279 
12 Parasite co-cultured with HBMEC at 20 hours (TNF +ve) 9.1 428 
 
The table presents the RIN and the RNA concentration of each sample. The high RIN 
calculated by the 2100 Bioanalyzer indicated the very high quality of the isolated RNA.  
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3.3.4 Quality control of the raw reads: 
Quality of the raw sequences was checked with FastQC. Several aspects of the 
sequences’ quality were demonstrated as figures, including: Per Base Sequence 
Quality, Per Sequence Quality Score and Per Sequence GC Content (Figure 3.4). 
Although scores of the quality reduce along with positions of the sequences, the 
quality bases on the 3’ end of reads in all the samples were observed to be above a 
score of 20. On the basis of quality score per read, quality of the most frequently 
mean in all samples were shown at score 37. In order to investigate the quality of the 
GC distribution over all reads, GC content across the whole length of each read in all 
samples were roughly similar to the modal of normal distribution of GC content. 
 
Figure 3.4: Quality control of the raw reads. 
	 
A 
B C 
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A: Box plots of base quality scores of read positions across all reads in a sample. The x-axis 
shows the position of the reads. The y-axis is the quality scores of the bases. B: Quality score 
distribution over all sequences in a sample. The x-axis is the quality of mean sequence. The 
y-axis shows the number of sequences. C: Quality of the GC distribution over all reads. The 
x-axis demonstrates the mean GC content. The y-axis represents the number of reads. 
 
3.3.5 Mapping of RNA sequencing reads: 
After checking the quality of the raw sequence data FASTQ files, TopHat v2.1.0 was 
used to map sequences to UCSC Homo sapiens reference genome hg38. The total 
number of sequences produced from each sample in this study across all time points 
was between 9,637,117 and 43,077,924, with an average across all samples of 
27,198,576. Before aligning to the human reference genome, between 2.8% and 
5.9% of the reads were removed due to low quality. On average, 92.1% of the 
sequences mapped to the human genome (Table 3.3). 
Table 3.3: Summary of reads mapping to the human reference genome (UCSC 
hg38) using TopHat v2.1.0. 
 
PRBC TNF+ 0h 
1 2 3 Average 
Total reads 35,185,811 33,174,010 43,077,924 37,145,915 
Reads removed 4.7% 4.0% 4.1% 4.3% 
Read aligned to 
reference genome 93.1% 95.6% 94.9% 94.53% 
 
PRBC TNF+ 2h 
1 2 3 Average 
Total reads 18,776,296 10,569,872 9,637,117 12,994,428 
Reads removed 5.9% 3.5% 3.1% 4.6% 
Read aligned to 
reference genome 89.9% 90.6% 90.8% 90.4% 
 
PRBC TNF+ 6h 
1 2 3 Average 
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Total reads 51,236,486 26,479,076 22,343,112 33,352,891 
Reads removed 4.2% 2.8% 2.9% 3.3% 
Read aligned to 
reference genome 91.8% 91.0% 91.0% 91.27% 
 
PRBC TNF+ 20h 
1 2 3 Average 
Total reads 22,577,870 27,386,295 25,939,044 25,301,069 
Reads removed 3.8% 3.3% 3.4% 3.5% 
Read aligned to 
reference genome 93.6% 89.0% 93.9% 92.2% 
 
Total reads and the percentages of those reads removed due to low quality and aligned to 
hg38 by TopHat. PRBC indicates the P. falciparum infected erythrocyte. 
 
3.3.6 Identification of differentially expressed genes: 
After mapping the sequencing reads to the human reference genome with TopHat, 
differential expression on a gene level was determined with Cuffdiff in FPKM. In 
this study, gene expression changes of HBMEC after incubation with P. falciparum 
parasite and TNFα were calculated as following: the ratio of examined groups FPKM 
(2, 6 and 20 hours) to the control group FPKM (0 hour). The results then were 
converted to Log2FC. 
3.3.6.1 Differentially expressed genes in HBMEC at 2 hours incubation: 
From the analysis, 109 genes were identified as significantly differentially expressed 
with an adjusted FDR < 0.05 and at least 1Log2-fold change, of them 33 genes were 
found up regulated and 76 genes were down regulated. Top ten up and down 
regulated genes in TNFα-stimulated HBMEC co-cultured with IT4var14 parasite at 2 
hours are presented in (Figure 3.5). In the up regulated genes, anoctamin 9 (ANO9) 
has the highest fold change around 19-fold, followed by alkaline phosphatase, 
liver/bone/kidney (ALPL) as a next highest fold change with 7-fold. Whereas, the 
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most down regulated genes at this time point were CKLF like MARVEL 
transmembrane domain containing 1 (CMTM1) and aquaporin 1 (AQP1) with fold 
changes of about -14 and -12 respectively. A full description about the top ten up and 
down regulated genes is given in appendix 3. 
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Figure 3.5: Top 10 up/down regulated genes in TNF-stimulated HBMEC incubated with IT4var14 parasite at 2 hours co-culture. 
The differentially expressed genes in TNF-stimulated HBMEC co-cultured with IT4var14 parasite isolate at 2 hours vs those in control group at 0 hour were 
determined by Cuffdiff. The fold change is the ratio of Fragments Per Kilobase of exon per Million fragments mapped (FPKM) of the examined group 
compared to FPKM of those genes in the control group. The differentially expressed genes were ranked on their log2 fold change and the 10 genes with 
highest or lowest fold changes are shown here. 
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3.3.6.2 Differentially expressed genes in HBMEC at 6 hours incubation: 
Based on the level of gene expression in TNFα-stimulated HBMEC incubated with 
IT4var14 parasite at 6 hours co-culture, there were 88 significantly expressed genes 
were detected in this current study. Of these genes 17% were identified as up 
regulated genes and 83% were down regulated genes. Among the top ten up and 
down regulated genes (Figure 3.6), the greatest fold change was observed with the 
complement component 3 (C3) in up regulated genes with approximately 121-fold 
change, while the lowest fold change in the same group was phospholipase A2 group 
IVA (PLA2G4A) with about 2.5-fold change. On the other hand, inhibitor of DNA 
binding 2, dominant negative helix-loop-helix protein (ID2) and AQP1 stand out as 
the top two most down regulated genes, respectively. ID2 was down regulated by -
18-fold change, whereas AQP1 was down regulated by -14-fold change. Appendix 4 
shows more information about the top ten up and down regulated genes. 
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Figure 3.6: Top 10 up/down regulated genes in TNF-stimulated HBMEC incubated with IT4var14 parasite at 6 hours co-culture. 
The differentially expressed genes in TNF-stimulated HBMEC co-cultured with IT4var14 parasite isolate at 6 hours vs those in control group at 0 hour were 
determined by Cuffdiff. The fold change is the ratio of Fragments Per Kilobase of exon per Million fragments mapped (FPKM) of the examined group 
compared to FPKM of those genes in the control group. The differentially expressed genes were ranked on their log2 fold change and the 10 genes with 
highest or lowest fold changes are shown here. 
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3.3.6.3 Differentially expressed genes in HBMEC at 20 hours incubation: 
In total of 226 differentially expressed genes were identified (log2 fold change >1, 
FDR value <0.05) in TNFα-stimulated HBMEC after co-culturing with IT4var14 
parasite at 20 hours co-culture. These included 25% up regulated and 75% down 
regulated genes. Also, 10% of genes showed a >2 log2 fold change of expression 
level. The fold change expression among the top ten up regulated genes varies from 5 
to 12, and the most robust up regulated gene was observed for cytochrome P450 
family 1 subfamily A member 1 (CYP1A1) which showed 12-fold change more 
expression (Figure 3.7). The fold change among the top ten down regulated genes 
varies from -4 to -41, and consistent with the finding that noggin (NOG) and ID2 are 
the top two regulated genes (Figure 3.7). More details about the top ten up and down 
regulated genes are shown in appendix 5. 
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Figure 3.7: Top 10 up/down regulated genes in TNF-stimulated HBMEC incubated with IT4var14 parasite at 20 hours co-culture. 
The differentially expressed genes in TNF-stimulated HBMEC co-cultured with IT4var14 parasite isolate at 20 hours vs those in control group at 0 hour were 
determined by Cuffdiff. The fold change is the ratio of Fragments Per Kilobase of exon per Million fragments mapped (FPKM) of the examined group 
compared to FPKM of those genes in the control group. The differentially expressed genes were ranked on their log2 fold change and the 10 genes with 
highest or lowest fold changes are shown here. 
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3.3.7 Visualization of different expression genes: 
A heatmap was used in this study to present the genes of HBMEC/TNF with high 
and low expression levels over different time points (2, 6 and 20 hours) that were 
incubated with the IT4var14 parasite. Several genes were differentially expressed 
over the time of co-culture from 2 to 20 hours, either increased such as CYP1A1 and 
DUSP1 or decreased like EBI3 and HEY2 (Figure 3.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Each column represents the incubation time of TNF-stimulated HBMEC with 
IT4var14parasite and each row represents 1 gene. PRBC indicates the P. falciparum infected 
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Figure 3.8: Heatmap of differentially expressed genes of HBMEC/TNF co-
cultured with IT4var14 parasite at 2, 6 and 20 hours. 
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erythrocyte. Green and red indicate expression levels above and below the mean for each 
gene, respectively. 
 
3.3.8 Functional analysis of differentially expressed genes: 
To functionally categorise differentially expressed genes of HBMEC/TNF in 
response to IT4var14 parasite at 2, 6 and 20 hours, GO analysis was performed on 
both up and down regulated genes separately. The GO data were categorised based 
on biological process, molecular function and cellular component categorise with P 
value <0.05. 
At 2 hours of incubation, the biological process ontology found that positive 
regulation of cell migration was enriched in the up regulated genes list, while 
regulation of transcription from RNA polymerase II promoter were enriched in down 
regulated genes. With regards to molecular function, the results indicate increased 
cytokine activity and decreased protein binding and transcription factor binding. In 
terms of the cellular component, extracellular space (a space that separates one cell 
membrane from another) was found associated with up regulated genes. Four terms 
are specific to down regulated genes, which are nucleus, cytoplasm, nucleoplasm and 
extracellular space (Table 3.4).  
Table 3.4: Functions analysis enrichment result at 2 hours incubation. 
Biological Process – Up Regulated Genes: 
Go term 
Size P-value FDR 
Positive regulation of cell migration 3 2.5E-2 2.8E1 
 
Biological Process – Down Regulated Genes: 
Go term 
Size P-value FDR 
Positive regulation of transcription from RNA 
polymerase II promoter 16 7.5E-8 1.2E-4 
Negative regulation of transcription from RNA 
polymerase II promoter 12 6.4E-6 9.8E-3 
Response to muscle stretch 4 1.5E-5 2.4E-2 
Ventricular septum morphogenesis 4 8.1E-5 1.2E-1 
Transforming growth factor beta receptor 5 1.5E-4 2.4E-1 
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signaling pathway 
Cellular response to calcium ion 4 4.4E-4 6.7E-1 
Peptidyl-threonine dephosphorylation 3 4.5E-4 6.9E-1 
Endoderm formation 3 5.4E-4 8.2E-1 
Negative regulation of ERK1 and ERK2 
cascade 4 6.4E-4 9.8E-1 
Somatic stem cell population maintenance 4 9.0E-4 1.4E0 
MAPK cascade 6 9.5E-4 1.5E0 
Intracellular signal transduction 7 1.1E-3 1.7E0 
Cellular response to retinoic acid 4 1.2E-3 1.8E0 
Response to lipopolysaccharide 5 1.3E-3 2.0E0 
Negative regulation of myeloid cell 
differentiation 3 1.2E-3 1.9E0 
Cellular response to glucocorticoid stimulus 3 1.5E-3 2.3E0 
Regulation of sequence-specific DNA binding 
transcription factor activity 3 2.4E-3 3.6E0 
Inactivation of MAPK activity 3 2.4E-3 3.6E0 
Negative regulation of DNA binding 3 3.0E-3 4.5E0 
Negative regulation of transcription, DNA-
templated 7 3.2E-3 4.7E0 
Negative regulation of Notch signaling pathway 3 3.2E-3 4.8E0 
Cell maturation 3 4.9E-3 7.3E0 
Positive regulation of cell differentiation 3 5.2E-3 7.7E0 
Positive regulation of tyrosine phosphorylation 
of Stat3 protein 3 5.5E-3 8.1E0 
Cellular response to hormone stimulus 3 7.6E-3 1.1E1 
Outflow tract morphogenesis 3 8.0E-3 1.2E1 
Response to camp 3 8.0E-3 1.2E1 
Skeletal muscle cell differentiation 3 9.0E-3 1.3E1 
Response to progesterone 3 9.4E-3 1.3E1 
Positive regulation of fibroblast proliferation 3 1.1E-2 1.5E1 
Positive regulation of smooth muscle cell 
proliferation 3 1.3E-2 1.8E1 
Cell migration 4 1.4E-2 1.9E1 
Response to cytokine 3 1.2E-2 1.7E1 
70 
Cell chemotaxis 3 1.5E-2 2.1E1 
Response to insulin 3 1.6E-2 2.2E1 
Transcription from RNA polymerase II 
promoter 6 1.6E-2 2.2E1 
Regulation of cell proliferation 4 1.7E-2 2.3E1 
Positive regulation of transcription, DNA-
templated 6 1.7E-2 2.3E1 
Negative regulation of cysteine-type 
endopeptidase activity involved in apoptotic 
process 
3 1.7E-2 2.3E1 
Liver development 3 2.0E-2 2.6E1 
Palate development 3 2.1E-2 2.7E1 
Negative regulation of inflammatory response 3 2.2E-2 2.9E1 
Dephosphorylation 3 2.6E-2 3.3E1 
Angiogenesis 4 2.7E-2 3.4E1 
Negative regulation of cell proliferation 5 2.8E-2 3.5E1 
Negative regulation of protein kinase activity 3 3.4E-2 4.1E1 
Peptidyl-tyrosine dephosphorylation 3 3.4E-2 4.1E1 
Cell-cell signaling 4 3.8E-2 4.5E1 
Activation of MAPK activity 3 3.9E-2 4.6E1 
Cellular response to tumor necrosis factor 3 4.1E-2 4.7E1 
Chemotaxis 3 4.9E-2 5.4E1 
 
Cellular Component – Up Regulated Genes: 
Go term 
Size P-value FDR 
Extracellular space 9 2.4E-4 2.2E-1 
Cell cortex 3 1.2E-2 1.1E1 
Extracellular region 7 1.6E-2 1.4E1 
 
Cellular Component – Down Regulated 
Genes: 
Go term 
Size P-value FDR 
Nucleus 30 1.9E-5 2.0E-2 
Nucleoplasm 16 5.1E-3 5.4E0 
Extracellular space 10 9.6E-3 9.9E0 
Cytoplasm 23 1.2E-2 1.2E1 
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Molecular Function – Up Regulated Genes: 
Go term 
Size P-value FDR 
cytokine activity 3 1.9E-2 1.8E1 
 
Molecular Function – Down Regulated 
Genes: 
Go term 
Size P-value FDR 
Transcription factor binding 7 2.0E-4 3.1E-2 
Transcription factor activity, sequence-specific 
DNA binding 11 4.9E-4 3.8E-2 
MAP kinase tyrosine/serine/threonine 
phosphatase activity 3 6.8E-4 3.5E-2 
Sequence-specific DNA binding 8 8.5E-4 3.4E-2 
Transcription factor activity, RNA polymerase 
II core promoter proximal region sequence-
specific binding 
3 2.3E-3 7.2E-2 
Protein binding 29 4.5E-3 1.1E-1 
Transcriptional activator activity, RNA 
polymerase II core promoter proximal region 
sequence-specific binding 
4 3.3E-2 4.9E-1 
Protein tyrosine phosphatase activity 3 3.6E-2 4.8E-1 
Transcriptional repressor activity, RNA 
polymerase II core promoter proximal region 
sequence-specific binding 
3 4.4E-2 5.1E-1 
 
Enriched functions of up and down regulated genes are listed in the table and separated into 
3 GO term categories (biological process, molecular function and cellular component). Size, 
number of expressed genes associated with the term. FDR, False discovery rate.  
 
 
For the HBMEC/TNF response to iRBC exposure at 6 hours, the biological process 
of up regulated genes demonstrated that members belonging to cell proliferation and 
proteolysis were more abundant. On the other hand, among down regulated genes in 
the same category, genes involved mostly in regulation of transcription, regulation of 
apoptotic process and regulation of Notch signalling pathway were in greater 
number. In the molecular function category, the majority of low expressed genes 
were involved in protein and DNA binding function. With respect to the cellular 
component, extracellular space was associated with up regulated genes. However, 
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cytoplasm, nucleus, nucleoplasm and cytosol were found as the most abundant terms 
in down regulated genes (Table 3.5). 
Table 3.5: Functions analysis enrichment result at 6 hours incubation. 
Biological Process – Up Regulated Genes: 
Go term 
Size P-value FDR 
Positive regulation of cell proliferation 3 3.8E-2 3.7E1 
Proteolysis 3 3.8E-2 3.7E1 
 
Biological Process – Down Regulated Genes: 
Go term 
Size P-value FDR 
Negative regulation of transcription from RNA 
polymerase II promoter 16 1.1E-10 1.7E-7 
Positive regulation of transcription from RNA 
polymerase II promoter 14 4.8E-7 1.6E-4 
Negative regulation of Notch signaling 
pathway 5 7.7E-7 1.7E-4 
Ventricular septum morphogenesis 4 5.1E-5 8.2E-3 
Transforming growth factor beta receptor 
signaling pathway 5 8.4E-5 1.1E-2 
Bicarbonate transport 4 1.8E-4 1.9E-2 
Notch signaling pathway 5 1.9E-4 1.8E-2 
Negative regulation of transcription, DNA-
templated 8 2.2E-4 1.7E-2 
Notch signaling involved in heart development 3 2.2E-4 1.6E-2 
Pulmonary valve morphogenesis 3 2.7E-4 1.7E-2 
Response to hydrogen peroxide 4 3.7E-4 2.1E-2 
Negative regulation of sequence-specific DNA 
binding transcription factor activity 4 5.2E-4 2.8E-2 
Oxygen transport 3 6.3E-4 3.1E-2 
Response to muscle stretch 3 8.1E-4 3.7E-2 
Labyrinthine layer blood vessel development 3 9.1E-4 3.9E-2 
BMP signaling pathway 4 9.4E-4 3.7E-2 
Negative regulation of apoptotic process 7 1.0E-3 3.7E-2 
Hydrogen peroxide catabolic process 3 1.1E-3 4.0E-2 
Artery morphogenesis 3 1.4E-3 4.6E-2 
Positive regulation of transcription, DNA-
templated 7 1.7E-3 5.3E-2 
Metanephros development 3 2.1E-3 6.2E-2 
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Positive regulation of cell death 3 2.7E-3 7.7E-2 
Ureteric bud development 3 4.1E-3 1.1E-1 
Negative regulation of osteoblast 
differentiation 3 4.7E-3 1.2E-1 
Negative regulation of BMP signaling pathway 3 5.7E-3 1.3E-1 
Skeletal muscle cell differentiation 3 6.9E-3 1.5E-1 
Response to progesterone 3 6.9E-3 1.5E-1 
Positive regulation of apoptotic process 5 7.6E-3 1.6E-1 
Response to cytokine 3 8.9E-3 1.8E-1 
Transcription from RNA polymerase II 
promoter 6 9.0E-3 1.7E-1 
SMAD protein signal transduction 3 1.1E-2 1.9E-1 
Cellular response to organic cyclic compound 3 1.1E-2 1.9E-1 
Cellular oxidant detoxification 3 1.2E-2 2.0E-1 
Cellular response to retinoic acid  3 1.4E-2 2.2E-1 
Protein heterooligomerization  3 1.4E-2 2.2E-1 
Regulation of apoptotic process  4 1.6E-2 2.4E-1 
Cellular response to interleukin-1  3 1.8E-2 2.5E-1 
Angiogenesis  4 1.9E-2 2.5E-1 
Transcription, DNA-templated  11 2.0E-2 2.6E-1 
Neuron differentiation  3 2.6E-2 3.0E-1 
Cellular response to tumor necrosis factor  3 3.1E-2 3.4E-1 
Nervous system development  4 3.5E-2 3.5E-1 
Regulation of cell cycle  3 3.8E-2 3.7E-1 
Negative regulation of gene expression  3 4.7E-2 4.2E-1 
 
Molecular Function – Down Regulated 
Genes: 
Go term 
Size P-value FDR 
Transcription factor activity, sequence-specific 
DNA binding  14 1.9E-7 2.4E-5 
Transcription factor binding  9 2.9E-7 1.9E-5 
Haptoglobin binding  3 1.7E-5 7.1E-4 
Transcription regulatory region DNA binding  6 1.5E-4 4.6E-3 
Transcriptional activator activity, RNA 6 2.2E-4 5.6E-3 
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polymerase II core promoter proximal region 
sequence-specific binding  
Oxygen transporter activity  3 5.0E-4 1.1E-2 
R-SMAD binding  3 1.1E-3 2.1E-2 
Peroxidase activity  3 1.2E-3 2.0E-2 
Sequence-specific DNA binding  7 1.3E-3 1.9E-2 
Histone deacetylase binding  4 2.0E-3 2.5E-2 
Protein binding  25 2.2E-3 2.5E-2 
Protein dimerization activity  4 5.4E-3 5.2E-2 
Oxygen binding  3 5.6E-3 5.0E-2 
Heme binding  3 4.2E-2 2.3E-1 
 
Cellular Component – Up Regulated Genes: 
Go term 
Size P-value FDR 
Extracellular space 4 4.4E-2 3.2E1 
 
Cellular Component – Down Regulated 
Genes: 
Go term 
Size P-value FDR 
Haptoglobin-hemoglobin complex  3 3.1E-5 2.0E-3 
Cytoplasm  25 1.1E-4 3.6E-3 
Nucleus  25 2.1E-4 4.5E-3 
Nucleoplasm  17 2.7E-4 4.4E-3 
Hemoglobin complex  3 3.4E-4 4.4E-3 
Endocytic vesicle lumen  3 6.1E-4 6.6E-3 
Transcription factor complex  5 1.1E-3 1.0E-2 
Blood microparticle  3 4.4E-2 2.8E-1 
Cytosol  13 7.8E-2 4.1E-1 
 
Enriched functions of up and down regulated genes are listed in the table and separated into 
3 GO term categories (biological process, molecular function and cellular component). Size, 
number of expressed genes associated with the term. FDR, False discovery rate.  
 
 
With regards to co-culturing the HBMEC/TNF with the IT4var14 parasite at 20 
hours, several GO terms were explored with both up and down regulated genes. In 
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the biological process category, highly expressed genes were found involved in cell 
chemotaxis, inflammatory response, immune response and cell adhesion. Whereas, 
low expressed genes were strongly associated with regulation of transcription, DNA-
templet, regulation of transcription from RNA polymerase II promoter and cell 
division. Molecular function terms demonstrated that chemokine activity was the 
only term identified in the up regulated genes. Most of the down regulated genes 
were involved in protein binding and DNA binding. In terms of the cellular 
component category, only 3 terms were specific to up regulated genes, which were 
plasma membrane, extracellular space and extracellular region. However, down 
regulated genes were found mostly associated with nucleus, cytoplasm, nucleoplasm, 
cytosol and membrane (Table 3.6). 
Table 3.6: Functions analysis enrichment result at 20 hours incubation. 
Biological Process – Up Regulated Genes: 
Go term 
Size P-value FDR 
Cell chemotaxis  5 1.5E-5 6.0E-3 
Chemokine-mediated signaling pathway  5 2.2E-5 4.3E-3 
Chemotaxis  5 1.8E-4 2.4E-2 
Lymphocyte chemotaxis  3 1.9E-3 1.7E-1 
Cellular response to tumor necrosis factor  4 2.1E-3 1.5E-1 
Monocyte chemotaxis  3 4.3E-3 2.5E-1 
Response to hypoxia  4 7.4E-3 3.4E-1 
Cellular response to interferon-gamma  3 7.7E-3 3.2E-1 
Response to mechanical stimulus  3 8.3E-3 3.1E-1 
Positive regulation of gtpase activity  6 9.5E-3 3.2E-1 
Regulation of blood pressure  3 1.0E-2 3.0E-1 
Neutrophil chemotaxis  3 1.0E-2 2.9E-1 
Cellular response to drug  3 1.1E-2 2.9E-1 
Inflammatory response  5 1.1E-2 2.8E-1 
Cellular response to interleukin-1  3 1.2E-2 2.7E-1 
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Positive regulation of inflammatory response  3 1.2E-2 2.7E-1 
Immune response  5 1.6E-2 3.0E-1 
Cell adhesion  5 2.1E-2 3.5E-1 
 
Biological Process – Down Regulated Genes: 
Go term 
Size P-value FDR 
Cell division  16 6.8E-9 1.1E-5 
Negative regulation of transcription from RNA 
polymerase II promoter  20 1.5E-7 2.3E-4 
Negative regulation of transcription, DNA-
templated  15 3.8E-6 6.0E-3 
Mitotic nuclear division  11 4.5E-6 7.1E-3 
Ventricular septum morphogenesis  5 3.4E-5 5.4E-2 
Positive regulation of transcription from RNA 
polymerase II promoter  19 5.1E-5 8.0E-2 
Sister chromatid cohesion  7 5.3E-5 8.4E-2 
Negative regulation of pathway-restricted 
SMAD protein phosphorylation  4 5.5E-5 8.6E-2 
Chromosome segregation  6 7.6E-5 1.2E-1 
Positive regulation of transcription, DNA-
templated  13 1.2E-4 1.9E-1 
Negative regulation of BMP signaling pathway  5 2.0E-4 3.1E-1 
Transforming growth factor beta receptor 
signaling pathway  6 3.2E-4 5.0E-1 
G1/S transition of mitotic cell cycle  6 5.1E-4 8.0E-1 
Negative regulation of sequence-specific DNA 
binding transcription factor activity  5 6.0E-4 9.4E-1 
Somatic stem cell population maintenance  5 8.1E-4 1.3E0 
Mitotic spindle organization  4 9.3E-4 1.5E0 
Notochord development  3 1.4E-3 2.2E0 
Notch signaling involved in heart development  3 1.4E-3 2.2E0 
Regulation of mitotic metaphase/anaphase 
transition  3 1.4E-3 2.2E0 
BMP signaling pathway  5 1.5E-3 2.3E0 
Mitotic metaphase plate congression  4 1.7E-3 2.7E0 
Protein localization to kinetochore  3 1.8E-3 2.8E0 
Pulmonary valve morphogenesis  3 1.8E-3 2.8E0 
Ureteric bud development  4 1.9E-3 2.9E0 
Negative regulation of osteoblast 
differentiation  4 2.0E-3 3.1E0 
Cellular response to peptide  3 2.2E-3 3.4E0 
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Positive regulation of astrocyte differentiation  3 2.2E-3 3.4E0 
Cell proliferation  9 2.5E-3 3.9E0 
Forebrain development  4 3.2E-3 5.0E0 
Positive regulation of cellular protein 
metabolic process  3 4.1E-3 6.3E0 
Regulation of G1/S transition of mitotic cell 
cycle  3 4.6E-3 7.1E0 
Labyrinthine layer blood vessel development  3 6.5E-3 9.8E0 
Positive regulation of gene expression  7 6.9E-3 1.0E1 
Artery morphogenesis  3 7.9E-3 1.2E1 
Peptidyl-serine phosphorylation  5 8.6E-3 1.3E1 
Positive regulation of cardiac muscle cell 
proliferation  3 8.7E-3 1.3E1 
Negative regulation of apoptotic process  9 9.1E-3 1.3E1 
Cellular response to drug  4 1.0E-2 1.5E1 
Positive regulation of erythrocyte 
differentiation  3 1.0E-2 1.5E1 
Transcription, DNA-templated  22 1.2E-2 1.8E1 
Metanephros development  3 1.3E-2 1.9E1 
Mesoderm formation  3 1.4E-2 2.0E1 
Ventricular septum development  3 1.4E-2 2.0E1 
Regulation of cell growth  4 1.5E-2 2.1E1 
Negative regulation of Notch signaling 
pathway  3 1.5E-2 2.1E1 
Microtubule-based movement  4 1.5E-2 2.2E1 
DNA replication  5 1.8E-2 2.5E1 
DNA replication initiation  3 1.8E-2 2.5E1 
Cell maturation  3 2.2E-2 3.0E1 
Male gonad development  4 2.3E-2 3.0E1 
Positive regulation of cytokinesis  3 2.4E-2 3.1E1 
Cellular response to hypoxia  4 2.4E-2 3.2E1 
Peptidyl-threonine phosphorylation  3 2.5E-2 3.3E1 
Osteoblast differentiation  4 3.0E-2 3.8E1 
Positive regulation of nitric oxide biosynthetic 
process  3 3.1E-2 3.9E1 
Outflow tract morphogenesis  3 3.5E-2 4.3E1 
Notch signaling pathway  4 3.8E-2 4.6E1 
Negative regulation of cell proliferation  7 4.3E-2 5.0E1 
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Positive regulation of apoptotic process  6 4.4E-2 5.1E1 
Transcription from RNA polymerase II 
promoter  8 4.8E-2 5.4E1 
Negative regulation of neuron differentiation  3 5.0E-2 5.6E1 
 
Molecular Function – Up Regulated Genes: 
Go term 
Size P-value FDR 
Chemokine activity 4 2.0E-4 2.3E-1 
 
Molecular Function – Down Regulated 
Genes: 
Go term 
Size P-value FDR 
Protein binding  83 6.2E-8 1.5E-5 
Transcription factor activity, sequence-specific 
DNA binding  20 7.5E-6 9.2E-4 
Transcription factor binding  10 7.5E-5 6.1E-3 
Transcription regulatory region DNA binding  8 3.9E-4 2.4E-2 
Chromatin binding  9 3.2E-3 1.5E-1 
ATP-dependent microtubule motor activity, 
plus-end-directed  3 5.0E-3 1.8E-1 
Transcriptional repressor activity, RNA 
polymerase II core promoter proximal region 
sequence-specific binding  
5 5.3E-3 1.7E-1 
Atpase activity  6 5.9E-3 1.7E-1 
Histone binding  5 7.3E-3 1.8E-1 
Peroxidase activity  3 8.3E-3 1.8E-1 
Microtubule motor activity  4 1.4E-2 2.5E-1 
Protein dimerization activity  5 1.5E-2 2.4E-1 
Histone deacetylase binding  4 2.6E-2 3.5E-1 
DNA binding  18 3.2E-2 3.7E-1 
RNA polymerase II transcription factor binding  3 3.5E-2 3.9E-1 
Transcription corepressor activity  5 3.9E-2 4.0E-1 
Protein homodimerization activity  10 4.0E-2 3.9E-1 
Microtubule binding  5 4.2E-2 3.9E-1 
Protein domain specific binding  5 4.2E-2 3.9E-1 
ATP binding  16 4.7E-2 4.1E-1 
RNA polymerase II core promoter sequence-
specific DNA binding  3 5.0E-2 4.2E-1 
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Cellular Component – Up Regulated Genes: 
Go term 
Size P-value FDR 
Extracellular space 11 5.1E-4 5.5E-1 
Extracellular region 9 2.2E-2 2.1E1 
Plasma membrane 16 2.4E-2 2.3E1 
 
Cellular Component – Down Regulated 
Genes: 
Go term 
Size P-value FDR 
Nucleoplasm 48 4.3E-12 5.2E-9 
Nucleus  64 1.6E-9 1.9E-6 
Cytoplasm  52 5.8E-5 7.0E-2 
Condensed chromosome outer kinetochore  3 9.9E-4 1.2E0 
Midbody  6 1.1E-3 1.3E0 
Nuclear chromatin  7 1.1E-3 1.3E0 
Transcription factor complex  7 1.1E-3 1.3E0 
Kinetochore  5 1.5E-3 1.7E0 
Cytosol  34 1.7E-3 2.1E0 
Condensed chromosome kinetochore  5 1.9E-3 2.3E0 
Spindle microtubule  4 2.4E-3 2.8E0 
Kinesin complex  4 4.0E-3 4.7E0 
Transcriptional repressor complex  4 4.5E-3 5.2E0 
Spindle midzone  3 5.8E-3 6.7E0 
Protein complex  8 1.2E-2 1.4E1 
Centrosome  8 1.5E-2 1.6E1 
Membrane  22 2.2E-2 2.3E1 
Spindle pole  4 2.8E-2 2.9E1 
Chromosome, centromeric region  3 4.6E-2 4.4E1 
 
Enriched functions of up and down regulated genes are listed in the table and separated into 
3 GO term categories (biological process, molecular function and cellular component). Size, 
number of expressed genes associated with the term. FDR, False discovery rate.  
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3.3.9 Pathway analysis of differentially expressed genes: 
The GO database does not cover every biological aspect of different regulated genes 
and several GO classes overlap with each other. The Reactome pathway enrichment 
analysis was used in order to illustrate selected sets of differentially expressed genes 
in HBMEC/TNF incubated with P. falciparum IT4var14 at 2, 6 and 20 hours in 
particular pathways. 
The study identified 59 host response pathways that were significantly up regulated 
in response to IT4var14 parasite in HBMEC/TNF (P <0.05 and at least 3 input 
genes) at 2 hours. The most affected pathways of the up regulated genes were 
immune system followed by cytokine signalling in the immune system (8 and 7 
genes respectively (Figure 3.9). On the basis of pathways of down regulated genes, 
100 host response pathways were identified for this time point of co-culture. The 
highly significant pathways in terms of numbers of genes were signal transduction 
and the immune system (Figure 3.9). 
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Figure 3.9: Top ten pathways of up and down regulated genes of HBMEC/TNF 
responding to iRBC at 2 hours. 
A) pathways of up regulated genes and B) pathways of down regulated genes. The pathways 
were selected according to the number of genes and P value <0.05. Values associated with 
each pathway represent the number of genes. 
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At 6 hours of incubation, only 2 pathways were observed with highly expressed 
genes, both of which are associated with the immune system (Table 3.7). In contrast, 
18 pathways were found associated with low expressed genes. The most significant 
pathways of the down regulated genes in terms of numbers of genes were signal 
transduction, the citric acid (TCA) cycle and respiratory electron transport and 
signalling by NOTCH1 (Figure 3.10). 
Table 3.7: pathways of up regulated genes of HBMEC responded to P. 
falciparum and TNF exposure at 6 hours. 
Rank Pathway name No. of genes P value 
1 Innate Immune System 4 1.87E-2 
2 Immune System 5 3.91E-2 
 
The pathways were selected based on number of genes and P value <0.05. 
 
 
 
Figure 3.10:  Top ten pathways of down regulated genes of HBMEC/TNF 
responding to iRBC at 6 hours. 
The pathways were selected according to numbers of genes and P value <0.05. Values 
associated with each pathway represent the number of genes. 
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The pathway analysis identified 22 and 73 pathways of up regulated and down 
regulated genes respectively at 20 hours of co-culture. Extracellular matrix 
organisation and developmental biology were found as top pathways of up regulated 
genes (Figure 3.11). However, signal transduction and the cell cycle were the 
majority of down regulated genes at this time point, with 49 and 34 genes 
respectively (Figure 3.11). 
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Figure 3.11: Top ten pathways of up and down regulated genes of HBMEC/TNF 
responding to iRBC at 20 hours. 
A) pathways of up regulated genes and B) pathways of down regulated genes. The pathways 
were selected according to number of genes and P value <0.05. Values associated with each 
pathway represent the number of genes. 
 
 
 
Signal	Transduction,	
49
Cell	Cycle,	Mitotic,	 34
Cell	Cycle,	34M	Phase,	21
Signaling	by	Rho	
GTPases,	20
RHO	GTPase	
Effectors,	 17
Mitotic	 Anaphase,	16
Mitotic	 Metaphase	
and	Anaphase,	16
Mitotic	
Prometaphase,	 15
Resolution	 of	Sister	
Chromatid	 Cohesion,	
14
B
Extracellular	 matrix	
organization,	 10
Developmental	
Biology,	 9
Non-integrin	
membrane-ECM	
interactions,	 7
NCAM	signaling	for	
neurite	 out-growth,	 7
Axon	guidance,	7
Degradation	 of	the	
extracellular	 matrix,	 6
Integrin	cell	surface	
interactions,	 6
Chemokine	receptors	
bind	chemokines,	 5
ECM	proteoglycans,	 5
Class	A/1	(Rhodopsin-
like	receptors),	 5
A
85 
3.3.10 Validation of seven differentially regulated gene by qRT-PCR: 
To validate the results of the RNA-seq in this study using an alternative method, we 
performed a qRT-PCR experiment to measure the expression of seven selected 
genes. In RNA-seq data, LAMC2, PLA2G4A and VCAM-1 were up regulated by 
5.7, 2.48 and 1.26-fold change respectively, whereas; ID2, AQP1, HBA2 and 
NFKBIA were down regulated by-17.75, -14.44, -6 and -2.21-fold change 
respectively. In qRT-PCR data, these corresponding numbers in up regulated genes 
were 4.19, 1.82 and 1.43-fold change respectively, while; in down regulated genes 
were -16.69, -16.64, -3.5 and -1.95-fold change respectively (Figure 3.12). The 
results of these seven genes examined by RNA-seq and qRT-PCR were in a good 
agreement, which corroborates our RNA-seq outputs. 
 
Figure 3.12: qRT-PCR validation of seven differentially expressed genes from 
HBMEC/TNF responding to IT4var14 iRBC at 6 hours co-culture.  
The scatter plot shows the fold changes of the seven genes determined from the qRT-PCR 
were compared to those detected by RNA-seq. Replicates (n=3) of each sample were run in 
qRT-PCR.  
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3.4 Discussion: 
Cerebral malaria pathogenesis is known to be associated with sequestration of P. 
falciparum iRBC in the brain microvasculature, resulting in immunomodulatory 
interactions and complex cellular responses, including co-regulators such as adhesion 
molecules and cytokines. The pathophysiological mechanisms of CM are not yet 
completely understood. The role of the endothelial cells in the CM pathogenicity was 
investigated previously using microarray technique (Chakravorty et al., 2007, 
Tripathi et al., 2009). However, there is still a need to further investigate the role of 
the brain endothelial cell in disease with more sensitive next generation sequencing 
techniques such as RNA-seq. To better understand the responses of the brain 
endothelium to interaction with P. falciparum iRBC after stimulation with the 
cytokine TNF, we performed the global transcriptional profile of the HBMEC after 
exposure with IT4var14 parasite isolate at 2, 6 and 20 hours. In addition, we 
investigated the functional and pathway analysis of the differentially expressed genes 
under the same conditions. 
Our study provides the first comprehensive insight into the transcriptome of human 
brain microvascular endothelial cells co-cultured with an ICAM-1 binding parasite 
line using RNA-seq, a powerful next generation sequencing platform, since a 
literature search for PubMed database with key words of cerebral malaria, HBMEC 
and RNA-seq retrieves zero records as of March 2017. 
In order to obtain parasite and EC at high quality for the co-culturing experiments, 
we monitored for the presence of mycoplasma contamination in parasite and brain 
endothelial cells, the binding of the IT4var14 parasite to ICAM-1 and CD36 proteins 
using static adhesion assays and the expression of ICAM-1 before and after TNF 
stimulation by FACS prior to setting up the co-cultures.  
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The first important step to obtain a good RNA sequencing is extraction of the RNA 
with high quality (RIN>8) (Bettscheider et al., 2011). Our RNA samples isolated 
from the co-culture experiments at 0, 2, 6 and 20 hours were observed to have RIN 
values more than (8.5), and that supports the robustness of our RNA-seq results. To 
investigate the quality of the RNA-seq raw data, we used the FastQC tool, and all the 
data of RNA-seq have passed all aspects of the sequence quality measures. The 
average of the total number of reads that were produced from each sample was 
27,198,576, which is enough to deliver sufficient sequence coverage for genome-
wide transcriptome profiling based to a pervious report by Sultan et al. (Sultan et al., 
2008). Our average of 92.1% total sequences that mapped to human reference 
genome met the standards of the quality of the RNA-seq technique (Mortazavi et al., 
2008). 
In this section, genes identified by the RNA-seq data from human brain endothelial 
cells after TNF stimulation exposed to IT4var14 parasite for 2, 6 and 20 hours will 
be discussed according to their functions and pathways. There are numerous reasons 
for selecting these time points in our co-culture model: First, the expression of 
ICAM-1 protein on human brain endothelial cells is significantly increased after 1 
hour of incubation with P. falciparum iRBC and TNF, thus increasing the probability 
of parasite sequestration to the host cell. Second, the maximum level of ICAM-1 
expression was observed at 6 hours of co-culture between malaria parasites and TNF 
induced human brain endothelial cells (Tripathi et al., 2006). Third, we hypothesised 
that at 20 hours of co-incubation, the IT4var14 parasite will be at a mature 
trophozoite stage, and some of the iRBCs will be ruptured and release several soluble 
molecules that may affect the host cells genes expression. The discussion will mainly 
focus on major pathways including immune system at 2 hours of co-culture; immune 
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system, arachidonic acid, pro-apoptotic as well as anti-apoptotic processes at 6 hours 
of incubation; and briefly, immune system and cell cycle at 20 hours of exposure.  
We observed significant up regulation of 33 HBMEC genes and down regulation of 
76 genes in response to P. falciparum and TNF exposure at 2 hours. Functional and 
pathways analysis of differentially regulated genes revealed impact on several 
substantial biological pathways. Among the up regulated genes were molecules 
belonging to the immune system (Table 3.8); whereas, the down regulated genes also 
belonged to immune system (Table 3.9). 
Table 3.8: Up regulated expression of selected genes representing specific 
pathways in HBMEC co-cultured with IT4var14 parasite and TNF at 2 hours, 
such as immune system. 
GO term Genes symbol Fold change 
Immune system 
IL32 3.24 
EBI3 5.3 
CTSK 4.65 
 
The table illustrates fold changes in HBMEC response to infected red blood cells and TNF, 
compare with control. 
 
Table 3.9: Down regulated expression of selected genes representing specific 
pathways in HBMEC co-cultured with IT4var14 parasite and TNF at 2 hours, 
such as immune system. 
GO term Genes symbol Fold change 
Immune system 
CCL2 -4.1 
CXCL1 -2.1 
FOS -4.71 
 
The table illustrates fold changes in HBMEC response to infected red blood cells and TNF, 
compare with control. 
 
Our study demonstrated an increase in mRNA for IL32, which was more than 3-fold 
change. IL32 is a cytokine that can induce proinflammatory mediators and further 
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contribute to autoimmune diseases (Heinhuis et al., 2012). A study by Netea et al 
found that stimulation of whole blood with Mycobacterium tuberculosis can induce 
the production of IL32 (Netea et al., 2006). Furthermore, it was reported that 
expression of IL32 increased in virus infections such as human immunodeficiency 
virus (HIV) (Rasool et al., 2008) and influenza virus (Li et al., 2008b). The role of 
the IL32 cytokine in CM is still unclear and needs to be investigated. 
Over expression of EBI3 genes have been observed in this study at 2 hours of 
incubation. EBI3 is a soluble α-receptor that consists of 2 fibronectin-like domains 
and is a unit of formation of the IL27 cytokine, which has apro- and anti-
inflammatory functions (Aparicio-Siegmund and Garbers, 2015). Compared with 
another report on endothelial response to malaria interaction, Tripathi et al found that 
EBI3 gene is a NF-kappaB target gene in brain endothelial cells, induced by P. 
falciparum and TNF exposure (Tripathi et al., 2009). Little is known about the effect 
of EBI3 in CM pathogenesis. 
Another overexpressed gene that is involved in immune system pathways at 2 hours 
exposure is the CTSK gene, which was highly activated with around 5-fold change. 
Cathepsin K is a peptidase C1 protein family member that is known to be a 
lysosomal cysteine protease (Chen et al., 2007, Dodds et al., 2001). Several studies 
demonstrated the role of CTSK in the immune system.  Work by Asagiri et al in 
mice suggested that CTSK is required in functions of Toll-like receptor (TLR) 9 in 
dendritic cells (DCs), which play a critical role in recognition of several microbial 
products and stimulation of defence responses (Asagiri et al., 2008). Furthermore, in 
terms of a role for CTSK in TLRs functions, TLRs are an essential part of the innate 
and adaptive immune system and have been suggested as driving the inflammation in 
the periodontitis (Beklen et al., 2008, Xie et al., 2011). Moreover, CTSK also has 
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important functions in the immune system during periapical diseases (Ma et al., 
2013). The role of the CTSK in cerebral malaria requires further investigations. 
In interacting of the IT4var14 malaria strain and TNF with brain endothelial cells at 
2 hours, our findings suggested that the potential role of malaria parasite in activation 
of the immune system in HBMEC during overexpression of the IL32, EBI3 and 
CTSK genes. 
The incubation of IT4var14 parasite isolate and TNF with human brain endothelial 
cells at 2 hours is also associated with reduction in mRNA expression level of 
several candidate genes involved in immune system (Table 3.9). We demonstrated 
that there is a reduction in expression of CCL2 gene by around -4-fold change. CCL2 
or chemokine monocyte chemoattractants protein-1(MCP-1) is considered to be one 
of the strongest chemoattractants for monocytes in inflammation (Ransohoff, 2002, 
De Groot and Woodroofe, 2001). In the brain, it is produced by astrocytes and 
resident microglia, and to some extent by endothelial cells (Glabinski et al., 1996, 
Hanisch, 2002, Harkness et al., 2003).  
In a study curried out by Stamatovic et al to clarify the influences of the CCL2 on 
BBB permeability, it was found that CCL2 induces a significant increase in the BBB 
permeability in in vivo conditions (Stamatovic et al., 2005). Moreover, in an in vitro 
study on mouse brain endothelial cells by Stamatovic et al, they showed that CCL2 
increases the brain endothelial permeability through induction of tight junction 
proteins such as ZO-1, ZO-2, occludin and claudin-5 (Stamatovic et al., 2003). In 
terms of the impact of the CCL2 in malaria disease, Abrams et al showed that 
placental malaria infection associates with induction in expression of CCL2 (Abrams 
et al., 2003). The results from the above studies demonstrate an increase in CCL2 
expression leads to dysfunction of the BBB and hence damaging of the brain cells, 
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whereas our outcomes showed a negative regulation in expression of CCL2 gene and 
that may play a protective role against the CM disease.  
As demonstrated by GO and pathway analysis, we found that the expression of 
CXCL1 gene was decreased by approximately -2-fold change. CXCL1 (also known 
as keratinocyte-derived chemokine, KC) is a chemoattractant for neutrophils, which 
plays an essential role in inflammation (Baggiolini et al., 1989), and has also been 
identified in human as growth-regulated gene-alpha (GROα) (Semple et al., 2010). 
Several studies have revealed the role of CXCL1 in brain, Parasadaniantz and 
Rostene in their study in mouse brain showed that the involvement of CXCL1 in 
neurotransmitter release (Melik-Parsadaniantz and Rostene, 2008). Furthermore, 
CXCL1 seems to be involved in the pathology of human multiple sclerosis (MS) 
(Lund et al., 2004) and also involved in ischemic brain injury during neutrophil 
infiltration in ischemic brain tissue (Emerich et al., 2002).  
Compared with other reports on malaria-endothelial cell responses, Tripathi et al 
observed that CXCL1 as a NF-kappaB target gene was up regulated consistent with 
the crucial role of the endothelial in enhancing leukocyte infiltration at the site of 
parasite sequestration or after sequestration (Tripathi et al., 2009). In contrast, our 
results showed a decrease in expression of this gene and emphasize the role of 
different malaria parasite variants in activation of the human brain endothelial cells 
and also giving a potential role of modulating host defence against the malaria 
parasite infection. 
Another down regulated gene which was involved in immune system pathway in our 
co-culture study at 2 hours was the FOS gene. FOS is known as a metabolic indicator 
and it triggers the overexpression of downstream genes during hypoxia. (Mishra et 
al., 1998). Stimulation of FOS is important for the neuron survival, because it 
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indicates the susceptibility of a particular region of the brain specially when exposed 
to tissue hypoxia (Ness et al., 2008). A study by Ma et al on P. berghei cerebral 
malaria showed that an induction in the expression level of FOS was observed in 
experimental murine P. berghei-induced cerebral malaria (Ma et al., 1997). In 
addition, the first study that was directly linking the expression levels of FOS to 
human malaria disease was carried out by Sobota et al in children aged between 6 
months and 5 years in Bandiagara and found that according to the microarray 
analysis, FOS gene was expressed at higher level in UM cases (Sobota et al., 2016). 
The author concluded that the possible reason for elevation this gene’s expression in 
uncomplicated malaria cases is prolonged suppression of FOS gene following severe 
infection. On the other hand, inhibition of this gene is likely to correlate with neuron 
dysfunction. Further studies should be conducted to clarify the role of this gene in 
human CM disease.  
As a result of interaction the IT4var14 parasite and TNF iRBC to modulate the gene 
expression pathways on host endothelium involved in the immune system as a 
protective role through induction of specific expression genes or pathogenic role 
during reduction of particular genes in HBMEC. 
The most critical time point in our study is a 6 hours incubation, as at this time we 
would expect the highest level of PfEMP-1-dependent iRBC adhesion to ICAM-1 
and thus increase the sequestration level in HBMEC. Our study observed that 15 and 
75 up and down regulation genes respectively were expressed by HBMEC under this 
condition. Analysis of functions and pathways of genes with differential expression 
showed that the significant over-expressed genes were involved in immune system 
pathway and arachidonic acid pathway (Table 3.10), while; the significantly under-
expressed genes were involved in several pathways such as immune system, positive 
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regulation of apoptotic process, negative regulation of apoptotic process 
(Table 3.11).  
Table 3.10: Up regulated expression of selected genes representing specific 
pathways in HBMEC co-cultured with IT4var14 parasite and TNF at 6 hours, 
such as immune system and arachidonic acid pathway. 
GO term Genes symbol Fold change 
Immune system 
C3  121.32 
TXNIP 2.14 
EBI3 4.67 
CTSK 3.9 
Arachidonic acid pathway PLA2G4A 2.45 
 
The table illustrates fold changes in HBMEC response to infected red blood cells and TNF, 
compare with control. 
 
Table 3.11: Down regulated expression of selected genes representing specific 
pathways in HBMEC co-cultured with IT4var14 parasite and TNF at 6 hours, 
such as immune system, Positive regulation of apoptotic process and Negative 
regulation of apoptotic process. 
GO term Genes symbol Fold change 
Immune system 
RELB  -3.17 
EGR1 -3.7 
CCL2 -2.02 
FOS -6.1 
Positive regulation of apoptotic process 
NFKBIA -2.21 
GADD45B -8.2 
ID1 -6.33 
Negative regulation of apoptotic process 
DUSP1 -2.4 
AQP1 -14.44 
ID3 -3.32 
 
The table illustrates fold changes in HBMEC response to infected red blood cells and TNF, 
compare with control. 
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The immune response of the host is considered to be a critical factor in the CM 
pathogenesis. The most significant up regulated gene at 6 hours of co-culture was C3 
with around 121-fold change. Complement component 3 is a central molecule in the 
complement system, it supports the activation of all three complement activation 
pathways; the classical, alternative and lectin pathways. C3 plays particular roles in 
the immune system, providing an immediate response to pathogens, also keeping the 
cascade alert, increasing the amplification of the complement response and assisting 
to coordinate downstream immune responses (Ricklin et al., 2016). Although, C3 is a 
common molecule which activates all three pathways of the complement system, it 
become the target for several viruses that have developed mechanisms against C3 
such as, vaccinia, herpes simplex virus (HSV) type 1 and type 2 (HSV-2) (Sahu et 
al., 1998). 
A study by Lackner et al on mice infected with Plasmodium berghei suggested that 
C1q and C5 as complement factors have roles in the neuropathology of CM, whereas 
C3 did not show any significant alterations in the brain (Lackner et al., 2008). On the 
other hand, our results provide evidence for a highly significant increase in 
expression of C3 on the brain endothelial cells and this may correlate with P. 
falciparum sequestration specifically when compared with the C3 expression at 2 
hours of incubation with IT4var14 parasite and TNF cytokine. Also, the induction of 
C3 expression suggests the role of the host immune response in this neuro-infectious 
disease.  
Another significantly up regulated gene, also involved in the immune response, is 
thioredoxin interacting protein (TXNIP). TXNIP is a vitamin D3-induced gene, an 
inhibitor of the thioredoxin (TRX), mediates inhibition of the proliferation of the cell 
and has a pro-apoptotic function through stimulation of apoptosis signal regulation 
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kinase 1 (ASK1) (Zhou and Chng, 2013). It has been reported its role also in increase 
the oxidative stress as a result of cellular apoptosis (Tobiume et al., 2001). Despite 
the expression of TNXIP in our study being high, it is still not known what the role 
of TXNIP is in the CM disease. 
When comparing the expression of EBI3 and CTSK genes in 2 and 6 hours of 
incubation HBMEC, we observed that the expression of these genes at 6 hours of co-
culture were slightly decreased and this may be explained with gradually increased 
expression of ICAM-1 and sequestration of iRBC on HBMEC, thus a little decrease 
of the immune system in response to increase P. falciparum infection. 
One of the most important observations in our study is induction of the PLA2G4A 
gene. PLA2G4A is a metabolic enzyme which catalyses hydrolysis of membrane 
phospholipids to release arachidonic acid and prostanoid biosynthesis (Hua et al., 
2015) (Figure 3.13). The expression of this gene is up regulated by the NF-kappaB 
pathway, which in turn is modulated by proinflammatory cytokine such as TNF (Lee 
and Burckart, 1998). 
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Figure 3.13: Prostanoid biosynthesis.  
Arachidonic acid (AA) is released from membrane phospholipids by the phospholipases. AA 
is metabolized by COX enzymes to form prostanoids. The COX product PGH2 is further 
metabolized by specific synthases to yield prostaglandins and thromboxane, which bind 
prostanoid receptors to evoke a wide array of biological effects. This figure is adapted from 
(Salvado et al., 2012). 
 
Pappa et al revealed that PLA2G4A is one of the mediators of brain swelling 
associated with CM disease in children (Pappa et al., 2015). Brain swelling has been 
shown to be the strongest predictor of mortality in paediatric CM (Seydel et al., 
2015). Several mechanisms for increased brain volume might exist in clinical cases 
such as CM (Nag et al., 2009), including processes that affect the function of BBB 
(Seydel et al., 2015, Dorovini-Zis et al., 2011, Brown et al., 2001a). There is a 
positive correlation between brain volume and the expression of PLA2G4A. 
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Arachidonic acid, which is released due to activation of PLA2G4A can be a source 
of energy, signalling and possible mediator of inflammation (Pappa et al., 2015). 
Also, arachidonic acid can induce the permeability of HBMEC monolayers by 
prostaglandin E2 stimulation of EP3 and EP4 receptors (Dalvi et al., 2015). The 
potential role of PLA2G4A in CM disease need to be more investigations in the 
future. 
Co-culturing the iRBC with HBMEC and TNF at 6 hours also leads to reduction of 
the expression of multiple significant genes involved in the immune system 
(Table 3.11). At this time point we demonstrated reduction of RELB gene expression 
with approximately -3-fold change. RELB is known as a member of the NF-kappaB 
family, which plays a key role in multiple biological process such as the 
inflammatory and immune response, as well as cancer development and cell survival 
(Gerondakis and Siebenlist, 2010, Baldwin, 2012). Our study revealed down 
regulated expression of RELB gene compared with the up regulated expression of 
RELB in other reports (Baud and Jacque, 2008, Vogel et al., 2013, Yoza et al., 
2006), the reason for this gene expression reduction and its role in CM is still 
unknown. 
Another down regulated gene which involved in immune system was EGR1. EGR1 
is described as a gene which participates in functions of cognition and memory 
(Jones et al., 2001, Bozon et al., 2002, Knapska and Kaczmarek, 2004). Gersten et al 
found that in their study on monkeys with SIV encephalitis (SIVE), EGR1 was down 
regulated in SIVE as a consequence of the host response to infection, leading to 
disruption in learning (Gersten et al., 2009). Moreover, Pouget et al found that 
reduction of EGR1 has been associated with autoimmune disease and schizophrenia 
(Pouget et al., 2016). Since EGR1 is down regulated gene in models of several 
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neurological diseases, we asked whether this gene reduction might be a consequence 
of brain cells response to IT4var14 parasite interaction, perhaps being responsible for 
some of the post-infection neurological deficits seen in CM survivors. Whether this 
gene has a role in CM disease is an important question to be addressed by future 
research. 
Comparing our results of significantly down regulated genes at 2 and 6 hours of 
interaction with the IT4var14 parasite with brain endothelial cells in the presence of 
TNF cytokine, we observed that the decreased expression of CCL2 became less 
marked with time (-2.02 (6 hours) and -4.1 (2 hours) FC). The reason for this 
increase might be because of the induction of ICAM-1 expression and malaria 
parasite sequestration, and therefor increase the BBB permeability and the 
probability of CM disease. In contrast, at 6 hours of co-culture the FOS gene 
expression decreased with around (-6 FC) when compared with its expression at 2 
hours (-4.7 FC). This reduction increases the question about whether the IT4var14 
parasite sequestration on HBMEC may leads to neuron dysfunction in CM disease.  
Exposure of IT4var14 parasite isolate to human brain endothelial cells in the 
presence of TNF at 6 hours can modulate the expression of genes in HBMEC. Of 
these genes identified in our study as differentially expressed, some work as 
activators for apoptosis and other inhibitors for apoptosis. Numerous studies have 
been conducted on CM and concluded that malaria parasite can mediate the 
expression of genes involved in pro-apoptotic process (Punsawad et al., 2013, Liu et 
al., 2016, N'Dilimabaka et al., 2014).  
The expression level of NFKBIA gene in our study was low with about -2-fold 
change. NFKBIA is also known as (IκBα), and its function is as an inhibitor of NF-
kappaB signalling. Activation of NFKBIA in most cells leads to anti-apoptotic 
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activity (Luo et al., 2005). A microarray study by Tripathi et al that evaluated the 
gene expression of HBMEC after exposure to 3D7 parasite isolate without TNF 
stimulation at 6 hours found that the expression level of the NFKBIA gene was high 
as NF-kappaB inhibitory protein (Tripathi et al., 2009). However, we observed a 
reduction in NFKBIA gene expression, and this may suggest that down regulation of 
this gene might activate the NF-kappaB pathway and thus increase the pro-apoptotic 
activity in human brain endothelial cells. 
Our results in this study revealed that mRNA level of growth arrest and DNA 
damage inducible beta gene (GADD45B) was significantly decreased with roughly -
8-fold change. GADD45B is recognized originally as an essential factor in apoptosis, 
DNA repair, growth arrest, cell survival and probably DNA demethylation (Liu et 
al., 2015). Overexpression of GADD45B gene inhibits apoptosis in ischemic stroke 
(Liu et al., 2015) and in other cell types such as NIH3T3 and INS-1Eb cells (Larsen 
et al., 2006, Engelmann et al., 2008). By contrast, GADD45B was found to increase 
apoptotic death in murine hepatocytes (Cho et al., 2010) and cardiomyocytes (Kim et 
al., 2010). Our research is the first in CM to find down regulation of expression of 
GADD45B, the mechanism of this reduction is still unknown but we suggest that this 
gene may involve in the pro-apoptotic death in CM, perhaps causing the 
phenomenon of ring haemorrhages (a neuropathological feature of CM disease) 
(Figure 3.14). 
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Figure 3.14: A summary of representative images from the histological 
examination of the brain in the autopsy series is shown for CM cases. 
The abrupt transition from grey to white matter (A) and the presence of ring haemorrhages 
are demonstrated in this classic case of CM (CM2, 100X, H&E). The cerebellum (B) with 
ring haemorrhages in all levels including white and grey matter are shown (100x, H&E). 
Visibly congested blood vessels (C) even at low power may be the result of dense 
sequestration downstream; these vessels can contain both parasitized and uninfected red 
bloods (200X, H&E). The classic appearance of a ring haemorrhage with fibrin (D) is 
shown; these haemorrhages can also include pigmented parasites, free pigment, and admixed 
fibrin within the microvessel at the nexus of the lesion; uninfected erythrocytes constituting 
the surrounding haemorrhage are seen (400X, H&E). Two examples of sequestration 
showing predominantly early (less pigmented) parasites (E), and late stage (more pigmented) 
parasites (F) densely packing vessels (1000X, H&E). The figure is adapted from (Milner et 
al., 2014). 
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Another highly down regulated gene at this time point is inhibitor of DNA binding 1 
(ID1) with approximately -6-fold change. ID1 belongs to the helix-loop-helix (HLH) 
family of proteins, and plays a key role in different cellular processes, such as 
cellular differentiation, cell proliferation and apoptosis (Perk et al., 2005). Induction 
of this gene is linked to tumorigenesis in a number of cancers such as breast and 
cervical cancers (Lin et al., 2000, Schindl et al., 2001). Hao et al revealed that 
increased expression of ID1 promotes osteosarcoma cell proliferation and inhibits 
cell apoptosis (Hao et al., 2016). On the other hand, our outcomes demonstrated a 
reduction of this gene and this may induce the apoptosis in brain endothelial cells as 
a result of sequestration of IT4var14 parasite on HBMEC.  
A reduced mRNA level of Dual-specificity phosphatase-1 (DUSP1) at 6 hours co-
culture has been observed in our results. DUSP1 is a member of the threonine-
tyrosine dual-specificity phosphatase family (Shen et al., 2016). It plays a role in a 
variety of biological processes including: cell proliferation, stress responses, 
differentiation and transformation, cycle arrest, inflammation and apoptosis mainly 
by regulation MAPK signalling (Owens and Keyse, 2007, Saxena and Mustelin, 
2000, Keyse, 2000). The transcriptional level of DUSP1 was investigated in different 
human tumours, prostate, colon, gastric, breast, bladder and lung cancer (Bang et al., 
1998, Loda et al., 1996, Manzano et al., 2002, Wang et al., 2003, Vicent et al., 2004). 
Gil-Araujo et al conducted research on DU145 prostate cells and found that 
overexpression of DUSP1 enhances apoptosis and decreases NF-kappaB activity 
(Gil-Araujo et al., 2014). According to the previous study we can suggest that 
incubation of IT4var14 parasite with brain endothelial cells and TNF may reduce the 
expression level of DUSP1 and thus decrease the pro-apoptotic activity as well as 
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increasing the expression level of ICAM-1, based on the induction of NF-kappaB 
level in HBMEC. However, further research is necessary. 
In the present study, we demonstrated reduction in the expression level of AQP1 
with around -14-fold change. AQP1 is known as a transmembrane protein 
responsible for water transport and is selectively expressed in several types of cells 
(Dong et al., 2012, Verkman et al., 2008, Esteva-Font et al., 2014). It has been 
reported that the AQP1 expression level is associated with apoptosis in different 
types of diseases such as osteoarthritis, myocardial infraction and various kinds of 
cancers (Gao et al., 2016, Li et al., 2015, Qin et al., 2016, Xia et al., 2013). When 
comparing the expression level of AQP1 at 6 hours of incubation with that at 2 hours 
in our study we found that the AQP1 slightly decreased from 2 to 6 hours in co-
culture (-14 and -12 FC respectively). Furthermore, this study suggests the role of 
AQP1 as a negative regulator of apoptosis in HBMEC and may support the 
protective role of the malaria parasite in reducing cell death in endothelial cells. 
The low expression levels of inhibitor of DNA-binding/differentiation 3 (ID3) have 
been detected in this research. ID3 is known as a member of the Id family of negative 
helix-loop-helix transcription factors, which function in the maturation and 
development of lymphocytes (Maruyama et al., 2011), vascular endothelial cell 
differentiation (Felty and Porther, 2008) and, in addition to oncogenes, in human 
cancers such as human lung adenocarcinoma, prostate cancer and breast cancer cells 
(Chen et al., 2015). The effect of ID3 on apoptosis of human lung adenocarcinoma 
A549 cell line has been examined by Chen et al, and they demonstrated that up 
regulation of ID3 significantly increased the rate of the apoptosis in A549 cell (Chen 
et al., 2016). To date, there is no research confirming the correlation between down 
regulation of ID3 and the apoptosis in the CM disease., but we suggest that there is a 
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role of ID3 in human CM disease by inhibition of the apoptosis in human brain 
endothelial cells.  
We observed in our research that 57 genes were over-expressed and 168 were under-
expressed in HBMEC incubated with IT4var14 malaria parasite and TNF at 20 hours 
co-culture. The functions and pathways analysis of significant differentially 
expressed genes showed that those with up regulated expression were involved in the 
immune system. While, down regulated genes were involved in cell cycle. At 20 
hours of co-culture, we demonstrated that CCL20, CXCL2 and CCL2 genes 
expression were up-regulated with around 6, 2 and 3-fold changes respectively 
(Table 3.12). 
Table 3.12: Up regulated expression of selected genes representing specific 
pathways in HBMEC co-cultured with IT4var14 parasite and TNF at 20 hours, 
such as immune system. 
GO term Genes symbol Fold change 
Immune system 
CCL2 3.1 
CCL20 5.97 
CXCL2 2.4 
 
The table illustrates fold changes in HBMEC response to infected red blood cells and TNF, 
compare with control. 
 
Cytokines and chemokines have important roles in the pathogenesis of CM (Hunt 
and Grau, 2003, Armah et al., 2005a). Ochiel et al observed that there was an 
increase in the production level of CCL2 with severe P. falciparum infection (Ochiel 
et al., 2005). Compared with our result for CCL2 at 2, 6 and 20 hours of incubation, 
we observed an increase in the expression level of CCL2 at 20 hours, and this 
induction in CCL2 may increase the BBB dysfunction and promote pathogenesis of 
CM disease. 
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CCL20 is expressed in mucosal sites, ectodermal tissue, peripheral blood 
mononuclear cells and to some extent in lymphoid tissues (Schutyser et al., 2003, 
Meissner et al., 2003). CCL20 stimulates the maturation and migration of leucocytes, 
as well as, together with CXCL2 participate in HBMEC protection during malaria 
parasite sequestration (Tripathi et al., 2009). We suggest that the CCL20 and CXCL2 
genes might play a crucial protective role in HBMEC against CM disease.  
Among the down regulated genes that significantly expressed at 20 hours of co-
culture IT4var14 parasite with human brain endothelial cells and TNF, most of them 
involved in cell cycle (34 genes). At 20 hours of incubation, the expression of 
ICAM-1 on HBMEC is still at a significant level promoting sequestration (Tripathi et 
al., 2006), but this is in addition to rupturing iRBC and release of several molecules 
such as hemozoin (Tyberghein et al., 2014). The reasons of the involvement of most 
of the down regulated genes in cell cycle are not known and need to be investigated 
further. 
In conclusion, the interaction of IT4var14 malaria parasite with HBMEC and TNF at 
2, 6 and 20 hours can mediate the differential expressed genes involved in various 
biological pathways. Possible pathways implicated in the pathogenesis of the human 
CM disease include the immune system at 2 hours of incubation; the immune system, 
arachidonic acid pathway, positive and negative apoptotic pathways at 6 hours of 
incubation as previously discussed in this chapter. These findings support the idea 
that sequestration of the IT4var14 parasite on human brain endothelial cells in the 
presence of TNF stimulation within 20 hours may alter the behaviour of the host cell 
toward either protection or susceptibility to CM disease. However, further studies are 
required to elucidate the influence of interaction of malaria parasite on human brain 
endothelial cells in terms of the CM disease.  
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CHAPTER 4 
4. MODULATION OF THE ENDOTHELIAL CELL 
TRANSCRIPTOME FOLLOWING CO-CULTURE WITH 
IT4VAR37 
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4.1 Introduction: 
Sequestration of the malaria infected erythrocytes on blood microvasculature 
endothelial cells is a major virulence mechanism besides the antigenic variation that 
protects the parasitized erythrocyte from immune detection and destruction, as well 
as ensuring prolonged survival for parasites at a population level. This mechanism is 
largely mediated by an infected erythrocyte surface protein called PfEMP-1 
(Kraemer and Smith, 2006). Each malaria parasite strain has the potential to encode 
around 60 PfEMP-1 proteins through their family of var genes (Frank and Deitsch, 
2006). Switches in the expression of var gene allow infected erythrocytes to avoid 
host immunity and may alter disease manifestations (Smith et al., 1995). 
It has been mentioned that despite of their gene diversity, var genes can be classified 
according to the upstream sequence (ups), direction of transcription and location in 
the chromosomes into three main groups (ups A, B and C) and two intermediate 
groups (B/A and B/C) (Lavstsen et al., 2003). UpsA and upsB genes are found 
characteristically in subtelomeric regions of the 14 chromosomes, while upsC genes 
are in four central regions (Kraemer et al., 2007, Kraemer and Smith, 2003, Lavstsen 
et al., 2003). Several studies have suggested robust association between upsA 
PfEMP-1 and CM (Lavstsen et al., 2012, Turner et al., 2013, Avril et al., 2012). 
Furthermore, Almelli and his colleagues found that in their study on cerebral malaria 
patients, upsA and upsB var genes were associated with CM disease (Almelli et al., 
2014). On the other hand, numerous studies found that upsC was associated with UM 
(Jensen et al., 2004, Kyriacou et al., 2006, Rottmann et al., 2006). 
qRT-PCR studies on malaria infected individuals have suggested that these 
associations come from var genes expression (Mugasa et al., 2012, Rottmann et al., 
2006, Kyriacou et al., 2006). In addition, Jensen et al, in their study on semi-immune 
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children from Ghana and Tanzania, showed that Group A and B/A var genes were 
up-regulated. However, members among group C var genes were down-regulated 
suggesting their correlation with UM (Jensen et al., 2004). 
The variability of the PfEMP-1 domains has been shown to mediate several 
interactions with human receptors such as DBLβ domains binding to ICAM-1 
(Howell et al., 2008, Smith et al., 2000) and some CIDRα domains binding to CD36 
(Baruch et al., 1997). IT4 strains from both upsB and upsC were CD36 binders, and 
this is more consistent with findings from previous studies that ups B and C PfEMP-
1 variants are more linked to CD36 (Cabrera et al., 2014, Kraemer and Smith, 2006, 
Robinson et al., 2003). The role of the CD36 in the pathogenesis in malaria disease is 
still not clear.  
Madkhali and his group have tried to assess the ability of upsC isolate (IT4var37) to 
bind CD36 and ICAM-1 proteins under static and flow conditions and they found 
that IT4var37 strain was a very good binder for CD36 under both static and flow 
conditions, whereas the same isolate did not bind to ICAM-1 protein (Madkhali et 
al., 2014).  
ICAM-1 is considered to be an important receptor that mediates the interaction of 
malaria parasite with the brain microvascular endothelial cells and plays a role in CM 
pathogenesis (Gray et al., 2003) as we discussed in the previous chapter. We aim in 
this chapter to assess the ability of IT4var37, an isogenic parasite variant to IT4var14 
expressing a different PfEMP-1, as a good binder to CD36 receptor to modulate the 
mRNA expression in HBMEC in the presence of TNF stimulation at 6 and 20 hours 
of co-culturing model using the RNA-seq technology. Findings in this chapter will be 
compared with the previous chapter results in terms of the functional and pathways 
analysis. 
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4.2 Methods: 
4.2.1 Parasite culture: 
In this chapter, IT4var37 malaria parasite lab strain was cultured using standard 
culturing techniques as previously described in the general methods chapter (Trager 
and Jensen, 1976). 
4.2.2 EC culture: 
HBMEC was cultured and used in this part of our project as explained before in the 
general methods chapter. 
4.2.3 Detection of mycoplasma infection in IT4var37 parasite strain and 
HBMEC: 
Potential infection with mycoplasma in both IT4var37 and HBMEC was assessed as 
shown in the general methods chapter. 
4.2.4 Characterization of the IT4var37 parasite and HBMEC: 
Static protein adhesion assays were carried out to examine the binding of IT4var37 
parasite to CD36 and ICAM-1 proteins and its procedure was described before in the 
general methods chapter.  
4.2.5 Co-culture malaria parasite with ECs: 
IT4var37 parasite was co-cultured with the HBMEC and TNF stimulation at 0, 6 and 
20 hours as explained in the general methods chapter. 
4.2.5.1 RNA extraction, quality control and RNA-seq data analysis: 
RNA from each co-cultured flask used in this part of the study was extracted, 
purified from contamination and checked for its quality using an Aglient 2100 
Bioanalyzer as shown previously in the general methods chapter. The workflow for 
RNA-seq data analysis was described in Figure 3.2.  
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4.3 Results: 
4.3.1 Identification of mycoplasma infection in IT4var37 parasite and 
HBMEC: 
 As we mentioned before in the beginning of this project, obtaining the EC and the 
parasite free from the infection by mycoplasma was the first important step to ensure 
a good quality in our results. The IT4var37 and the HBMEC were free from the 
mycoplasma infection as shown in Appendix 6. 
4.3.2 Static adhesion of IT4var37 parasite on CD36 and ICAM-1 proteins: 
The binding level of IT4var37 isolate to CD36 was high, and this result is in 
agreement with Madkhali et al (Madkhali et al., 2014), including no binding 
observed with ICAM-1 protein (Appendix 7). 
4.3.3 Quality control of RNA extraction samples: 
RNA samples were isolated in this study from three independent interaction 
experiments of IT4var37 with HBMEC/TNF at 0, 6 and 20 hours. An Agilent 
Bioanalyzer 2100 was used to identify the RNA samples’ quality. According to the 
RIN value that was measured in each RNA sample in this study, all samples showed 
a good RIN of more than 9 (Table 4.1). 
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Table 4.1: RIN calculated by Agilent 2100 Bioanalyzer. 
First Experiment 
Sample 
number Description of sample RIN 
RNA Conc 
(ng/µl) 
1 Parasite co-cultured with HBMEC at 0 hour (TNF +ve) 9.6 124 
2 Parasite co-cultured with HBMEC at 6 hours (TNF +ve) 9.3 131 
3 Parasite co-cultured with HBMEC at 20 hours (TNF +ve) 9.4 139 
Second Experiment 
Sample 
number Description of sample RIN 
RNA Conc 
(ng/µl) 
4 Parasite co-cultured with HBMEC at 0 hour (TNF +ve) 10 124 
5 Parasite co-cultured with HBMEC at 6 hours (TNF +ve) 10 127 
6 Parasite co-cultured with HBMEC at 20 hours (TNF +ve) 9.8 145 
Third Experiment 
Sample 
number Description of sample RIN 
RNA Conc 
(ng/µl) 
7 Parasite co-cultured with HBMEC at 0 hour (TNF +ve) 9.7 120 
8 Parasite co-cultured with HBMEC at 6 hours (TNF +ve) 10 132 
9 Parasite co-cultured with HBMEC at 20 hours (TNF +ve) 9.4 129 
 
The table presents the RIN and the RNA concentration of each sample. The high RIN 
calculated by the 2100 Bioanalyzer indicated the very high quality of the isolated RNA.  
 
 
4.3.4 Identification of differentially expressed genes in HBMEC at 6 hours 
incubation:  
Gene expressions changes of TNF-stimulated HBMEC exposed to IT4var37 were 
measured by Cuffdiff in FPKM as described in the previous chapter section 3.3.6. At 
6 hours of incubation, 418 genes were seen as being significantly differentially 
expressed genes with an adjusted FDR < 0.05 and 1Log2-fold change. Among these, 
140 genes were described as up-regulated genes and 278 genes were down-regulated 
genes. The top ten up and down-regulated genes are presented in Figure 4.1. The 
most up-regulated gene at this time point was the neuronal pentraxin 1 (NPTX1) with 
around 16-fold change. While, ladinin 1 (LAD1) was the highest down regulated 
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gene with about -36-fold change. A table with the full description of up and down-
regulated genes is shown in appendix 8. 
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Figure 4.1: Top 10 up/down regulated genes in TNF-stimulated HBMEC incubated with IT4var37 parasite at 6 hours co-culture. 
The differentially expressed genes in TNF-stimulated HBMEC co-cultured with IT4var37 parasite isolate at 6 hours vs those in control group at 0 hour were 
determined by Cuffdiff. The fold change is the ratio of Fragments Per Kilobase of exon per Million fragments mapped (FPKM) of the examined group 
compared to FPKM of the genes in the control group. The differentially expressed genes were ranked on their log2 fold change and the 10 genes with highest 
or lowest fold changes are shown here. 
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4.3.5 Identification of differentially expressed genes in HBMEC at 20 hours 
incubation:  
In total of 1312 genes with differential expression were identified in TNFα-
stimulated HBMEC interacted with IT4var37 parasite at 20 hours, approximately 
38% were found belonging to over-expressed genes, however; nearly 68% were 
shown belonging to lower-expressed genes. Analysis of the gene expression fold 
change among the top ten up-regulated genes demonstrated that the fold changes 
varied from 10 to 64, and the highest expressed gene was the sex hormone binding 
globulin (SHBG) (Figure 4.2). On the other hand, fold changes of the top ten down-
regulated genes varied from -38 to -222, and the most robust down-regulated gene 
was observed with colony stimulating factor 2 (CSF2) (Figure 4.2). Further details 
about both top ten up and down-regulated genes are described in appendix 9. 
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Figure 4.2: Top 10 up/down regulated genes in TNF-stimulated HBMEC incubated with IT4var37 parasite at 20 hours co-culture.  
The differentially expressed genes in TNF-stimulated HBMEC co-cultured with IT4var37 parasite isolate at 20 hours vs those in control group at 0 hour were 
determined by Cuffdiff. The fold change is the ratio of Fragments Per Kilobase of exon per Million fragments mapped (FPKM) of the examined group 
compared to FPKM of the genes in the control group. The differentially expressed genes were ranked on their log2 fold change and the 10 genes with highest 
or lowest fold changes are shown here. 
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4.3.6 Functional and Pathway analysis of differentially expressed genes: 
GO analysis was carried out in this RNA-seq study on genes that were significantly 
up and down-regulated as a result of co-culturing IT4var37 iRBC with HBMEC/TNF 
at 6 and 20 hours based on the three categorisations; biological process, molecular 
function and cellular component. Tables which describe data of the GO analysis at 6 
and 20 hours co-culture can be seen in appendices 10 and 11. 
Reactome pathway enrichment analysis was used in this study amongst the over and 
under-expressed genes in TNF-stimulated HBMEC after exposure to P. falciparum 
IT4var37 at 6 and 20 hours. The research identified 15 host response pathways 
involved in genes with up-regulation (P <0.05 and at least 3 input genes) from co-
culturing IT4var37 parasite with HBMEC/TNF at 6 hours. Hemostasis and cell 
surface interactions at the vascular wall were the most affected pathways regarding 
the up-regulated genes (25 and 7 genes respectively) (Figure 4.3). In contrast, 82 host 
response pathways were shown in the same time point and conditions with 
significantly down-regulated genes. The highly significant pathways with respect to 
number of genes were the immune system, followed by cytokine signalling in 
immune system (162 and 101 genes respectively) (Figure 4.3). 
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Figure 4.3: Top ten pathways of up and down regulated genes of HBMEC/TNF 
responding to IT4var37 at 6 hours. 
A) pathways of up regulated genes and B) pathways of down regulated genes. The pathways 
were selected according to the number of genes and P value <0.05. Values associated with 
each pathway represent the number of genes. 
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The pathway analysis of significant genes at 20 hours of incubation HBMEC/TNF 
with IT4var37 identified 9 and 121 pathways in over and under-expressed genes 
respectively. With regard to the number of genes involved in each pathway, 
regulation of cholesterol biosynthesis by Sterol Regulatory Element Binding 
Transcription Factor (SREBF) and non-integrin membrane-ECM interactions were 
shown as top two pathways of over-expressed genes (Figure 4.4). On the other hand, 
cytokine signalling in immune system and cell cycle pathways were the majority of 
under-expressed genes at the same time point of co-culture with 124 and 97 genes 
respectively (Figure 4.4). 
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Figure 4.4: Top ten pathways of up and down regulated genes of HBMEC/TNF 
responding to IT4var37 at 20 hours. 
A) pathways of up regulated genes and B) pathways of down regulated genes. The pathways 
were selected according to the number of genes and P value <0.05. Values associated with 
each pathway represent the number of genes. 
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4.4 Discussion: 
One of the fundamental questions that has not been addressed yet is how malaria 
pathogenesis takes place and what are the roles of various protein receptors in the 
disease. Sequestration of the infected erythrocytes on the blood microvascular 
endothelial cells can protects the parasite from being destroyed by the host immune 
system (Newbold et al., 1999). This interaction can be mediated by proteins on the 
infected erythrocyte surface, for example PfEMP-1 (Kraemer and Smith, 2006) and 
microvascular endothelial cells proteins such as, ICAM-1 (Howell et al., 2008), 
CD36 (Baruch et al., 1997) and EPCR (Turner et al., 2013). 
Furthermore, cytoadherence can mediate the downstream effect on the host 
endothelial cells that can impact the susceptibility to the disease. From the previous 
chapter, the interaction of the IT4var14 parasite with ICAM-1 in the presence of 
TNF to modulate the downstream effects on mRNA expression levels in HBMEC 
was discussed. In this chapter, we aimed to examine the effect of the IT4var37 
parasite strain to modulate the transcriptional levels in HBMEC using RNA-seq 
technique and comparing the outcomes with IT4var14 parasite co-culture from the 
previous chapter results. 
IT4var37 parasite line had been identified as a good binder for CD36 protein 
(Madkhali et al., 2014). The role of CD36 in CM pathogenesis is still not understood. 
Almelli and his group found that in their binding study on children under 5 years of 
age with CM, CD36 is a common binding receptor in CM (Almelli et al., 2014). 
However, there are some concerns about the methods of adhesion that were used in 
this study due to the time of incubation and concentration of the proteins. In this 
thesis, it was unexpected to obtain the huge number of significantly differentially 
expressed genes after incubation IT4var37 parasite isolate with HBMEC/TNF at 6 
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and 20 hours, especially because HBMEC have not expressed CD36 to malaria 
parasite isolates (Newbold et al., 1997, Ochola et al., 2011).  
The RNA-seq results of incubation IT4var37 with TNF-stimulated HBMEC at 6 
hours demonstrated that 418 genes were shown as significantly differentially 
expressed genes, whereas the IT4var14 parasite incubation from the previous chapter 
on the same time point showed 88 significant genes. Comparison of the expressed 
genes in incubation IT4var14 and IT4var37 parasites with brain endothelial cells and 
TNF at 6 hours revealed differences in the results. There are 18 significant genes 
only detected in both outputs of RNA-seq at this time point of co-culture model. 
(Figure 4.5). 
 
Figure 4.5: Comparison between number of significant genes in HBMEC/TNF 
co-cultured with IT4var14 and IT4var37 parasite at 6 hours. 
The Venn diagram showing 18 genes were found expressed in both IT4var37 and IT4var14 
iRBC incubated with TNF-stimulated HBMEC at 6 hours. 
 
 
The number of genes showing differences and similarities in differentially expressed 
genes in IT4var37 and IT4var14 parasites incubated with human brain endothelial 
cells in the presence of TNF at 20 hours were also identified in Figure 4.6. 69 
overlapping expressed genes were identified between the two RNA-seq results. 
121 
 
Figure 4.6: Comparison between number of significant genes in HBMEC/TNF 
co-cultured with IT4var14 and IT4var37 iRBC at 20 hours. 
The Venn diagram showing 69 genes were found expressed in both IT4var37 and IT4var14 
parasites incubated with TNF-stimulated HBMEC at 20 hours. 
 
 
In this discussion, we tried to compare our previous chapter results with this chapter 
results regarding the functional and pathway analysis. Analysis of the functions and 
pathways of up-regulated genes at 6 hours of incubation IT4var14 parasite with 
HBMEC/TNF from the previous chapter revealed that among this group of genes, 
there are several genes involved in immune system (C3, TXNIP, EBI3, and CTSK) 
and arachidonic acid pathway (PLA2G4A). These gene expressions will be 
compared with the gene expressions from incubation IT4var37 with HBMEC/TNF at 
6 hours in the next section. 
Exposure of the TNF-stimulated HBMEC to IT4var37 parasite at 6 hours leads to 
reduce the expression levels of several important genes that may play role in immune 
system comparing to the previous chapter results (Figure 4.7). This reduction in C3, 
EBI3 and CTSK genes expressions suggest different parasite isolates with different 
PfEMP-1 cause variations in modulating the host cells gene expression on the brain 
endothelial cells. However, the expression of TXNIP gene might have a common 
role in immune response as it was nearly equal in both different parasite strains 
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exposed to HBMEC/TNF at 6 hours. On the other hand, the level of PLA2G4A 
expression was around 1.8-fold change in this study compared to its expression from 
the prior chapter with 2.45-fold change. The expression of this gene from different 
parasite variants may suggest an importance of this gene in CM pathogenesis.  
 
 
Figure 4.7: Comparison of the expression of selected genes representing immune 
system and arachidonic acid pathways in TNF-stimulated HBMEC incubated 
with IT4var14 and IT4var37 parasites at 6 hours. 
The results show log2 fold change of differentially expressed genes in HBMEC/TNF co-
cultured with IT4var14 and IT4var37 parasite strains at 6 hours. 
 
We compared in this study also the down-regulated genes that were involved in the 
immune system, positive and negative regulation of apoptotic process from the 
previous chapter with the findings in this chapter at 6 hours of incubation 
(Figure 4.8). We observed that the mRNA levels of genes related to the immune 
response such as FOS, CCL2 and RELB were decreased more with IT4var37 parasite 
than that with IT4var14 isolate, whereas the expression level of EGR1 with IT4var14 
strain was more reduced. Response of the brain endothelial cells to the IT4var37 
parasite at 6 hours of incubation in terms of the immune system was varied from one 
parasite strain to the other according to their PfEMP-1, and these observations may 
emphasize the role of parasite var gene switching to protect itself from destruction by 
the immune system.  
-2
0
2
4
6
8
C3 TXNIP EBI3 CTSK PLA2G4A
L
og
2 
fo
ld
 c
ha
ng
e
Gene name
IT4var14
IT4var37
123 
With respect to genes involved in positive regulation of apoptotic process pathways 
from the previous chapter and comparing them with this study at 6 hours of 
incubation, we can find that there is a different response of HBMEC co-cultured with 
IT4var37 parasite strain than that with IT4var14 parasite in terms of GADD45B and 
ID1 genes, IT4var37 strain leads to increased expression of these two genes and may 
reduce the pro-apoptotic process. However, the transcriptional level of NFKBIA 
decreased more in this work compared with the previous chapter (Figure 4.8).  
The expression levels of all genes correlated to negative regulation of apoptosis 
process pathway in this chapter were completely different from the previous results 
chapter. The co-culture model of IT4var14 parasite demonstrated that DUSP1, AQP1 
and ID3 gene expressions were clearly reduced at 6 hours of incubation, while 
IT4var37 showed an opposite effect on these genes in HBMEC and this may lead to 
increased EC apoptosis and cell death (Figure 4.8). These observations also show 
more information about the response of HBMEC to different parasites isolates with 
different ups groups in the presence of TNF activation. 
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Figure 4.8: Comparison of the expression of selected genes representing immune system and positive and negative regulation of 
apoptotic process pathways in TNF-stimulated HBMEC incubated with IT4var14 and IT4var37 parasites at 6 hours.  
The results show log2 fold change of differentially expressed genes in HBMEC/TNF co-cultured with IT4var14 and IT4var37 parasite strains at 6 hours. 
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We identified in our study that co-culture of the brain endothelial cells to different P. 
falciparum iRBC (IT4var14 and IT4var37) in the presence of TNF stimulation at 20 
hours can modulate the expression of several genes involved in the immune system. 
From the previous chapter, the IT4var14 experiments led to induced expression of 
CCL2, CCL20 and CXCL2 genes. While, the IT4var37 incubation with 
HBMEC/TNF works in other way and leads to reduce the expression of these three 
genes (Figure 4.9). The RNA-seq findings in this study illustrate a potential 
technique used by the malaria parasite based on var gene switching to protect itself 
from the host immune response to the infection.  
 
 
Figure 4.9: Comparison of the expression of selected genes representing immune 
system in TNF-stimulated HBMEC incubated with IT4var14 and IT4var37 
parasites at 20 hours. 
The results show log2 fold change of differentially expressed genes in HBMEC/TNF co-
cultured with IT4var14 and IT4var37 parasite strains at 20 hours. 
 
One of the most interesting findings among the down-regulated genes in both co-
culture models at 20 hours is the contribution of both P. falciparum parasite variants 
to the cell cycle pathway. It is possible that molecules released from rupturing the 
mature iRBC rather than PfEMP-1 type may have a role in inducing pathway, and 
the mechanisms underpinning this need further investigation in the future. 
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In summary, the incubation of IT4var37 parasite isolate with human brain 
endothelial cells and TNF at 6 and 20 hours can modulate genes with differential 
expression, but these genes often expressed in opposite levels compared to the 
IT4var14 strain under the same conditions. These results confirm the ability of 
various parasites from the same family to modulate different gene expressions in host 
cells and emphasize also the capability of the parasite to protect itself and avoid the 
host defensive system to survive for long time using PfEMP-1 var gene switching 
technique. More information about the effect of different parasite isolates on the 
human brain endothelial cells may provide a useful link for CM therapeutic 
interventions. 
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CHAPTER 5 
5. TRANSCRIPTIONAL CHANGES OF DERMAL 
ENDOTHELIAL CELL FOLLOWING INCUBATION 
WITH IT4VAR14 
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5.1 Introduction: 
The adhesion of iRBC with human malaria parasite, P. falciparum to small blood 
vessels is a major virulence factor (Gray et al., 2003). Adhesion takes place due to 
specific interactions between the parasite protein termed PfEMP-1, encoded by var 
gene family, with several host cell adhesion molecules including ICAM-1 (Berendt 
et al., 1989) and EPCR (Turner et al., 2013) CD36 (Barnwell et al., 1989, 
Ockenhouse et al., 1989, Oquendo et al., 1989). Interestingly, evidence showing that 
parasites strains from children with severe malaria bind multiple endothelial 
receptors (Heddini et al., 2001), suggests that synergistic impacts between 
endothelial adhesion molecules might contribute to cytopathology.  
One of the adhesion molecules which is up-regulated and binds iRBC in severe 
malaria is ICAM-1 (Berendt et al., 1989, Turner et al., 1994). CD36 is another target 
for malaria parasite interaction, however its role in the pathogenesis is still 
controversial (Cabrera et al., 2014). Study by Cooke et al using malaria patient 
isolates has found that ICAM-1 modulated rolling adhesion whereas CD36 mediated 
stationary adhesion (Cooke et al., 1994), which suggests that ICAM-1 capture and 
CD36 stationary adhesion might co-operate to enhance efficient sequestration. 
Indeed, it has been shown that the synergy between ICAM-1 and CD36 occurs under 
static binding assay conditions on HDMEC (McCormick et al., 1997). Interaction 
with several protein receptors, including ICAM-1 and CD36 have also been shown 
under flow conditions on HDMEC (Yipp et al., 2000). Dermal EC expresses both 
ICAM-1 and CD36 (McCormick et al., 1997), whereas brain EC does not express 
CD36 (Wassmer et al., 2011). 
The IT4var14 parasite isolate has been identified as an ups Group B and classified as 
a long PfEMP-1varient with 7 domains (Buckee and Recker, 2012). This strain of 
129 
parasite has been shown to modulate the interaction with ICAM-1 receptor via DBLβ 
domain (Howell et al., 2008, Smith et al., 2000) and with CD36 via CIDRα domain 
(Baruch et al., 1997). The efficacy of binding IT4var14 parasite to ICAM-1 and 
CD36 proteins has been observed before in several studies under static conditions 
(McCormick et al., 1997, Madkhali et al., 2014) and under flow conditions (Gray et 
al., 2003, Madkhali et al., 2014) and they found that IT4var14 parasite can mediate 
the binding to ICAM-1 protein but its role in mediating the binding to CD36 was 
bigger. 
We discussed in the previous chapters the ability of different parasite strains to 
modulate the gene expression of HBEMC/TNF at several time points of co-culture. It 
is interesting to assess the role of the IT4var14 as a good binder for ICAM-1 and 
CD36 proteins to mediate the gene expression levels of different microvascular 
endothelial cells such as HDMEC, so we aim in this part of the thesis to evaluate the 
gene expression of TNF-stimulated HDMEC in response to IT4var14 incubation at 2, 
6 and 20 hours using RNA-seq technique and then compare the results to chapter 3 
outcomes regarding the functional and pathway analysis. 
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5.2 Methods: 
5.2.1 Parasite culture: 
IT4var14 parasite lab isolate was cultured and used in this study as described before 
in the general methods chapter. 
5.2.2 EC culture:  
HDMEC was used in this chapter as showed previously in the general methods 
chapter. 
5.2.3 Detection of mycoplasma infection in IT4var14 parasite isolate and 
HDMEC: 
The potential existence of mycoplasma infection in the IT4var14 parasite and 
HDMEC was examined as explained before in the general methods chapter. 
5.2.4 Characterization of the IT4var14 parasite and HDMEC: 
In this chapter, FACS was used to confirm the expression of CD36, ICAM-1 and 
CD31 proteins in the presence and absence of TNF stimulation on HDMEC. Static 
adhesion assays were carried out to evaluate the binding of iRBC to CD36 and 
ICAM-1 proteins. The complete procedures were described previously in the general 
methods chapter. 
5.2.5 Co-culture IT4var14 with HDMEC: 
The method of co-culturing the IT4var14 parasite with TNF-stimulated HDMEC was 
described before in the general methods chapter. 
5.2.6 RNA extraction, quality control and analysis of the RNA-seq data: 
RNA from each incubated flask was extracted and examined its quality using an 
Aglient Bioanalyzer 2100 as shown before in the general methods chapter. The 
workflow for the analysis of the RNA-seq data was described in Figure 3.2. 
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5.3 Results: 
5.3.1 Identification of mycoplasma infection in IT4var14 parasite and 
HDMEC: 
The mycoplasma infection in cells can change the host gene expression (Hopfe et al., 
2013), so in this study we have tried to avoid this kind of infection in both IT4var14 
parasite and HDMEC cultures to ensure results with good quality. HDMEC and 
parasite cultures were showed no contamination with mycoplasma (Appendix 12). 
5.3.2 Characterization of the IT4var14 parasite and HDMEC: 
5.3.2.1 Static adhesion assays of IT4var14 parasite on ICAM-1 and CD36 
proteins: 
Regarding the binding levels to CD36 and ICAM-1, IT4var14 bound to both proteins 
at varying levels, in agreement with the results from Madkhali et al outcomes 
(Madkhali et al., 2014) (Appendix 2).  
5.3.2.2 Detection the expression of HDMEC proteins receptors: 
The endothelial cell markers CD36, ICAM-1 and CD31 expression, with and without 
TNF activation, were examined using FACS (Figure 5.1). Expression of CD36 and 
CD31 were slightly increased with TNF stimulation compared to non-TNF 
activation. However, ICAM-1 was hugely up-regulated with TNF treatment. 
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Figure 5.1: Detection of HDMEC receptor expression. 
FACS analysis of CD36, ICAM-1 and CD31 expression on HDMEC without (left panel) and 
with (right panel) TNF stimulation. Stimulation was for 24 hrs using 10 ng/ml TNF. CD36, 
ICAM-1and an endothelial marker (CD31) are shown at the upper, the middle and the 
bottom panels respectively. 
 
 
5.3.3 Quality control of RNA extraction samples: 
In this chapter, all RNA samples were extracted from three independent co-culture 
experiments of IT4var14 with TNF-stimulated HDMEC at 0, 2, 6 and 20 hours. An 
Agilent 2100 Bioanalyzer machine was used to identify the quality of the RNA 
samples. All samples were with a RIN of more than 9 (Table 5.1). 
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Table 5.1: RIN calculated by Agilent 2100 Bioanalyzer. 
First Experiment 
Sample 
number Description of sample RIN 
RNA Conc 
(ng/µl) 
1 Parasite co-cultured with HDMEC at 0 hour (TNF +ve) 9.4 41 
2 Parasite co-cultured with HDMEC at 2 hours (TNF +ve) 10 89 
3 Parasite co-cultured with HDMEC at 6 hours (TNF +ve) 10 58 
4 Parasite co-cultured with HDMEC at 20 hours (TNF +ve) 10 89 
Second Experiment 
Sample 
number Description of sample RIN 
RNA Conc 
(ng/µl) 
5 Parasite co-cultured with HDMEC at 0 hour (TNF +ve) 10 96 
6 Parasite co-cultured with HDMEC at 2 hours (TNF +ve) 10 115 
7 Parasite co-cultured with HDMEC at 6 hours (TNF +ve) 9.7 89 
8 Parasite co-cultured with HDMEC at 20 hours (TNF +ve) 9.7 85 
Third Experiment 
Sample 
number Description of sample RIN 
RNA Conc 
(ng/µl) 
9 Parasite co-cultured with HDMEC at 0 hour (TNF +ve) 9.9 82 
10 Parasite co-cultured with HDMEC at 2 hours (TNF +ve) 9.8 91 
11 Parasite co-cultured with HDMEC at 6 hours (TNF +ve) 9.9 279 
12 Parasite co-cultured with HDMEC at 20 hours (TNF +ve) 9.3 78 
 
The table presents the RIN and the RNA concentration of each sample. The high RIN 
calculated by the 2100 Bioanalyzer indicated the very high quality of the isolated RNA.  
 
 
5.3.4 Identification of differentially expressed genes in HDMEC at 2 hours 
incubation: 
Cuffdiff in FPKM was used in this thesis to measure the gene expression changes of 
TNF-activated HDMEC exposed to IT4var14 iRBC as described in chapter 3 section 
3.3.6. At 2 hours of co-culture, 75 genes were identified as being significantly 
differentially expressed genes with 1Log2-fold change and adjusted FDR < 0.05. Of 
these 47 genes were found as over-expressed genes and 28 genes were under-
expressed genes. The top nine over and eleven under-expressed genes are described 
in Figure 5.2. The most over-expressed gene at this time point was cytochrome P450 
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family 1 subfamily B member 1 (CYP1B1) with about 84 FC. On the other hand, the 
PARP1 binding protein (PARPBP) was the most under-expressed gene with around 
16-fold reduction in expression. A table with a full description of the top nine over 
and eleven under-expressed genes is shown in appendix 13. 
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Figure 5.2: Top 9 up/11 down regulated genes in TNF-stimulated HDMEC incubated with IT4var14 parasite at 2 hours co-culture. 
The differentially expressed genes in TNF-stimulated HDMEC co-cultured with IT4var14 parasite isolate at 2 hours vs those in control group at 0 hour were 
determined by Cuffdiff. The fold change is the ratio of Fragments Per Kilobase of exon per Million fragments mapped (FPKM) of the examined group 
compared to FPKM of the genes in the control group. The differentially expressed genes were ranked on their log2 fold change and the 10 genes with highest 
or lowest fold changes are shown here. 
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5.3.5 Identification of differentially expressed genes in HDMEC at 6 hours 
incubation: 
With respect to the gene expression levels of TNF-stimulated HDMEC co-cultured 
with IT4var14 iRBC at 6 hours, 77 significantly differentially expressed genes were 
identified in this study. Among these genes about 23% were shown as up-regulated 
genes and 77% were down-regulated genes. The top ten up and down regulated 
genes are shown in Figure 5.3, the highest FC was observed with carboxypeptidase 
M (CPM) followed by CYP1A1in up-regulated genes. MORN repeat containing 1 
(MORN1) and zinc finger protein 345 were the top two down regulated genes 
(Figure 5.3). Further information about the top ten up and down-regulated genes can 
be seen in appendix 14. 
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Figure 5.3: Top 10 up/down regulated genes in TNF-stimulated HDMEC incubated with IT4var14 parasite at 6 hours co-culture. 
The differentially expressed genes in TNF-stimulated HDMEC co-cultured with IT4var14 parasite isolate at 6 hours vs those in control group at 0 hour were 
determined by Cuffdiff. The fold change is the ratio of Fragments Per Kilobase of exon per Million fragments mapped (FPKM) of the examined group 
compared to FPKM of the genes in the control group. The differentially expressed genes were ranked on their log2 fold change and the 10 genes with highest 
or lowest fold changes are shown here. 
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5.3.6 Identification of differentially expressed genes in HDMEC at 20 hours 
incubation: 
A total of 163 significantly differentially expressed genes were shown in TNF-
stimulated HDMEC co-cultured with IT4var14 iRBC at 20 hours. 58 genes were 
found belonging to up-regulated genes, while 105 genes were identified belonging to 
down-regulated genes. The gene expression FC analysis among the top ten over-
expressed genes revealed that the FCs varied from 6 to 89, and the most robust 
highly expressed gene was the CYP1A1 (Figure 5.4). In contrast, FCs of the top ten 
under-expressed genes varied from -9 to -20, and the lowest expressed gene was 
CSF2 (Figure 5.4). More information about the top ten up and down-regulated genes 
can be found in appendix 15. 
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Figure 5.4: Top 10 up/down regulated genes in TNF-stimulated HDMEC incubated with IT4var14 parasite at 20 hours co-culture. 
The differentially expressed genes in TNF-stimulated HDMEC co-cultured with IT4var14 parasite isolate at 20 hours vs those in control group at 0 hour were 
determined by Cuffdiff. The fold change is the ratio of Fragments Per Kilobase of exon per Million fragments mapped (FPKM) of the examined group 
compared to FPKM of the genes in the control group. The differentially expressed genes were ranked on their log2 fold change and the 10 genes with highest 
or lowest fold changes are shown here. 
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5.3.7 Functional and pathway analysis of differentially expressed genes:  
In this chapter, analysis of the GO was performed on genes that were significantly 
differentially expressed as a result of incubation IT4var14 iRBC with TNF-
stimulated HDMEC at 2, 6 and 20 hours according to the three GO categorizations; 
biological process, molecular function and cellular component. GO analysis data of 
co-culture models at 2, 6 and 20 hours can be seen in appendices 16, 17 and 18 
respectively. 
Analysis of the enrichment pathways amongst the up and down regulated genes of 
TNF-activated HDMEC exposed to P. falciparum IT4var14 at 2, 6 and 20 hours was 
carried out using the Reactome. The analysis identified only 2 host response 
pathways involved in genes with over-expression (P<0.05 and at least 3 input genes) 
from incubation IT4var14 iRBC with HDMEC/TNF at 2 hours. Signalling by 
NOTCH and arachidonic acid metabolism were the only pathways identified in this 
time point of co-culture (Table 5.2). 
Table 5.2: pathways of up regulated genes of HDMEC responded to P. 
falciparum and TNF exposure at 2 hours. 
Rank Pathway name No. of genes P value 
1 Signalling by NOTCH 3 5.62E-3 
2 Arachidonic acid metabolism 3 4.33E-2 
 
The pathways were selected based on number of genes and P value <0.05. 
 
At 6 hours of incubation, the pathway analysis identified 15 pathways in up-
regulated genes. Peptide ligand-binding receptors, class A/1 (Rhodopsin-like 
receptors, GPCR ligand binding and hemostasis were all found as the top four 
pathways with 7 up-regulated genes but with different P-values (Figure 5.5). 
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Figure 5.5: Top ten pathways of up regulated genes of HDMEC/TNF 
responding to iRBC at 6 hours. 
The pathways were selected according to numbers of genes and P value <0.05. Values 
associated with each pathway represent the number of genes. 
 
The analysis of the enriched pathways at 20 hours of exposure TNF-activated 
HDMEC to IT4var14 iRBC found 6 and 39 host response pathways in over and 
under-expressed genes respectively. The most significant pathway of the over-
expressed genes based on the number of genes and the P-value was PPARA activates 
gene expression pathway. However, with respect to the gene numbers involved in 
each pathway, the immune system pathway was shown as the top pathway of under-
expressed genes (Figure 5.6). 
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Figure 5.6: Top ten pathways of up and down regulated genes of HDMEC/TNF 
responding to iRBC at 20 hours. 
A) pathways of up regulated genes and B) pathways of down regulated genes. The pathways 
were selected according to numbers of genes and P value <0.05. Values associated with each 
pathway represent the number of genes. 
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5.4 Discussion: 
Multiple receptor interactions are essential for several adhesion processes, delivering 
signals, and increasing the adhesion strength (McCormick et al., 1997). Several 
studies demonstrated the role of receptors acting synergistically in modulating the 
adhesion of different cells (Languino et al., 1993, Duperray et al., 1997, Savill et al., 
1992). McCormick et al found that ICAM-1 and CD36 work in a synergetic way to 
mediate the adhesion of a number of different parasite lines, such as IT4var14, under 
static conditions, with the majority of iRBCs binding in this system mediated by 
CD36 protein (McCormick et al., 1997). Other observations under flow conditions 
have also found co-operation between several receptors (Yipp et al., 2000, Ho et al., 
2000). 
This synergy is a property of malaria parasites expressing specific var genes, and the 
levels of synergy with IT4var14 strain were greater than those observed with other 
isolates (McCormick et al., 1997). Chapter 3 and 4 in this thesis have discussed the 
influence of different parasite isolates (IT4var14 and IT4var37) to modulate the 
transcriptional levels in TNF-stimulated HBMEC. In this chapter, we purposed to 
assess the effect of IT4var14 iRBC to change the mRNA expression levels in 
HDMEC using RNA-seq technique, then comparing the results with chapter 3 
outcomes (using HBMEC). 
IT4var14 parasite isolate had been identified as a good binder for ICAM-1 and CD36 
proteins (Madkhali et al., 2014, Gray et al., 2003). HDMEC express both ICAM-1 
(Swerlick et al., 1991) and CD36 (Swerlick et al., 1992) protein receptors and the 
expression of ICAM-1 can be modulated by cytokines such as TNF (McCormick et 
al., 1997). In this current study, the RNA-seq outcomes of TNF-activated HDMEC to 
IT4var14 iRBC at 2 hours demonstrated that 75 genes were identified as significantly 
144 
differentially expressed, while the incubation of IT4var14 iRBC with HBMEC/TNF 
from chapter 3 at the same time point showed 109 significant genes. There are 
differences in the results of the expressed genes in both types of endothelial cells 
(HDMEC and HBMEC) exposed to the same P. falciparum iRBC at 2 hours. Only 
11 genes from both RNA-seq results overlapped as shown in the Venn diagram 
(Figure 5.7). 
 
Figure 5.7: Comparison between number of significant genes in HBMEC/TNF 
and HDMEC/TNF co-cultured with IT4var14 parasite at 2 hours. 
Venn diagram showing 11 genes were found expressed in the co-culture model of IT4var14 
iRBC incubated with TNF-stimulated HBMEC and HDMEC at 2 hours. 
 
 
At 6 hours of incubation IT4var14 iRBC with TNF-stimulated HDMEC, 77 genes 
were identified as differentially expressed. On the other hand, at the same period of 
incubation IT4var14 iRBC with HBMEC/TNF there were 88 genes observed with 
differential expression. Although, there was no big difference between number of 
significant expressed genes of HDMEC and HBMEC co-culture models, variation 
was observed in the genes themselves, with only 5 genes overlapping between the 
co-culture models (Figure 5.8). 
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Figure 5.8: Comparison between number of significant genes in HBMEC/TNF 
and HDMEC/TNF co-cultured with IT4var14 parasite at 6 hours. 
Venn diagram showing 5 genes were found expressed in the co-culture model of IT4var14 
iRBC incubated with TNF-stimulated HBMEC and HDMEC at 6 hours. 
 
 
The number of genes showing similarities and variances in differentially expressed 
genes in TNF-activated HDMEC and HBMEC co-cultured with IT4var14 at 20 hours 
are identified in Figure 5.9. 13 genes only were similar in both RNA-seq findings. 
 
Figure 5.9: Comparison between number of significant genes in HBMEC/TNF 
and HDMEC/TNF co-cultured with IT4var14 parasite at 20 hours. 
Venn diagram showing 13 genes were found expressed in the co-culture model of IT4var14 
iRBC incubated with TNF-stimulated HBMEC and HDMEC at 20 hours. 
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According to the differences and similarities in the number of genes that were 
described in the previous paragraphs, we may observe that when ICAM-1 and CD36 
proteins work in a synergetic manner during iRBC binding, they might mediate 
expression of a largely different set of genes in HDMEC than those seen with 
HBMEC co-cultured in the same conditions, and this may suggest a role of multiple 
protein receptors on the surface of endothelial cells to modulate the iRBC adhesion 
and then express different genes. Moreover, we described in chapter 3 the possibility 
of the gene expression changes as a results of binding IT4var14 parasite line to 
ICAM-1, however in this chapter it is perhaps the CD36 playing a major role to 
mediate the iRBC binding based on findings of several studies (McCormick et al., 
1997, Yipp et al., 2000, Ho et al., 2000) and thereby give different expression 
patterns. 
Our previous results from chapter 3 have been compared to this chapter findings in 
terms of the functional and pathway analysis. High-throughput screening from 
exposure of the TNF-activated HDMEC to IT4var14 iRBC at 2 hours could identify 
differential expressions in important genes involved in immune response pathway. 
The expression of IL32, EBI3 and CTSK genes were reduced in this study in 
comparison to chapter 3 results (Figure 5.10). In contrast, other genes also involved 
in immune system pathway such as FOS, CCL2 and CXCL1 were at the same levels 
of expression in both co-culture models from this study and chapter 3 as shown in 
Figure 5.10. These variations and similarities give more explanations about the effect 
of the malaria parasite that displays a long PfEMP-1 variant on endothelial cells 
expressing both ICAM-1 and CD36 proteins. 
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Figure 5.10: Comparison of the expression of selected genes representing 
immune system pathway in TNF-stimulated HDMEC and HBMEC incubated 
with IT4var14 iRBC at 2 hours. 
The results show log2 fold change of differentially expressed genes in HDMEC/TNF and 
HBMEC/TNF co-cultured with the IT4var14 parasite strain at 2 hours. 
 
Incubation of the IT4var14 iRBC with TNF-stimulated HDMEC at 6 hours leads to 
gene expression that might have a role in the immune system. C3, TXNIP and CTSK 
genes expressed in this current study had different up-regulation levels compared to 
chapter 3 outcomes, but the most fold change expressed gene is still C3, with nearly 
121-fold change in HBMEC co-culture model from chapter 3. This investigation may 
suggest the role ICAM-1 as a major protein on HBMEC that modulates the adhesion 
to iRBC (Gray et al., 2003), however its role in HDMEC is changed because there is 
possibility of working in synergism with CD36. The expression level of PLA2G4A 
gene in this study is still over-expressed, especially when compared to the previous 
results from chapter 3 (Figure 5.11), which may indicate a link between expression 
of this gene and ICAM-1 expression on endothelium. 
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Figure 5.11: Comparison of the expression of selected genes representing 
immune system and arachidonic acid pathways in TNF-stimulated HDMEC 
and HBMEC incubated with IT4var14 parasite at 6 hours. 
The results show log2 fold change of differentially expressed genes in HDMEC/TNF and 
HBMEC/TNF co-cultured with IT4var14 parasite strain at 6 hours. 
 
The under-expressed genes that were involved in the immune system, as well as 
‘positive and negative regulation of apoptotic process’ in this study also have been 
compared to chapter 3 findings at 6 hours of incubation (Figure 5.12). RELB, CCL2 
and NFKBIA gene expressions were roughly the same, on the other hand the 
expression level of EGR1 gene was double in HDMEC/TNF exposed to IT4var14 
iRBC compared to HBMEC/TNF. These observations may emphasize the role of 
ICAM-1 expression on endothelial cells to mediate the iRBC adhesion and develop 
the malaria pathogenesis even though it works in a synergism with CD36.   
Variations in gene expression were also observed in several genes related to ‘positive 
and negative regulation of apoptotic process’ pathways in this study compared to 
chapter 3 results (Figure 5.12). Incubation of TNF-stimulated HDMEC with 
IT4var14 iRBC at 6 hours gave a little reduction in GADD45B gene expression in 
comparison to a high reduction observed in the same gene with HBMEC co-culture 
model. However, the expression pattern for ID1 is very different between HDMEC 
and HBMEC. Furthermore, a very little reduction in gene expression was found in 
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ID3 gene in this chapter, whereas the DUSP1 gene expression in HDMEC was 
nearly the same as HBMEC under the same conditions. Response of the ECs from 
different organs to IT4var14 iRBC in vitro is varied, and the reason may be due to 
the different array of proteins expressed on the surface of the microvascular 
endothelial cells and the nature of the endothelial cell organs (Ye et al., 2014).  
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Figure 5.12: Comparison of the expression of selected genes representing immune system, positive and negative regulation of apoptotic 
process pathways in TNF-stimulated HDMEC and HBMEC incubated with IT4var14 parasite at 6 hours. 
The results show log2 fold change of differentially expressed genes in HDMEC/TNF and HBMEC/TNF co-cultured with IT4var14 parasite strain at 6 hours. 
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At 20 hours of exposure HDMEC/TNF to IT4var14 iRBC, it can be seen that the 
expression level of genes involved in immune response pathway were completely 
different from that with HBMEC in chapter 3 results (Figure 5.13). In chapter 3, it 
has been shown that CCL2, CCL20 and CXCL2 genes were expressed at high levels, 
while in this chapter all of these selected genes were at low levels of expression. It is 
likely that the expression level of ICAM-1 and CD36 on HDMEC at this time point 
of co-culture are still at significant levels enhancing sequestration (Tripathi et al., 
2006) and rupturing the mature iRBC may lead to changes in the transcriptional level 
in genes involved in immune pathway due to the release of soluble mediators. 
 
Figure 5.13: Comparison of the expression of selected genes representing 
immune system pathway in TNF-stimulated HDMEC and HBMEC incubated 
with IT4var14 parasite at 20 hours. 
The results show log2 fold change of differentially expressed genes in HDMEC/TNF and 
HBMEC/TNF co-cultured with IT4var14 parasite strain at 20 hours. 
 
Several similarities and differences were observed between HDMEC and HBMEC 
gene expression that were activated by TNF and incubated with IT4var14 iRBC at 
several time points. One possible explanation for the different patterns of expression 
is the lack of CD36 on HBMEC such that engagement with iRBC will lead to the 
transduction of different signals in HDMEC and HBMEC. Further work looking at 
the response to iRBC/ EC co-culture on the blocking of specific adhesion pathways 
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will be required to understand the contribution of key receptor/ ligand interactions on 
controlling the EC response to cytoadherence. 
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CHAPTER 6 
6. EFFECTS OF TNF STIMULATION ON DIFFERNTIAL 
GENE EXPRESSION IN HBMEC CO-CULTURED 
WITH INFECTED AND UNINFECTED RBC 
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6.1 Introduction: 
Infection by P. falciparum is a major cause of severe malaria disease associated with 
a range of clinical complications and syndromes including CM (Wu et al., 2011). 
The exact nature of the CM pathology is still not fully understood, but the 
cytoadherence and inflammation have been considered as two main mechanisms 
involved in this disease (Wu et al., 2011). There are several inflammatory and 
immune mediators likely to be implicated in this disease (Schofield and Grau, 2005, 
Marsh and Kinyanjui, 2006). During infection, factors such as high levels of 
circulating immune-complexes and plasma pro-inflammatory cytokines may play a 
crucial role in activating and damaging EC (Tripathi et al., 2009). 
The cytoadherence mechanism of the asexual-stage iRBC is complex involving a 
family of parasite-encoded proteins (PfEMP-1) interacting with a range of host 
receptors such as ICAM-1, CD36, CD31, P-selectin (Cooke et al., 2000) and EPCR 
(Turner et al., 2013). This complication is elevated when these receptors cooperate to 
achieve efficient iRBC binding to EC (Gray et al., 2003, McCormick et al., 1997, 
Yipp et al., 2000).  
Additionally, a feature of malaria infection is the production of high levels of TNF 
and pro-inflammatory mediators that may contribute to organ-related malaria disease 
(Brown et al., 1999b). These cytokines can activate the EC by over-expression of 
adhesion receptors to induce sequestration of iRBC within the microvessels, and 
contribute in some cases in chronic inflammation development by recruiting 
leukocytes into tissues (Pober and Cotran, 1990, Nitcheu et al., 2003). For instance, 
ICAM-1 is up-regulated in severe malaria and has been implicated in progression to 
cerebral malaria (Graninger et al., 1994, Berendt et al., 1989, Turner et al., 1994). 
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Usually, an in vitro model is used for studying the interaction between iRBC and EC 
in vivo, and this interaction can be promoted with TNF stimulation (Chakravorty et 
al., 2007). In the presence of the TNF, normal RBC also had an impact on the EC. 
The ability of uninfected RBC to bind to and modulate EC in vitro is not a novel 
result. Indeed, uninfected RBC can bind to EC, modulated by plasma factors such as 
fibronectin and fibrinogen (Wautier et al., 1983) and the binding can increase the 
expression of ICAM-1 in in vitro (Brown et al., 2001b).  
A wide range of molecules can be expressed on the normal RBC surface which have 
been implicated in modulating adhesion to EC under several conditions. These 
include: (i) the blood group Lutheran molecule (LU), up-regulated on sickle cell 
RBC (sRBC), can bind to extracellular matrix protein laminin which contribute to the 
sickle cell pathogenesis related to vasoocclusive events (Eyler and Telen, 2006); (ii) 
VLA-4 (alpha4beta1) which can bind to VCAM-1 molecule on EC (Walmet et al., 
2003); (iii) ICAM-4, a molecule related to Rhesus blood group, binds to integrins on 
platelets (alpha2beta4) which can be involved in thrombosis and on leukocytes 
(CD11-CD18) (Wautier and Wautier, 2004); and (iv) advanced glycation end 
products (AGEs) exist on normal RBC and bind to EC via their receptor (RAGE) 
(Wautier and Schmidt, 2004). 
We propose in this chapter to compare the ability of IT4var14 iRBC to modulate the 
transcriptional expression levels of genes in HBMEC in the presence and absence of 
TNF, furthermore comparing the mRNA expression in TNF-stimulated HBMEC co-
cultured with IT4var14 and uninfected RBC at 2, 6 and 20 hours using the high-
throughput sequencing technique (RNA-seq). 
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6.2 Methods: 
6.2.1 Parasite culture: 
IT4var14 parasite line was cultured and used in this study as described previously in 
the general methods chapter. 
6.2.2 EC culture: 
HBMEC was cultured using the standard culturing techniques as shown before in the 
main methods chapter. 
6.2.3 Detection of mycoplasma infection in IT4var14 parasite strain, RBC and 
HBMEC: 
The possibility of mycoplasma infection in IT4var14, RBC and HBMEC were 
examined as described in the general methods chapter. 
6.2.4 Co-culture ECs with malaria parasite: 
IT4var14 iRBC was incubated with HBMEC in the presence and absence of TNF, at 
0, 2, 6 and 20 hours as described in general methods chapter. 
6.2.5 Co-culture ECs with normal RBC: 
Uninfected RBC was co-cultured with TNF-stimulated HBMEC at 0, 2, 6 and 20 
hours as parasite co-cultured methods that shown in the general methods chapter. 
6.2.6 RNA extraction, quality control and RNA-seq data analysis: 
RNA was isolated from each incubated flask and examined for its quality using 
Aglient Bioanalyzer 2100 as described previously in the main methods chapter. The 
RNA-seq data analysis workflow is described in Figure 3.2. 
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6.3 Results: 
6.3.1 Comparing the differentially expressed genes in HBMEC stimulated and 
non-stimulated with TNF at 2 hours incubation:  
Stimulating the brain EC cells by TNF in our co-culture models of IT4var14 iRBC at 
2 hours can modulate differentially expressed genes in HBMEC, especially when 
compared to gene expressions of non-stimulated HBMEC at the same time point 
(Figure 6.1). Most of the top ten up-regulated genes seen in TNF-stimulated HBMEC 
had different expression levels compared to non-stimulated HBMEC. On the other 
hand, the pattern of expression levels of the top ten down-regulated genes in brain 
EC stimulated with TNF was largely similar to that without TNF, albeit with some 
exceptions (e.g. CMTM1 and AQP1) and a less marked effect (e.g. HES1 and KIT). 
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Figure 6.1: Comparison of the expression levels of the top ten up and down regulated genes of HBMEC stimulated and non-stimulated 
with TNF in co-culture model of IT4var14 iRBC at 2 hours. 
The results show log2 fold change of differentially expressed genes in HBMEC stimulated and non-stimulated with TNF and co-cultured with IT4var14 
parasite strain at 2 hours. 
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6.3.2 Comparing the differentially expressed genes in HBMEC stimulated and 
non-stimulated with TNF at 6 hours incubation:  
Gene expression of human brain EC incubated with IT4var14 iRBC in the presence 
and absence of TNF stimulation at 6 hours were different (Figure 6.2). Among the 
top ten over-expressed genes, C3 was observed as a highly significantly over-
expressed gene in the presence of TNF, compared to a small reduction in expression 
of the same gene without TNF activation. As seen at 2 hours, the top ten under-
expressed genes at this time point of co-culture demonstrated that most of the genes 
showed expression pattern in EC with both activated and non-activated TNF that 
were roughly on the same level of reduction, except AQP1 and FOS genes. 
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Figure 6.2: Comparison of the expression levels of the top ten up and down regulated genes of HBMEC stimulated and non-stimulated 
with TNF in co-culture model of IT4var14 iRBC at 6 hours. 
The results show log2 fold change of differentially expressed genes in HBMEC stimulated and non-stimulated with TNF and co-cultured with IT4var14 
parasite strain at 6 hours. 
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6.3.3 Comparing the differentially expressed genes in HBMEC stimulated and 
non-stimulated with TNF at 20 hours incubation:  
At 20 hours of co-culture the IT4var14 iRBC with stimulated and non-stimulated 
TNF HBMEC, we observed that most of the gene expression levels of the top ten up-
regulated genes in both conditions (presence and absence of TNF) were high, but 
genes in TNF stimulated EC were still at higher levels of expression compared to 
non-TNF stimulation, except for PRND and PAPLN genes, which had opposite 
expression levels under the two conditions (Figure 6.3). However, among the top ten 
down-regulated genes, the expression levels of the genes were mostly the same for 
with and without TNF, with some exceptions observed with FAM19A2 and 
GADD45B gene expression (Figure 6.3). 
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Figure 6.3: Comparison of the expression levels of the top ten up and down regulated genes of HBMEC stimulated and non-stimulated 
with TNF in co-culture model of IT4var14 iRBC at 20 hours. 
The results show log2 fold change of differentially expressed genes in HBMEC stimulated and non-stimulated with TNF and co-cultured with IT4var14 
parasite strain at 20 hours. 
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6.3.4 Comparing the differentially expressed genes in TNF-stimulated 
HBMEC Co-cultured with both IT4var14 iRBC and uninfected RBC at 2 
hours: 
In this study, co-culturing the TNF-activated HBMEC with both iRBC and normal 
RBC showed that the gene expression levels of EC in the co-culture model using 
uninfected RBC were slightly higher than that with iRBC in the top ten up-regulated 
genes (Figure 6.4). On the other hand, among the top ten down-regulated genes of 
the same co-culture models of both iRBC and normal RBC at 2 hours, the 
transcriptional levels of genes for iRBC co-culture had a slightly larger reduction 
compared to levels expressed with RBC co-culture (Figure 6.4), with the exception 
of CMTM1. 
164 
 
 
Figure 6.4: Comparison of the expression levels of the top ten up and down regulated genes of TNF- stimulated HBMEC co-cultured 
with both IT4var14 iRBC and uninfected RBC at 2 hours. 
The results show log2 fold change of differentially expressed genes in HBMEC/TNF co-cultured with both IT4var14 parasite strain and normal RBC at 2 
hours. 
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6.3.5 Comparing the differentially expressed genes in TNF-stimulated 
HBMEC Co-cultured with both IT4var14 iRBC and uninfected RBC at 6 
hours: 
At 6 hours incubation with either iRBC or uninfected RBC on TNF-stimulated 
human brain EC, most of the top ten over-expressed gene expressions were nearly 
the same in both co-culture models (Figure 6.5). There was an exception in the 
expression of the C3 gene. Levels of mRNA expression among the top ten under-
expressed genes of iRBC co-culture were roughly the same as those with normal 
RBC, with slightly higher reductions of the gene expression seen with IT4var14 
iRBC incubation. 
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Figure 6.5: Comparison of the expression levels of the top ten up and down regulated genes of TNF- stimulated HBMEC co-cultured 
with both IT4var14 iRBC and uninfected RBC at 6 hours. 
The results show log2 fold change of differentially expressed genes in HBMEC/TNF co-cultured with both IT4var14 parasite strain and normal RBC at 6 
hours. 
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6.3.6 Comparing the differentially expressed genes in TNF-stimulated 
HBMEC Co-cultured with both IT4var14 iRBC and uninfected RBC at 20 
hours: 
Incubation TNF-activated HBMEC with both IT4var14 iRBC and uninfected RBC at 
20 hours again produced relatively similar patterns of differentially expressed genes 
in EC (Figure 6.6). At this time point of incubation with both co-culture models we 
observed that, among the top ten up-regulated genes, exposure of the EC to iRBC 
increased the expression of most of the genes compared to the levels seen with 
uninfected RBC. Vasoactive intestinal peptide receptor 1 (VIPR1) was the only gene 
showing slightly more induction with uninfected RBC than iRBC in the co-culture 
model. In contrast, transcriptional levels of the top ten down-regulated genes were 
observed with more reduction in EC exposed to IT4var14 iRBC than those with 
uninfected RBC. Haemoglobin subunit beta (HBB) was the only gene observed with 
a higher reduction in expression in uninfected RBC co-culture compared to iRBC co-
culture. 
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Figure 6.6: Comparison of the expression levels of the top ten up and down regulated genes of TNF- stimulated HBMEC co-cultured 
with both IT4var14 iRBC and uninfected RBC at 20 hours. 
The results show log2 fold change of differentially expressed genes in HBMEC/TNF co-cultured with both IT4var14 parasite strain and normal RBC at 20 
hours. 
 
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
L
og
2 
fo
ld
 c
ha
ng
e
Gene name
PRBC TNF+ve 
RBC TNF+ve
169 
6.4 Discussion: 
Pro-inflammatory cytokines have been implicated with CM disease (Schofield and 
Grau, 2005, Marsh and Kinyanjui, 2006), however a study from Mbale et al shows 
that TNF is not required for CM to occur (Mbale et al., 2016).  High levels of these 
inflammatory mediators can activate the EC (Brown et al., 1999b) and the expression 
of several adhesion receptors such as ICAM-1 (Graninger et al., 1994, Turner et al., 
1994, Berendt et al., 1989). Among these cytokines is TNF, which has a role in 
promoting the interaction between both iRBC and uninfected RBC to EC 
(Chakravorty et al., 2007). 
With our work, we wanted to describe the detailed comparison of the mRNA 
expression levels of genes in HBMEC co-cultured with IT4var14 iRBC in the 
presence and absence of TNF at 2, 6 and 20 hours, as well as comparing the 
transcriptional expression levels of TNF-stimulated HBMEC incubated with both 
IT4var14 parasite isolate and uninfected RBC at 2, 6 and 20 hours using high-
throughput RNA-seq technique. 
Several studies have been investigated the role of TNF in mediating EC gene 
expression in an in vitro model of severe malaria using microarray technology 
(Barbier et al., 2011, Chakravorty et al., 2007). This study is the first to compare the 
mRNA expression levels of HBMEC co-cultured with IT4var14 iRBC in the 
presence and absence of TNF using the RNA-seq technology.  
In the present study, it is interesting to know that comparing the gene expression 
profiles of the co-culture models before and after TNF stimulation, most of the top 
ten up or down-regulated genes were observed with high expression in the presence 
of TNF at the three different time points of co-culture (2, 6 and 20 hours) compared 
to non-TNF stimulation.  
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At 2 hours of incubation, the expression of EBI3, CTSK IL32 and FOS genes were 
completely different between with and without TNF categories; these genes were 
classified in chapter 3 as involved in the immune system pathway. On the other hand, 
co-culturing human brain EC with iRBC in the presence and absence of TNF at 6 
hours demonstrated that the effect of the TNF stimulation on EC was obvious in both 
top ten over and under-expressed genes. C3 gene expression was the highest 
expressed gene observed in HBMEC after stimulation by TNF at this time point of 
co-culture model, but very little change was seen without TNF treatment; the role of 
C3 gene in immune response was discussed in chapter 3. The expression level of 
AQP1 in HBMEC, which was classified previously using the pathway analysis in 
chapter 3 as a negative regulator of apoptotic process, was totally different in the 
presence and absence of TNF stimulation. TNF has been identified as an 
inflammatory mediator that increase expression of ICAM-1, thus increasing the 
sequestration of the iRBC to EC (Chakravorty et al., 2007). This suggests a role of 
the TNF stimulation to modulate differentially expressed genes of EC co-cultured 
with iRBC at 6 hours. 
It is clear from our work that exposure of the IT4var14 iRBC to brain EC before and 
after TNF stimulation can change the expression of the top ten up and down-
regulated genes. However, the expression of genes at the 20 hours of co-culture was 
not totally different, despite genes with TNF-stimulated HBMEC were observed with 
higher expression than the pattern without TNF-stimulation. It is likely that at 20 
hours of incubation iRBC with TNF-activated brain EC, the ICAM-1 expression may 
be decreased but is still with the significant levels (Tripathi et al., 2006), and this 
reduction in ICAM-1 might leads to reduce the expression of the significant genes. 
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Chakravorty and her colleague found that there was no significant modulation in 
transcriptional levels of EC exposed to iRBC or uninfected RBC without TNF 
stimulation, however significant changes of the EC transcriptome were observed in 
combination with TNF stimulation. Furthermore, in the same study, the author 
demonstrated that the expression level of ICAM-1 was significantly increased in EC 
when incubated with either iRBC or uninfected RBC but the level of ICAM-1 
induction with iRBC was much higher than that observed with normal RBC 
(Chakravorty et al., 2007).  
In our results, we demonstrate that at 2, 6 and 20 hours of exposure of TNF-
stimulated HBMEC to both IT4var14 iRBC and uninfected RBC, the transcriptional 
levels of the top ten up and down-regulated genes were roughly the same. At 2 hours 
of incubation, it was the only exception that the expression levels of the top ten over-
expressed genes were observed as being a little higher with uninfected RBC than 
iRBC co-culture. The C3 gene was the only gene expressed at different levels at 6 
hours of co-culture between incubation with iRBC and RBC, with the increase in 
expression being associated with iRBC; the role of this gene in the immune system 
was discussed in chapter 3. 
Our findings in this chapter have tried to explain the role of TNF stimulation in 
modulating the gene expression over the human brain EC in co-culture model of 
IT4var14 iRBC at different time points compare to non-TNF stimulation model of 
co-culture. On the other hand, the results also have compared the effect of the TNF 
activation on the HBMEC co-cultured with both iRBC and normal RBC at several 
time points of incubation to modulate genes with differential expression. Indeed, 
these outcomes may support the role of inflammatory cytokine especially TNF, in 
developing the CM disease. However, further investigations are required to study the 
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influence of other inflammatory mediators in interactions of iRBC to brain EC and 
thus understanding the pathogenesis of CM disease. 
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CHAPTER 7 
7. GENERAL DISCUSSION, LIMITATIONS AND 
FUTURE PERSPECTIVES 
  
174 
7.1 General discussion: 
Cerebral malaria is a complicated syndrome with no specific process that has been 
identified as being responsible for its pathogenesis. It has been proposed that CM 
pathogenesis can be explained by the integration of P. falciparum iRBC 
sequestration in the microvasculature of brain EC, which can be lethal through blood 
flow obstruction, inflammation mediation and endothelial activation and dysfunction. 
Cytoadhesion of iRBC to HBMEC can be enhanced by several host inflammatory 
cytokines such as TNF, which in turn results in an increased level of iRBC 
sequestration in the brain microvasculature (van der Heyde et al., 2006). It has been 
shown that the interaction between iRBC and EC lining brain microvessels can result 
in modulation several EC genes, which could be involved in activation of EC, 
intracellular signalling pathways, BBB disruption and EC apoptosis. The current 
study aims to understand how the P. falciparum parasite isolates can modulate the 
gene expression of ECs in order to better understand CM pathogenesis.  
Several transcriptomic studies have been conducted to measure the level of gene 
expression in both P. falciparum parasites and ECs following the interaction between 
infected erythrocytes with endothelial cells using a microarray technique. Although 
the microarray is a cost effective, it is not a more sensitive manner to detect the 
aspects of RNA molecules (Wang et al., 2009, Casneuf et al., 2007). On the other 
hand, using the RNA-seq technique is more expensive than other NGS techniques, 
but it is more reliable and can detect 25% more genes (Sultan et al., 2008). Our study 
is the first RNA-seq study that investigates the response of the ECs to the iRBC co-
adhesion interaction. 
In chapter 3, we tried to address the question of how the IT4var14 parasite strain can 
modulate the gene expression of brain endothelial cells in the presence of TNF 
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stimulation at 2, 6 and 20 hours of co-culture. We demonstrated that iRBC adhesion 
induced expression of genes involved in immune system (IL32, EBI3 and CTSK) at 
2 hours of co-culture. Stimulation of these genes in human brain EC might be 
resulting from the presence of the malaria parasite, with the host starting to defend 
itself against the infection. We also found that iRBC interaction reduced the 
transcriptional levels of genes involved in immune system (CCL2, CXCL1 and FOS) 
in HBMEC at 2 hours of incubation. Reduction in expression of CCL2 and CXCL1 
genes may explain a potential role of HBMEC to protect itself from the malaria 
infection. On the other hand, down-regulation of FOS gene may lead to neuron 
dysfunction and hence damaging of the brain cells. 
The ability of IT4var14 parasite to modulate gene expression and pathways in 
HBMEC differs from 2 to 6 hours of co-culture. At 6 hours of exposure the human 
brain EC to iRBC in the present of TNF, the transcriptional levels of C3, TXNIP, 
EBI3 and CTSK genes, that are involved in the immune system pathways, were high. 
When we compared the differential regulation of gene transcription of immune 
system pathway between 2 and 6 hours of co-culture, we observed that the 
expression of EBI3 and CTSK genes are downregulated at 6 hours, which may 
induce inflammation in the endothelium, resulting in higher cytoadherence. One of 
the most important observations in our study is the high expression of the C3 gene at 
6 hours. We discussed in chapter 3 the possible role of C3 expression in CM. 
Moreover, interaction of iRBC to HBMEC at 6 hours led to increase expression of 
the PLA2G4A gene, which catalyses breakdown of phospholipids membrane to 
release arachidonic acid and promote prostanoid biosynthesis (Hua et al., 2015). Up-
regulation of these genes in HBMEC at 6 hours of co-culture may result in the 
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increase of a pro-adhesive effect that potentially enhance the pathological 
sequestration in the CM. 
On the other hand, we demonstrated that cytoadhesion of iRBC to brain endothelial 
cells at 6 hours of the co-incubation system can reduce expression of several genes 
involved in immune system (RELB, EGR1, CCL2 and FOS), positive regulation of 
apoptosis (NFKBIA, GADD45B and ID1) and negative regulation of apoptosis 
pathways (DUSP1, AQP1 and ID3). Increase in the time of co-culture from 2 to 6 
hours might potentially induce the sequestration of iRBC on HBMEC that leads to 
increase the effect of iRBC modulation on the EC, this may be observed in the 
expression of CCL2 gene at 6 hours. CCL2 expression became less marked with time 
(-2.02 (6 hours) and -4.1 (2 hours) FC), thus it might increase the permeability of 
BBB and the likelihood of CM disease. However, at 6 hours of incubation, we 
observed that the transcriptional level of FOS gene was decreased with the time of 
co-culture and that may suggest the role of the IT4var14 parasite interaction to 
modulate genes in human brain EC which lead to induce CM pathology. 
The differential expression of genes involved in pro and anti-apoptotic pathways 
resulting from interaction of the IT4var14 parasite with HBMEC in the presence of 
TNF opens questions such as, does the parasite want to kill the host cells or keep 
them alive? Or this process is a normal response from the host to protect itself? We 
suppose the needs of the parasite are to keep the host alive as long as it can because it 
depends on it to complete its life cycle and undergo transmission to the insect vector.  
Therefore, as well as inducing pathology in the host, the parasite may also activate 
protective mechanisms to prevent the interaction between itself and the host from 
causing too much damage that would prevent eventual gametocyte transmission. 
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One of the most critical time points that we used in our co-culture models was at 20 
hours. It has been supposed that the ICAM-1 expression at this time point is still at a 
significant level enhancing sequestration (Tripathi et al., 2006), moreover most of the 
iRBC can be ruptured and released several molecules that modulate the gene 
expression in HBMEC such as hemozoin (Tyberghein et al., 2014). At 20 hours of 
co-culture, we observed that the mRNA level of CCL2 gene, which is involved in an 
immune response pathway, was totally different from that observed at 2 and 6 hours. 
Expression of CCL2 was induced at 20 hours of co-culture and this may explain the 
role of molecules that are released from rupturing iRBC to alter the gene expression 
levels in brain endothelial cells. In contrast, exposure of HBMEC to IT4var14 
parasite and TNF at 20 hours reduced expression of genes mostly involved in cell 
cycle, and we do not have any understanding of why, at this time point, we should 
see decreased expression of these genes. The proposed effect of iRBC cytoadhesion 
to modulate gene expression pathways in the brain EC can be seen in Figure 7.1.  
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Figure 7.1: The proposed effect of iRBC cytoadhesion to modulate gene 
expression pathways in the brain EC. 
 
In chapter 4, we tried to compare the transcriptional profile of HBMEC between two 
different PfEMP-1 variants, IT4var14 (upsB) and IT4var37 (upsC). We found that 
exposure of brain endothelial cells to the IT4var37 parasite isolate in the presence of 
TNF can modulate different expression of genes in HBMEC, but these genes often 
expressed in opposite levels compared to IT4var14 interaction at 6 and 20 hours of 
co-culture. These findings may emphasize the ability of different parasite strains 
from the same family to cause different gene expressions in host cells and confirm 
also the ability of the parasite to protect itself from the host defensive system using 
PfEMP-1 var gene switching technique. Furthermore, these results may also show 
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the response of HBMEC to long and short PfEMP-1 isolates (IT4var14 and IT4var37 
isolates respectively). 
In chapter 5, we used the RNA-seq technique to reveal the differences in the mRNA 
levels in HBMEC and HDMEC following the interaction with IT4var14 isolate in the 
presence of TNF stimulation. We demonstrated that the adhesion of iRBC led to 
modulate expression of several genes in the dermal endothelial cells, and there were 
variations in the expression of these genes when compared to HBMEC induced 
genes. These differences and similarities may be for several reasons; first: the nature 
of the endothelial cells such as, HDMEC express ICAM-1 and CD36 (McCormick et 
al., 1997) whereas HBMEC does not express CD36 (Wassmer et al., 2011). Second, 
the affinity of IT4var14 binding might play a role in these differences and 
similarities. The IT4var14 parasite can mediate binding to CD36 more than that with 
ICAM-1 (McCormick et al., 1997, Gray et al., 2003, Madkhali et al., 2014).  Lastly, 
ICAM-1 and CD36 may work in a synergistic manner during iRBC binding 
(McCormick et al., 1997), thus they might mediate transcription of different sets of 
genes in HDMEC.  
In the final chapter, we attempted to examine the ability of systemic TNF and 
uninfected erythrocytes to modulate gene expression in HBMEC during 
cytoadherence. To aid this work, first we co-cultured the brain endothelial cells to 
IT4var14 iRBC in the presence and absence of TNF and second incubated the 
HBMEC with uninfected RBC in the presence of TNF. We found that the 
inflammatory cytokine. It is possible that TNF activated HBMEC (Brown et al., 
1999b) and then stimulated expression of the adhesion receptor ICAM-1 (Graninger 
et al., 1994, Turner et al., 1994, Berendt et al., 1989) to induce sequestration of iRBC 
on EC, thus leading to modulation of the downstream effects on mRNA expression 
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levels in brain EC. Exposure of HBMEC to IT4var14 parasite in the absence of TNF 
modulated different genes expression, especially when compared to transcriptional 
levels in TNF-stimulated HBMEC. These findings are in agreement with the 
published data of Chakravorty and colleagues (Chakravorty et al., 2007). On the 
other hand, we demonstrated that the transcriptional level of genes in brain EC 
incubated with both iRBC and uninfected erythrocyte in the present of TNF were 
nearly the same. We suggested that the main reason for these similarities in 
expression of genes with iRBC and uninfected erythrocytes co-culture models is 
probably that an infected erythrocyte contains many proteins that are found in an 
uninfected erythrocyte.  Uninfected erythrocytes do not normally come into contact 
with EC, but with a malaria parasite inside them, they do.  
7.2 Limitations and future perspectives: 
Although this work generated data that contributed to the understanding of how the 
P. falciparum parasite can modulate the gene expressions of EC in response to the 
interaction in terms of understanding the mechanism of CM pathogenesis, there are 
limitations in the study which need to be considered in the future experiments. These 
include: 
I. All parasite isolates that were used in this thesis were lab adapted. Although 
using patient strains in the lab may give more relevant results about the effect 
of the parasite on the EC in the co-culture model, it is sometimes difficult to 
culture and grow patient isolates in the lab, and it is not clear how long they 
retain their “patient” characteristics. 
II. It has been suggested that ICAM-1 plays a key role in mediating 
sequestration of iRBC on EC, hence it can mediate the downstream effect on 
the human brain EC. To emphasize this role, it will be important to block the 
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ICAM-1 receptor on EC using ICAM-1 monoclonal antibody and examine 
the expression of genes following iRBC interaction. 
III. Although we used the RNA-seq technique to assess the gene expression 
change in EC after co-culturing with iRBC at different time points, it was 
also interesting to understand how does the cytoadhesion alter the gene 
expressions in P. falciparum over time. 
   In future, we have several aims that should be achieved: 
I. We depended in this thesis on understanding how the parasite can modulate 
the transcriptional levels in EC following cytoadhesion, but the need for 
experimental validation of these findings on the protein levels should be the 
next step to assure if these significant genes translate to proteins and perform 
their functions or not. 
II. It is interesting to understand deeply how the IT4var37 parasite (CD36 
binder) can modulate these huge number of significant changes in gene 
expression on HBMEC, despite this isolate not binding to ICAM-1. 
Furthermore, we should investigate more the functional pathways of these 
genes to distinguish between effect of the isolate that bind to ICAM-1 from 
other isolates that bind to other receptors. 
III. It would be interesting to examine how the IT4var19 (EPCR binder) (Avril et 
al., 2012) can modulate the gene expression on HBMEC using co-culture 
system under different time points. This would be followed by pathway 
analysis to look at the gene functions and comparing the findings to our 
results in this thesis.   
In brief, sequestration of the parasite may be not only the mediator of CM. There are 
many investigations have confirmed the role of inflammatory mediators in CM 
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infection. Nowadays, dysfunction of the vascular endothelium is thought to play an 
important role in CM pathogenesis. EC activation can be stimulated by the 
interaction of iRBC or the inflammatory response mediators. In December 2014, a 
comment was published in Nature that discussed the thought that microbiologists 
usually are paying their attention to the microbes’ variables and often ignoring the 
host variables. It was stated that a microbe alone does not have the ability to cause 
the sickness without a host response. Many potential consequences result from 
contacts between the pathogen and the host to cause illness. It was thought that 
scientists should concentrate on the interactions between a pathogen and a host rather 
than the microbes alone (Casadevall and Pirofski, 2014).  
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Appendix1:  
 
Screening for mycoplasma infection in IT4var14 parasite and HBMEC. 
Lane M, Promega pGEM® DNA Markers (Cat.# G1741); lane 1, IT4var14 parasite; lane 2, 
HBMEC; lane 3, HBMEC growth media; lane 4, Parasite growth media; lane 5, -ve control; 
lane 6, +ve control. 
 
 
 
 
 
 
 
 
 
 
 
 
M         1         2         3         4         5         6
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Appendix 2: 
 
 
Static Adhesion of IT4var14 parasite to ICAM-1 and CD36. 
2 µl spots of 50 µg/ml ICAM-1, CD36 and PBS were placed onto 60 mm dishes and standard 
protein static binding assays carried out with iRBC suspended in binding buffer at a 
haematocrit of 1% and a parasitemia of 3%. The outcomes show the mean of binding and the 
bars represent standard error (SE). 
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Appendix 3: 
Ensemble Gene ID Gene Name Description Coordinates 
FPKM 
PRBC 0h 
FPKM 
PRBC 2h 
Log2 Fold 
Change P-value FDR 
ENSG00000185101 ANO9  loanoctamin 9 chr11:417932-442011 0.0403979 0.782521 4.27578 0.0002 0.0322867 
ENSG00000162551 ALPL alkaline phosphatase, liver/bone/kidney chr1:21509371-21578412 0.149733 1.06215 7 0.00035 0.0466528 
ENSG00000215218 UBE2QL1 
ubiquitin conjugating 
enzyme E2 Q family like 
1 
chr5:6448622-6494909 0.146029 0.895465 2.61638 0.00035 0.0466528 
ENSG00000105246 EBI3 Epstein-Barr virus induced 3 chr19:4229497-4237531 0.662777 3.51066 2.40515 0.0002 0.0322867 
ENSG00000151136 BTBD11 BTB domain containing 11 chr12:107318412-107659642 0.96968 4.68185 2.2715 5e-05 0.0111762 
ENSG00000143387 CTSK cathepsin K chr1:150796207-150808323 3.85458 17.9079 2.21595 5e-05 0.0111762 
ENSG00000100767 PAPLN papilin, proteoglycan-like sulfated glycoprotein chr14:73237496-73274640 1.78988 8.2048 2.19661 5e-05 0.0111762 
ENSG00000058085 LAMC2 laminin subunit gamma 2 chr1:183186237-183244900 2.53443 10.0178 1.98284 5e-05 0.0111762 
ENSG00000068078 FGFR3 fibroblast growth factor receptor 3 chr4:1793306-1808872 0.617387 2.35091 1.92897 0.00035 0.0466528 
ENSG00000008517 IL32 interleukin 32 chr16:3065296-3087100 67.7863 219.525 1.69532 5e-05 0.0111762 
ENSG00000089505 CMTM1 
CKLF like MARVEL 
transmembrane domain 
containing 1 
chr16:66552562-66579137 0.782157 0.057398 -3.76839 5e-05 0.0111762 
ENSG00000240583 AQP1 aquaporin 1 chr7:30651942-30925516 42.8405 3.62057 -.  5e-05 0.0111762 
ENSG00000114315 HES1 hes family bHLH transcription factor 1 chr3:194136144-194138732 85.1669 8.44216 -3.33461 5e-05 0.0111762 
ENSG00000157404 KIT KIT proto-oncogene receptor tyrosine kinase chr4:54657917-54740715 2.80319 0.454706 -2.62406 5e-05 0.0111762 
210 
ENSG00000099860 GADD45B 
growth arrest and DNA 
damage inducible beta chr19:2476121-2478259 91.6759 15.5255 -2.5619 5e-05 0.0111762 
ENSG00000136826 KLF4 Kruppel-like factor 4 chr9:107484851-107490482 6.1146 1.05327 -2.53738 5e-05 0.0111762 
ENSG00000143816 WNT9A Wnt family member 9A chr1:227918655-227947898 2.07033 0.4154 -2.31729 5e-05 0.0111762 
ENSG00000170345 FOS FBJ murine osteosarcoma viral oncogene homolog chr14:75278773-75282230 12.2643 2.60224 -2.23664 5e-05 0.0111762 
ENSG00000155090 KLF10 Kruppel-like factor 10 chr8:102648778-102655902 22.8943 4.90231 -2.22345 5e-05 0.0111762 
ENSG00000106852 LHX6 LIM homeobox 6 chr9:122202576-122229626 11.7219 2.58449 -2.18126 5e-05 0.0111762 
 
A full description of top ten up and down regulated genes in HBMEC/TNF interacted with IT4var14 parasite at 2 hours. 
The table presents the ensemble gene ID of the top ten up and down regulated genes, gene name, location of the gene in the genome, Fragments Per Kilobase 
of exon per Million fragments mapped (FPKM) at 0 and 2 hours, log2 fold change, P-value and FDR value of each gene involve in this study. PRBC indicates 
the P. falciparum infected erythrocyte. 
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Appendix 4: 
Ensemble Gene 
ID 
Gene 
Name Description Coordinates 
FPKM 
PRBC 0h 
FPKM 
PRBC 6h 
Log2 Fold 
Change P-value FDR 
ENSG00000125730 C3 complement component 3 chr19:6677703-6737603 0.00336973 0.408815 6.92267 5e-05 0.013328 
ENSG00000058085 LAMC2 laminin subunit gamma 2 chr1:183186237-183244900 2.6679 15.2133 2.51156 5e-05 0.013328 
ENSG00000100767 PAPLN papilin, proteoglycan-like sulfated glycoprotein chr14:73237496-73274640 1.88296 10.2331 2.44217 5e-05 0.013328 
ENSG00000140465 CYP1A1 cytochrome P450 family 1 subfamily A member 1 chr15:74719541-74725610 3.93862 20.5203 2.38129 5e-05 0.013328 
ENSG00000185352 HS6ST3 heparan sulfate 6-O-sulfotransferase 3 chr13:96090838-96839562 0.0938523 0.476322 2.34347 5e-05 0.013328 
ENSG00000105246 EBI3 Epstein-Barr virus induced 3 chr19:4229497-4237531 0.697018 3.2518 2.22197 5e-05 0.013328 
ENSG00000143387 CTSK cathepsin K chr1:150796207-150808323 4.06572 15.743 1.95312 5e-05 0.013328 
ENSG00000003137 CYP26B1 cytochrome P450 family 26 subfamily B member 1 chr2:72129237-72148038 0.505962 1.78734 1.82071 0.0002 0.036154 
ENSG00000118971 CCND2 cyclin D2 chr12:4248764-4305350 0.694087 2.11321 1.60624 5e-05 0.013328 
ENSG00000116711 PLA2G4A phospholipase A2 group IVA chr1:186828952-186988981 8.92585 22.208 1.31502 5e-05 0.013328 
ENSG00000115738 ID2 
inhibitor of DNA binding 
2, dominant negative 
helix-loop-helix protein 
chr2:8666635-8684453 60.8568 3.42801 -4.14998 5e-05 0.013328 
ENSG00000240583 AQP1 aquaporin 1 (Colton blood group) chr7:30651942-30925516 45.1979 3.12909 -3.85244 5e-05 0.013328 
ENSG00000127325 BEST3 bestrophin 3 chr12:69643359-69699476 0.410644 0.0464148 -3.14523 0.0001 0.0209693 
ENSG00000125968 ID1 
inhibitor of DNA binding 
1, dominant negative 
helix-loop-helix protein 
chr20:31605282-31606515 559.984 88.4692 -2.66214 5e-05 0.013328 
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ENSG00000170345 FOS FBJ murine osteosarcoma viral oncogene homolog chr14:75278773-75282230 12.9083 2.12447 -2.60312 5e-05 0.013328 
ENSG00000188536 HBA2 hemoglobin subunit alpha 2 chr16:172846-173710 30.8493 5.11327 -2.59292 5e-05 0.013328 
ENSG00000136826 KLF4 Kruppel-like factor 4 (gut) chr9:107484851-107490482 6.45825 1.11226 -2.53765 5e-05 0.013328 
ENSG00000206172 HBA1 hemoglobin subunit alpha 1 chr16:176679-177522 9.21904 1.73907 -2.4063 0.0001 0.0209693 
ENSG00000160180 TFF3 trefoil factor 3 chr21:42311666-42315651 2.87366 0.629691 -2.19017 0.0002 0.036154 
ENSG00000114315 HES1 hes family bHLH transcription factor 1 chr3:194136144-194138732 89.9483 22.1294 -2.02313 5e-05 0.013328 
 
A full description of top ten up and down regulated genes in HBMEC/TNF interacted with IT4var14parasite at 6 hours. 
The table presents the ensemble gene ID of the top ten up and down regulated genes, gene name, location of the gene in the genome, Fragments Per Kilobase 
of exon per Million fragments mapped (FPKM) at 0 and 6 hours, log2 fold change, P-value and FDR value of each gene involve in this study. PRBC indicates 
the P. falciparum infected erythrocyte. 
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Appendix 5:  
Ensemble Gene ID Gene Name Description Coordinates 
FPKM 
PRBC 0h 
FPKM 
PRBC 20h 
Log2 Fold 
Change P-value FDR 
ENSG00000140465 CYP1A1 cytochrome P450 family 1 subfamily A member 1 chr15:74719541-74725610 3.76103 46.2772 3.6211 5e-05 0.00818138 
ENSG00000171864 PRND prion protein 2 chr20:4721909-4728460 0.0571954 0.622117 3.44322 0.00015 0.0176118 
ENSG00000162777 DENND2D 
DENN domain containing 
2D chr1:111187173-111243440 0.0805743 0.595492 2.88569 0.0002 0.021817 
ENSG00000162692 VCAM1 vascular cell adhesion molecule 1 chr1:100719741-100739045 0.533853 3.25258 2.60707 5e-05 0.00818138 
ENSG00000115009 CCL20 C-C motif chemokine ligand 20 chr2:227813841-227817564 0.234889 1.40141 2.57683 0.0004 0.0339912 
ENSG00000265972 TXNIP thioredoxin interacting protein chr1:145992434-145996600 11.1227 66.2085 2.57351 5e-05 0.00818138 
ENSG00000114812 VIPR1 vasoactive intestinal peptide receptor 1 chr3:42489298-42537573 0.0766432 0.450533 2.5554 5e-05 0.00818138 
ENSG00000006210 CX3CL1 C-X3-C motif chemokine ligand 1 chr16:57372457-57385048 0.206721 1.14051 2.46392 5e-05 0.00818138 
ENSG00000100767 PAPLN papilin, proteoglycan-like sulfated glycoprotein chr14:73237496-73274640 1.79858 9.7613 2.44021 5e-05 0.00818138 
ENSG00000272636 DOC2B double C2 domain beta chr17:142788-181636 0.173891 0.906035 2.38138 5e-05 0.00818138 
ENSG00000183691 NOG noggin chr17:56593698-56595590 5.49245 0.134192 -5.35508 5e-05 0.00818138 
ENSG00000115738 ID2 inhibitor of DNA binding 2 chr2:8666635-8684453 58.1397 4.92853 -3.56029 5e-05 0.00818138 
ENSG00000188536 HBA2 hemoglobin subunit alpha 2 chr16:172846-173710 29.3289 4.74045 -2.62923 5e-05 0.00818138 
ENSG00000198673 FAM19A2 
family with sequence 
similarity 19 (chemokine 
(C-C motif)-like), 
member A2 
chr12:61708258-62417431 0.576024 0.0976469 -2.56048 0.0006 0.0433268 
214 
ENSG00000244734 HBB hemoglobin subunit beta chr11:5225463-5229395 51.6099 9.63441 -2.42138 5e-05 0.00818138 
ENSG00000125968 ID1 inhibitor of DNA binding 1 chr20:31605282-31606515 534.501 107.681 -2.31143 5e-05 0.00818138 
ENSG00000135547 HEY2 
hes related family bHLH 
transcription factor with 
YRPW motif 2 
chr6:125578557-125761269 4.14179 0.864693 -2.25999 5e-05 0.00818138 
ENSG00000099860 GADD45B 
growth arrest and DNA 
damage inducible beta chr19:2476121-2478259 91.8943 20.5668 -2.15966 5e-05 0.00818138 
ENSG00000165899 OTOGL otogelin like chr12:80209452-80379090 0.63461 0.14639 -2.11605 0.00035 0.0311176 
ENSG00000168874 ATOH8 atonal bHLH transcription factor 8 chr2:85751343-85788066 29.1582 6.75063 -2.11081 5e-05 0.00818138 
 
A full description of top ten up and down regulated genes in HBMEC/TNF interacted with IT4var14 parasite at 20 hours. 
The table presents the ensemble gene ID of the top ten up and down regulated genes, gene name, location of the gene in the genome, Fragments Per Kilobase 
of exon per Million fragments mapped (FPKM) at 0 and 20 hours, log2 fold change, P-value and FDR value of each gene involve in this study. PRBC 
indicates the P. falciparum infected erythrocyte. 
  
215 
Appendix 6:  
 
Screening for mycoplasma infection in IT4var37 parasite and HBMEC. 
Lane M, Promega pGEM® DNA Markers (Cat.# G1741); lane 1, IT4var37 parasite; lane 2, 
HBMEC; lane 3, HBMEC growth media; lane 4, Parasite growth media; lane 5, -ve control; 
lane 6, +ve control. 
 
M         1         2         3         4         5         6
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Appendix 7: 
 
Static Adhesion of IT4var37 parasite to CD36 and ICAM-1. 
2 µl spots of 50 µg/ml CD36, ICAM-1 and PBS were placed onto 60 mm dishes and standard 
protein static binding assays carried out with iRBC suspended in binding buffer at a 
haematocrit of 1% and a parasitemia of 3%. The outcomes show the mean of binding and the 
bars represent standard error (SE). 
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Appendix 8:  
Ensemble Gene ID Gene Name Description Coordinates 
FPKM 
PRBC 0h 
FPKM 
PRBC 6h 
Log2 Fold 
Change P-value FDR 
ENSG00000171246 NPTX1 neuronal pentraxin 1 chr17:80467147-80477843 0.321097 5.1817 4.01234 5e-05 0.00137067 
ENSG00000109846 CRYAB crystallin alpha B chr11:111908564-111926872 0.0713443 1.01792 3.83469 5e-05 0.00137067 
ENSG00000140465 CYP1A1 cytochrome P450 family 1 subfamily A member 1 chr15:74719541-74725610 4.39485 43.3712 3.30285 5e-05 0.00137067 
ENSG00000055955 ITIH4 
inter-alpha-trypsin 
inhibitor heavy chain 
family member 4 
chr3:52812974-52897596 0.211062 1.51545 2.84401 0.00105 0.0188944 
ENSG00000171227 TMEM37 transmembrane protein 37 chr2:119429900-119438520 0.315049 2.025 2.68428 0.0011 0.0195588 
ENSG00000010319 SEMA3G semaphorin 3G chr3:52433052-52445085 0.552651 3.04747 2.46317 5e-05 0.00137067 
ENSG00000221866 PLXNA4 plexin A4 chr7:132123331-132648688 0.600831 3.27809 2.44782 5e-05 0.00137067 
ENSG00000099338 CATSPERG 
cation channel sperm 
associated auxiliary 
subunit gamma 
chr19:38335774-38370943 0.22432 1.0911 2.28216 0.0011 0.0195588 
ENSG00000139187 KLRG1 killer cell lectin like receptor G1 chr12:8950043-9010760 0.829622 4.02734 2.2793 5e-05 0.00137067 
ENSG00000092068 SLC7A8 solute carrier family 7 member 8 chr14:23125294-23183674 0.929502 4.31291 2.21413 5e-05 0.00137067 
ENSG00000159166 LAD1 ladinin 1 chr1:201359007-201401190 2.54089 0.0713469 -5.15434 5e-05 0.00137067 
ENSG00000164400 CSF2 colony stimulating factor 2 chr5:132073789-132076170 346.736 9.82972 -5.14055 5e-05 0.00137067 
ENSG00000189283 FHIT fragile histidine triad chr3:59749309-61251459 7.18337 0.222274 -5.01425 5e-05 0.00137067 
ENSG00000163734 CXCL3 C-X-C motif chemokine ligand 3 chr4:74036588-74038807 516.207 21.0543 -4.61576 5e-05 0.00137067 
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ENSG00000163121 NEURL3 neuralized E3 ubiquitin protein ligase 3 chr2:96497642-96508109 26.9812 1.32155 -4.35165 5e-05 0.00137067 
ENSG00000163082 SGPP2 sphingosine-1-phosphate phosphatase 2 chr2:222424516-222560948 1.66013 0.0883764 -4.23149 5e-05 0.00137067 
ENSG00000198535 C2CD4A C2 calcium dependent domain containing 4A chr15:62066976-62070917 5.71198 0.360262 -3.98688 5e-05 0.00137067 
ENSG00000108342 CSF3 colony stimulating factor 3 chr17:40015360-40017813 411.958 30.1414 -3.77268 5e-05 0.00137067 
ENSG00000006210 CX3CL1 C-X3-C motif chemokine ligand 1 chr16:57372457-57385048 504.14 37.4382 -3.75124 5e-05 0.00137067 
ENSG00000123610 TNFAIP6 TNF alpha induced protein 6 chr2:151357591-151380048 23.0279 1.73143 -3.73335 5e-05 0.00137067 
 
A full description of top ten up and down regulated genes in HBMEC/TNF interacted with IT4var37 parasite at 6 hours. 
The table presents the ensemble gene ID of the top ten up and down regulated genes, gene name, location of the gene in the genome, Fragments Per Kilobase 
of exon per Million fragments mapped (FPKM) at 0 and 6 hours, log2 fold change, P-value and FDR value of each gene involve in this study. PRBC indicates 
the P. falciparum infected erythrocyte. 
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Ensemble Gene ID Gene Name Description Coordinates 
FPKM 
PRBC 0h 
FPKM 
PRBC 20h 
Log2 Fold 
Change P-value FDR 
ENSG00000129214 SHBG sex hormone binding globulin chr17:7561874-7633383 0.208592 13.4055 6.00599 0.00515 0.0347625 
ENSG00000140465 CYP1A1 cytochrome P450 family 1 subfamily A member 1 chr15:74719541-74725610 4.4154 119.122 4.75375 5e-05 0.000799012 
ENSG00000132470 ITGB4 integrin subunit beta 4 chr17:75721327-75765711 0.428689 9.7628 4.50929 5e-05 0.000799012 
ENSG00000122432 SPATA1 spermatogenesis associated 1 chr1:84498324-84574480 0.0721602 1.57334 4.44648 0.0006 0.00655469 
ENSG00000240583 AQP1 aquaporin 1 (Colton blood group) chr7:30651942-30925516 0.591723 10.1785 4.10446 5e-05 0.000799012 
ENSG00000167244 IGF2 insulin like growth factor 2 chr11:2129111-2161341 0.0499515 0.767225 3.94105 5e-05 0.000799012 
ENSG00000101115 SALL4 spalt like transcription factor 4 chr20:51782330-51802520 0.195634 2.50621 3.67928 0.00015 0.00206973 
ENSG00000167748 KLK1 kallikrein 1 chr19:50819147-50823787 0.18301 2.23133 3.60791 0.0013 0.0119027 
ENSG00000171227 TMEM37 transmembrane protein 37 chr2:119429900-119438520 0.316035 3.56295 3.49492 5e-05 0.000799012 
ENSG00000068831 RASGRP2 RAS guanyl releasing protein 2 chr11:64726910-64745456 0.430621 4.09626 3.24982 5e-05 0.000799012 
ENSG00000164400 CSF2 colony stimulating factor 2 chr5:132073789-132076170 348.492 1.57203 -7.79235 5e-05 0.000799012 
ENSG00000007908 SELE selectin E chr1:169662006-169894267 1043.6 8.67812 -6.90996 5e-05 0.000799012 
ENSG00000232070 TMEM253 transmembrane protein 253 chr14:21016762-21104722 3.0488 0.0268986 -6.82457 0.0018 0.0154996 
ENSG00000163734 CXCL3 C-X-C motif chemokine ligand 3 chr4:74036588-74038807 518.849 4.89534 -6.72776 5e-05 0.000799012 
ENSG00000108342 CSF3 colony stimulating factor 3 chr17:40015360-40017813 414.151 4.5349 -6.51294 5e-05 0.000799012 
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ENSG00000198535 C2CD4A C2 calcium dependent domain containing 4A chr15:62066976-62070917 5.74157 0.0749541 -6.25929 0.00265 0.0210758 
ENSG00000227507 LTB lymphotoxin beta chr6:31580524-31582522 143.925 2.12652 -6.08068 5e-05 0.000799012 
ENSG00000163121 NEURL3 neuralized E3 ubiquitin protein ligase 3 chr2:96497642-96508109 27.1193 0.640732 -5.40346 5e-05 0.000799012 
ENSG00000123610 TNFAIP6 TNF alpha induced protein 6 chr2:151357591-151380048 23.1399 0.547297 -5.40192 5e-05 0.000799012 
ENSG00000171236 LRG1 leucine rich alpha-2-glycoprotein 1 chr19:4522530-4540474 5.9073 0.154951 -5.25261 5e-05 0.000799012 
 
A full description of top ten up and down regulated genes in HBMEC/ TNF interacted with IT4var37 parasite at 20 hours. 
The table presents the ensemble gene ID of the top ten up and down regulated genes, gene name, location of the gene in the genome, Fragments Per Kilobase 
of exon per Million fragments mapped (FPKM) at 0 and 20 hours, log2 fold change, P-value and FDR value of each gene involve in this study. PRBC 
indicates the P. falciparum infected erythrocyte. 
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Biological Process – Up Regulated Genes: 
Go term 
Size P-value FDR 
Aging 6 3.5E-3 5.1E0 
Negative regulation of cell proliferation 8 1.1E-2 1.5E1 
Response to drug 6 3.9E-2 4.5E1 
Ovulation from ovarian follicle 2 4.2E-2 4.7E1 
Regulation of insulin-like growth factor receptor 
signaling pathway 2 4.2E-2 4.7E1 
Negative regulation of platelet activation 2 4.8E-2 5.2E1 
 
Biological Process – Down Regulated Genes: 
Go term 
Size P-value FDR 
Inflammatory response 44 2.3E-27 3.9E-24 
Chemokine-mediated signaling pathway 16 3.1E-14 5.2E-11 
Immune response 30 7.1E-13 1.2E-9 
Chemotaxis 17 9.7E-12 1.6E-8 
Response to lipopolysaccharide 19 1.0E-11 1.7E-8 
Cellular response to lipopolysaccharide 16 3.7E-11 6.2E-8 
Signal transduction 42 1.6E-8 2.6E-5 
Cell chemotaxis 11 1.7E-8 2.9E-5 
Positive regulation of NF-kappab transcription 
factor activity 14 3.4E-8 5.7E-5 
Cellular response to interleukin-1 10 5.0E-7 8.4E-4 
Positive regulation of inflammatory response 10 6.3E-7 1.1E-3 
Positive regulation of leukocyte chemotaxis 6 3.3E-6 5.6E-3 
Defense response 9 3.5E-6 5.8E-3 
Lipopolysaccharide-mediated signaling pathway 7 4.1E-6 6.8E-3 
Cell-cell signaling 15 1.1E-5 1.8E-2 
Aging 12 1.7E-5 2.8E-2 
Cell adhesion 20 1.8E-5 3.1E-2 
Cellular response to tumor necrosis factor 10 2.0E-5 3.3E-2 
Neutrophil chemotaxis 8 3.1E-5 5.3E-2 
Apoptotic process 22 3.4E-5 5.7E-2 
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Positive regulation of gene expression 14 6.6E-5 1.1E-1 
Defense response to virus 11 9.0E-5 1.5E-1 
I-kappab kinase/NF-kappab signaling 7 1.6E-4 2.7E-1 
Positive regulation of transcription from RNA 
polymerase II promoter 29 1.7E-4 2.9E-1 
Response to molecule of bacterial origin 4 2.0E-4 3.3E-1 
Nucleotide-binding oligomerization domain 
containing signaling pathway 5 3.4E-4 5.7E-1 
Leukocyte migration involved in inflammatory 
response 4 3.8E-4 6.4E-1 
Single organismal cell-cell adhesion 8 4.6E-4 7.8E-1 
Lymphocyte chemotaxis 5 5.3E-4 8.9E-1 
Positive regulation of nitric-oxide synthase 
biosynthetic process 4 6.5E-4 1.1E0 
Positive regulation of ERK1 and ERK2 cascade 10 6.8E-4 1.1E0 
Negative regulation of inflammatory response 7 7.3E-4 1.2E0 
Response to virus 8 7.8E-4 1.3E0 
Regulation of cell proliferation 10 1.0E-3 1.7E0 
Protein kinase B signaling 5 1.0E-3 1.7E0 
Humoral immune response 6 1.1E-3 1.8E0 
Negative regulation of cell proliferation 15 1.1E-3 1.9E0 
Tumor necrosis factor-mediated signaling 
pathway 8 1.2E-3 2.0E0 
Response to muscle stretch 4 1.2E-3 2.0E0 
Positive regulation of I-kappab kinase/NF-kappab 
signaling 9 1.7E-3 2.8E0 
Regulation of inflammatory response 6 1.7E-3 2.8E0 
Type I interferon signaling pathway 6 1.8E-3 3.0E0 
Nucleotide-binding oligomerization domain 
containing 2 signaling pathway 3 1.8E-3 3.0E0 
Myeloid dendritic cell differentiation 4 2.1E-3 3.4E0 
Monocyte chemotaxis 5 2.5E-3 4.1E0 
Positive regulation of nitric oxide biosynthetic 
process 5 2.7E-3 4.5E0 
G-protein coupled receptor signaling pathway 24 2.8E-3 4.6E0 
Interferon-gamma-mediated signaling pathway 6 2.8E-3 4.7E0 
Positive regulation of neutrophil chemotaxis 4 3.2E-3 5.2E0 
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Positive regulation of interleukin-6 production 5 3.2E-3 5.3E0 
Positive regulation of interleukin-10 production 4 3.6E-3 5.9E0 
Positive regulation of tumor necrosis factor 
production 5 3.8E-3 6.2E0 
Leukocyte cell-cell adhesion 4 4.6E-3 7.5E0 
Positive regulation of cell proliferation 15 4.9E-3 7.9E0 
Positive regulation of angiogenesis 7 4.9E-3 8.0E0 
Positive regulation of peptidyl-tyrosine 
phosphorylation 6 5.3E-3 8.5E0 
Positive regulation of interferon-beta production 4 5.8E-3 9.2E0 
Innate immune response 14 6.2E-3 1.0E1 
Cellular response to lipoteichoic acid 3 6.3E-3 1.0E1 
Hyperosmotic response 3 6.3E-3 1.0E1 
Negative regulation of smooth muscle cell 
proliferation 4 7.0E-3 1.1E1 
Face morphogenesis 4 7.7E-3 1.2E1 
Regulation of tumor necrosis factor-mediated 
signaling pathway 4 7.7E-3 1.2E1 
Negative regulation of blood pressure 4 7.7E-3 1.2E1 
Negative regulation of ERK1 and ERK2 cascade 5 8.0E-3 1.3E1 
Cellular response to organic cyclic compound 5 8.5E-3 1.3E1 
Positive regulation of T cell proliferation 5 9.0E-3 1.4E1 
Cytokine-mediated signaling pathway 7 9.2E-3 1.4E1 
Response to antibiotic 4 9.3E-3 1.5E1 
Response to hypoxia 8 9.4E-3 1.5E1 
Response to muramyl dipeptide 3 9.4E-3 1.5E1 
Positive regulation of macrophage chemotaxis 3 9.4E-3 1.5E1 
Neutrophil mediated immunity 3 9.4E-3 1.5E1 
Negative regulation of apoptotic process 14 9.8E-3 1.5E1 
Response to interleukin-1 4 1.0E-2 1.6E1 
Positive regulation of gtpase activity 16 1.1E-2 1.7E1 
Extrinsic apoptotic signaling pathway in absence 
of ligand 4 1.1E-2 1.7E1 
Positive regulation of leukocyte migration 3 1.1E-2 1.7E1 
Negative regulation of gene expression 7 1.1E-2 1.7E1 
224 
Positive regulation of protein secretion 4 1.3E-2 2.0E1 
Negative regulation of extrinsic apoptotic 
signaling pathway in absence of ligand 4 1.4E-2 2.1E1 
Negative regulation of cysteine-type 
endopeptidase activity involved in apoptotic 
process 
5 1.5E-2 2.2E1 
Positive regulation of interleukin-2 production 3 1.5E-2 2.3E1 
Activation of MAPK activity 6 1.6E-2 2.3E1 
Response to progesterone 4 1.6E-2 2.4E1 
Negative regulation of NF-kappab transcription 
factor activity 5 1.6E-2 2.4E1 
Negative regulation of viral genome replication 4 1.7E-2 2.5E1 
Regulation of I-kappab kinase/NF-kappab 
signaling 3 1.7E-2 2.5E1 
Positive regulation of cellular protein metabolic 
process 3 1.7E-2 2.5E1 
Extracellular matrix organization 8 1.8E-2 2.6E1 
Positive regulation of DNA replication 4 1.9E-2 2.8E1 
Positive regulation of monocyte chemotaxis 3 2.0E-2 2.8E1 
Positive regulation of macrophage derived foam 
cell differentiation 3 2.0E-2 2.8E1 
Establishment of endothelial barrier 3 2.0E-2 2.8E1 
Positive regulation of chemokine production 3 2.2E-2 3.1E1 
Toll-like receptor 4 signaling pathway 3 2.5E-2 3.4E1 
Positive regulation of interferon-gamma 
production 4 2.5E-2 3.4E1 
Divalent metal ion transport 2 2.7E-2 3.7E1 
Nucleotide-binding oligomerization domain 
containing 1 signaling pathway 2 2.7E-2 3.7E1 
Activation of MAPK activity involved in innate 
immune response 2 2.7E-2 3.7E1 
T cell proliferation 3 2.7E-2 3.7E1 
Defense response to protozoan 3 2.7E-2 3.7E1 
Muscle cell cellular homeostasis 3 2.7E-2 3.7E1 
Positive regulation of protein kinase B signaling 5 2.8E-2 3.8E1 
Calcium-independent cell-cell adhesion via 
plasma membrane cell-adhesion molecules 3 3.3E-2 4.3E1 
Positive regulation of NF-kappab import into 
nucleus 3 3.3E-2 4.3E1 
Angiogenesis 8 3.3E-2 4.3E1 
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Muscle organ development 5 3.3E-2 4.4E1 
Positive regulation of translation 4 3.6E-2 4.6E1 
Positive regulation of cell-matrix adhesion 3 3.6E-2 4.6E1 
Cellular response to cytokine stimulus 3 3.6E-2 4.6E1 
Negative regulation of peptidyl-serine 
phosphorylation 3 3.9E-2 4.9E1 
Response to bacterium 3 3.9E-2 4.9E1 
Negative regulation of toll-like receptor 3 
signaling pathway 2 4.0E-2 5.0E1 
Cytokine secretion involved in immune response 2 4.0E-2 5.0E1 
Positive regulation of mononuclear cell 
proliferation 2 4.0E-2 5.0E1 
Positive regulation of cellular extravasation 2 4.0E-2 5.0E1 
T cell antigen processing and presentation 2 4.0E-2 5.0E1 
Positive regulation of cell migration 7 4.1E-2 5.0E1 
Response to interferon-gamma 3 4.2E-2 5.1E1 
Cellular response to hydrogen peroxide 4 4.3E-2 5.2E1 
Cellular response to interferon-gamma 4 4.3E-2 5.2E1 
Response to tumor necrosis factor 3 4.5E-2 5.4E1 
Positive regulation of interleukin-12 production 3 4.5E-2 5.4E1 
Positive regulation of interleukin-8 production 3 4.9E-2 5.7E1 
Positive regulation of smooth muscle cell 
proliferation 4 4.9E-2 5.7E1 
Transcription from RNA polymerase II promoter 13 4.9E-2 5.7E1 
Positive regulation of transcription, DNA-
templated 13 5.0E-2 5.8E1 
 
Cellular Component – Up Regulated Genes: 
Go term 
Size P-value FDR 
Plasma membrane 37 1.7E-2 1.8E1 
Integral component of membrane 44 1.9E-2 2.0E1 
Cell junction 8 2.5E-2 2.6E1 
 
 
 
Cellular Component – Down Regulated Genes: 
Go term 
Size P-value FDR 
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Extracellular space 44 3.0E-8 3.7E-5 
Integral component of plasma membrane 42 8.6E-7 1.1E-3 
Cell surface 22 8.3E-6 1.0E-2 
Plasma membrane 83 1.3E-5 1.7E-2 
External side of plasma membrane 11 4.8E-4 6.0E-1 
I-kappab/NF-kappab complex 3 1.6E-3 2.0E0 
Extracellular region 36 1.7E-3 2.1E0 
Perinuclear region of cytoplasm 18 3.1E-3 3.9E0 
Membrane raft 9 5.5E-3 6.8E0 
Alpha9-beta1 integrin-vascular cell adhesion 
molecule-1 complex 2 2.6E-2 2.8E1 
Mitochondrial outer membrane 6 4.5E-2 4.4E1 
 
Molecular Function – Up Regulated Genes: 
Go term 
Size P-value FDR 
Transmembrane receptor protein tyrosine 
phosphatase activity 3 4.8E-3 6.0E0 
Carbohydrate binding 5 3.3E-2 3.5E1 
Amino acid transmembrane transporter activity 3 3.4E-2 3.6E1 
Microtubule binding 5 4.0E-2 4.0E1 
Insulin-like growth factor II binding 2 4.8E-2 4.7E1 
 
Molecular Function – Down Regulated Genes: 
Go term 
Size P-value FDR 
Chemokine activity 12 4.4E-11 6.1E-8 
Cytokine activity 15 1.3E-7 1.9E-4 
CXCR chemokine receptor binding 5 4.0E-6 5.6E-3 
Growth factor activity 12 1.4E-5 1.9E-2 
Receptor binding 15 3.6E-4 5.0E-1 
Receptor activity 10 3.0E-3 4.1E0 
Protein self-association 5 3.5E-3 4.7E0 
CCR chemokine receptor binding 4 3.6E-3 4.9E0 
Transcription factor activity, RNA polymerase II 
core promoter proximal region sequence-specific 
binding 
4 3.6E-3 4.9E0 
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Heparin binding 8 6.4E-3 8.5E0 
Tumor necrosis factor receptor binding 4 7.0E-3 9.3E0 
Identical protein binding 19 1.4E-2 1.8E1 
Integrin binding 6 1.4E-2 1.8E1 
Tumor necrosis factor-activated receptor activity 3 4.2E-2 4.5E1 
 
Functions analysis enrichment result at 6 hours incubation of IT4var37 with 
HBMEC/TNF. 
Enriched functions of up and down regulated genes are listed in the table and separated into 
3 GO term categories (biological process, molecular function and cellular component). Size, 
number of expressed genes associated with the term. FDR, False discovery rate.  
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Appendix 11: 
 
Biological Process – Up Regulated Genes: 
Go term 
Size P-value FDR 
Cholesterol biosynthetic process 6 1.2E-3 1.9E0 
Positive regulation of insulin-like growth factor 
receptor signaling pathway 4 2.3E-3 3.8E0 
Regulation of cell growth 7 7.0E-3 1.1E1 
Drug transmembrane transport 4 7.1E-3 1.1E1 
Regulation of insulin-like growth factor receptor 
signaling pathway 3 8.8E-3 1.4E1 
Regulation of glucose metabolic process 4 1.1E-2 1.7E1 
Phospholipid translocation 4 1.1E-2 1.7E1 
Response to estradiol 7 1.3E-2 1.9E1 
Cellular protein metabolic process 8 1.3E-2 1.9E1 
Type B pancreatic cell proliferation 3 1.5E-2 2.2E1 
Oxidation-reduction process 22 1.5E-2 2.3E1 
Transmembrane transport 12 1.5E-2 2.3E1 
G-protein coupled receptor signaling pathway, 
coupled to cyclic nucleotide second messenger 5 1.6E-2 2.4E1 
Negative regulation of smooth muscle cell 
proliferation 4 2.3E-2 3.2E1 
Positive regulation of MAPK cascade 6 2.9E-2 3.9E1 
Negative regulation of camp biosynthetic process 3 3.0E-2 4.0E1 
Isoprenoid biosynthetic process 3 3.4E-2 4.4E1 
Smooth muscle hyperplasia 2 4.2E-2 5.1E1 
Angiogenesis 10 4.9E-2 5.7E1 
Regulation of blood pressure 5 4.9E-2 5.7E1 
Intracellular signal transduction 15 4.9E-2 5.7E1 
Response to fatty acid 3 4.9E-2 5.7E1 
Monocyte differentiation 3 4.9E-2 5.7E1 
 
 
Biological Process – Down Regulated Genes: 
Go term 
Size P-value FDR 
Inflammatory response 57 7.8E-18 1.4E-14 
Defense response to virus 31 2.1E-12 3.8E-9 
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DNA replication 28 7.6E-11 1.4E-7 
Type I interferon signaling pathway 18 2.8E-10 5.0E-7 
Interferon-gamma-mediated signaling pathway 18 1.6E-9 2.9E-6 
Immune response 44 1.2E-8 2.2E-5 
Negative regulation of viral genome replication 13 2.7E-8 4.8E-5 
Negative regulation of type I interferon 
production 11 1.3E-7 2.3E-4 
Cell chemotaxis 15 1.9E-7 3.4E-4 
Apoptotic process 50 2.4E-7 4.3E-4 
Positive regulation of NF-kappab transcription 
factor activity 21 2.7E-7 4.9E-4 
Response to virus 19 2.9E-7 5.3E-4 
Chemotaxis 20 3.1E-7 5.5E-4 
Chemokine-mediated signaling pathway 15 5.9E-7 1.1E-3 
Positive regulation of neutrophil chemotaxis 9 1.1E-6 2.0E-3 
Response to lipopolysaccharide 22 2.1E-6 3.7E-3 
Cellular response to lipopolysaccharide 18 2.1E-6 3.8E-3 
DNA replication initiation 10 2.8E-6 5.0E-3 
Positive regulation of inflammatory response 14 5.0E-6 8.9E-3 
Positive regulation of interleukin-6 production 11 7.9E-6 1.4E-2 
Innate immune response 38 8.1E-6 1.5E-2 
G1/S transition of mitotic cell cycle 16 1.1E-5 2.0E-2 
Positive regulation of I-kappab kinase/NF-kappab 
signaling 20 2.1E-5 3.7E-2 
Lipopolysaccharide-mediated signaling pathway 9 2.6E-5 4.7E-2 
Defense response 12 5.8E-5 1.0E-1 
Positive regulation of interferon-beta production 8 6.5E-5 1.2E-1 
Cellular response to interferon-gamma 11 7.0E-5 1.3E-1 
Positive regulation of tumor necrosis factor 
production 10 7.9E-5 1.4E-1 
I-kappab kinase/NF-kappab signaling 11 1.1E-4 2.0E-1 
Positive regulation of gene expression 25 1.2E-4 2.2E-1 
Signal transduction 72 1.6E-4 2.8E-1 
Regulation of inflammatory response 11 1.7E-4 3.0E-1 
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Positive regulation of ERK1 and ERK2 cascade 19 2.0E-4 3.6E-1 
Regulation of transcription involved in G1/S 
transition of mitotic cell cycle 7 2.1E-4 3.8E-1 
Regulation of cell proliferation 19 4.0E-4 7.2E-1 
Cellular response to interleukin-1 11 4.6E-4 8.2E-1 
Cellular response to organic cyclic compound 10 4.8E-4 8.6E-1 
Positive regulation of leukocyte chemotaxis 6 5.3E-4 9.5E-1 
Toll-like receptor signaling pathway 7 5.4E-4 9.7E-1 
TRIF-dependent toll-like receptor signaling 
pathway 7 6.7E-4 1.2E0 
Negative regulation of bone resorption 5 9.3E-4 1.7E0 
Negative regulation of cell proliferation 30 1.1E-3 2.0E0 
Toll-like receptor 2 signaling pathway 4 1.1E-3 2.0E0 
Positive regulation of NF-kappab import into 
nucleus 6 1.1E-3 2.0E0 
Positive regulation of fibroblast proliferation 9 1.2E-3 2.1E0 
Cell-cell signaling 22 1.2E-3 2.1E0 
Positive regulation of transcription from RNA 
polymerase II promoter 59 1.4E-3 2.5E0 
Angiogenesis 20 1.4E-3 2.5E0 
DNA duplex unwinding 8 1.6E-3 2.8E0 
Negative regulation of NF-kappab transcription 
factor activity 10 1.9E-3 3.3E0 
Positive regulation of DNA-directed DNA 
polymerase activity 4 1.9E-3 3.4E0 
Response to type I interferon 4 1.9E-3 3.4E0 
DNA synthesis involved in DNA repair 7 2.3E-3 4.0E0 
Negative regulation of apoptotic process 32 2.4E-3 4.2E0 
Positive regulation of T cell proliferation 9 2.4E-3 4.2E0 
Positive regulation of smooth muscle cell 
proliferation 9 2.4E-3 4.2E0 
Tumor necrosis factor-mediated signaling 
pathway 13 2.5E-3 4.3E0 
Nucleotide-binding oligomerization domain 
containing signaling pathway 6 2.6E-3 4.6E0 
Leukocyte cell-cell adhesion 6 2.6E-3 4.6E0 
Cell proliferation 27 3.0E-3 5.2E0 
DNA replication checkpoint 4 3.0E-3 5.2E0 
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Positive regulation of interleukin-8 production 6 3.1E-3 5.5E0 
Positive regulation of type I interferon production 8 3.7E-3 6.5E0 
Somitogenesis 7 4.0E-3 6.9E0 
Cellular response to tumor necrosis factor 12 4.2E-3 7.2E0 
Viral entry into host cell 10 4.2E-3 7.4E0 
Response to molecule of bacterial origin 4 4.3E-3 7.5E0 
Hyperosmotic response 4 4.3E-3 7.5E0 
Negative regulation of protein ubiquitination 7 5.2E-3 8.9E0 
Monocyte chemotaxis 7 5.8E-3 1.0E1 
Positive regulation of DNA replication 7 5.8E-3 1.0E1 
DNA damage checkpoint 6 6.0E-3 1.0E1 
Fibroblast migration 4 6.0E-3 1.0E1 
Positive regulation of chemokine biosynthetic 
process 4 6.0E-3 1.0E1 
Positive regulation of T cell migration 4 6.0E-3 1.0E1 
Positive regulation of cell migration 16 6.5E-3 1.1E1 
Single organismal cell-cell adhesion 11 6.6E-3 1.1E1 
Humoral immune response 8 7.0E-3 1.2E1 
JAK-STAT cascade 6 7.9E-3 1.3E1 
Leukocyte migration involved in inflammatory 
response 4 8.0E-3 1.3E1 
Response to muramyl dipeptide 4 8.0E-3 1.3E1 
Positive regulation of macrophage chemotaxis 4 8.0E-3 1.3E1 
Immunoglobulin mediated immune response 4 8.0E-3 1.3E1 
Positive regulation of apoptotic process 22 8.4E-3 1.4E1 
Regulation of cell migration 9 8.7E-3 1.4E1 
Positive regulation of cytokine secretion involved 
in immune response 3 8.9E-3 1.5E1 
Negative regulation of macrophage apoptotic 
process 3 8.9E-3 1.5E1 
Positive regulation of hyaluronan biosynthetic 
process 3 8.9E-3 1.5E1 
Response to interleukin-1 6 9.0E-3 1.5E1 
Myd88-dependent toll-like receptor signaling 
pathway 6 9.0E-3 1.5E1 
Positive regulation of defense response to virus by 5 1.0E-2 1.7E1 
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host 
Positive regulation of interleukin-1 beta secretion 5 1.0E-2 1.7E1 
Response to exogenous dsrna 6 1.0E-2 1.7E1 
Positive regulation of interferon-alpha production 4 1.0E-2 1.7E1 
Cell morphogenesis 8 1.1E-2 1.8E1 
Cellular senescence 5 1.2E-2 1.9E1 
Cell division 24 1.2E-2 2.0E1 
DNA damage response, detection of DNA damage 6 1.3E-2 2.1E1 
Translesion synthesis 6 1.3E-2 2.1E1 
Myd88-independent toll-like receptor signaling 
pathway 4 1.3E-2 2.1E1 
Regulation of cytokine production 4 1.3E-2 2.1E1 
Positive regulation of nitric-oxide synthase 
biosynthetic process 4 1.3E-2 2.1E1 
Positive regulation of interleukin-17 production 4 1.3E-2 2.1E1 
Regulation of type I interferon production 4 1.3E-2 2.1E1 
Regulation of innate immune response 4 1.3E-2 2.1E1 
Response to interferon-gamma 5 1.4E-2 2.2E1 
Nucleotide-excision repair, DNA gap filling 5 1.4E-2 2.2E1 
Aging 14 1.4E-2 2.2E1 
Detection of virus 3 1.4E-2 2.3E1 
Intracellular transport of viral protein in host cell 3 1.4E-2 2.3E1 
Nucleotide-binding oligomerization domain 
containing 2 signaling pathway 3 1.4E-2 2.3E1 
Cellular response to interleukin-3 3 1.4E-2 2.3E1 
Negative regulation of extrinsic apoptotic 
signaling pathway in absence of ligand 6 1.5E-2 2.3E1 
NIK/NF-kappab signaling 8 1.5E-2 2.4E1 
Cell adhesion 29 1.6E-2 2.5E1 
Positive regulation of peptidyl-tyrosine 
phosphorylation 9 1.6E-2 2.5E1 
Positive regulation of interleukin-12 production 5 1.6E-2 2.5E1 
Response to tumor necrosis factor 5 1.6E-2 2.5E1 
Positive regulation of protein tyrosine kinase 
activity 5 1.8E-2 2.8E1 
Strand displacement 5 1.8E-2 2.8E1 
233 
Mitotic chromosome condensation 4 2.0E-2 3.0E1 
DNA strand elongation involved in DNA 
replication 4 2.0E-2 3.0E1 
Positive regulation of type 2 immune response 3 2.1E-2 3.2E1 
Positive regulation of dendritic cell differentiation 3 2.1E-2 3.2E1 
Regulation of apoptotic process 16 2.2E-2 3.3E1 
Lymphocyte chemotaxis 5 2.3E-2 3.5E1 
Response to muscle stretch 4 2.3E-2 3.5E1 
Positive regulation of monocyte chemotaxis 4 2.3E-2 3.5E1 
Positive regulation of chemokine production 4 2.8E-2 4.0E1 
Positive regulation of cytokine-mediated signaling 
pathway 3 2.9E-2 4.1E1 
Positive regulation of macrophage cytokine 
production 3 2.9E-2 4.1E1 
Positive regulation of viral entry into host cell 3 2.9E-2 4.1E1 
Antigen processing and presentation of 
endogenous peptide antigen via MHC class I 3 2.9E-2 4.1E1 
Viral process 20 2.9E-2 4.1E1 
Regulation of tumor necrosis factor-mediated 
signaling pathway 5 2.9E-2 4.1E1 
Necroptotic process 4 3.2E-2 4.4E1 
Toll-like receptor 4 signaling pathway 4 3.2E-2 4.4E1 
Positive regulation of interferon-gamma 
production 6 3.4E-2 4.7E1 
Cytokine-mediated signaling pathway 11 3.5E-2 4.7E1 
Positive regulation of transcription, DNA-
templated 30 3.6E-2 4.8E1 
Defense response to protozoan 4 3.7E-2 4.9E1 
Error-free translesion synthesis 4 3.7E-2 4.9E1 
Myeloid dendritic cell differentiation 4 3.7E-2 4.9E1 
Cellular response to zinc ion 4 3.7E-2 4.9E1 
Error-prone translesion synthesis 4 3.7E-2 4.9E1 
T cell proliferation 4 3.7E-2 4.9E1 
Negative regulation of platelet activation 3 3.7E-2 4.9E1 
Toll-like receptor 3 signaling pathway 3 3.7E-2 4.9E1 
Neutrophil activation 3 3.7E-2 4.9E1 
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Positive regulation of protein ubiquitination 7 4.0E-2 5.2E1 
Protein complex assembly 10 4.0E-2 5.2E1 
Cell migration 13 4.1E-2 5.3E1 
Positive regulation of MAPK cascade 8 4.1E-2 5.3E1 
Positive regulation of smooth muscle cell 
migration 4 4.3E-2 5.4E1 
Positive regulation of JNK cascade 7 4.3E-2 5.5E1 
Protein stabilization 11 4.4E-2 5.5E1 
Double-strand break repair 7 4.6E-2 5.7E1 
Neutrophil chemotaxis 7 4.6E-2 5.7E1 
Negative regulation of activated T cell 
proliferation 3 4.7E-2 5.8E1 
Positive regulation of type I interferon-mediated 
signaling pathway 3 4.7E-2 5.8E1 
Response to interferon-beta 3 4.7E-2 5.8E1 
Positive regulation of T cell apoptotic process 3 4.7E-2 5.8E1 
Cellular response to lipoteichoic acid 3 4.7E-2 5.8E1 
Regulation of autophagy 6 4.7E-2 5.8E1 
Stress-activated MAPK cascade 4 4.8E-2 5.9E1 
Protein heterooligomerization 7 4.9E-2 5.9E1 
Cell cycle 15 5.0E-2 6.0E1 
 
Cellular Component – Up Regulated Genes: 
Go term 
Size P-value FDR 
Plasma membrane 109 6.8E-3 8.6E0 
Vacuolar membrane 3 3.4E-2 3.7E1 
Golgi membrane 20 4.8E-2 4.7E1 
 
Cellular Component – Down Regulated Genes: 
Go term 
Size P-value FDR 
Cytoplasm 267 8.2E-8 1.2E-4 
Membrane 127 3.4E-6 4.9E-3 
MCM complex 6 9.5E-6 1.4E-2 
Nucleoplasm 151 1.0E-5 1.4E-2 
Cytosol 169 8.2E-5 1.2E-1 
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Extracellular space 79 2.2E-4 3.2E-1 
Nucleus 252 3.8E-4 5.4E-1 
Perinuclear region of cytoplasm 41 1.2E-3 1.7E0 
Early endosome 20 1.5E-3 2.2E0 
Cell surface 36 2.3E-3 3.2E0 
Ctf18 RFC-like complex 4 2.8E-3 3.9E0 
Replication fork 5 3.6E-3 4.9E0 
Intracellular membrane-bounded organelle 36 3.6E-3 5.0E0 
TAP complex 3 4.4E-3 6.1E0 
 
Molecular Function – Up Regulated Genes: 
Go term 
Size P-value FDR 
Insulin-like growth factor I binding 5 8.1E-5 1.2E-1 
Insulin-like growth factor II binding 4 4.7E-4 6.9E-1 
Symporter activity 6 4.2E-3 6.0E0 
Transmembrane transporter activity 5 1.9E-2 2.5E1 
Enzyme inhibitor activity 4 2.4E-2 3.0E1 
Collagen binding 5 3.7E-2 4.2E1 
 
Molecular Function – Down Regulated Genes: 
Go term 
Size P-value FDR 
Protein binding 436 5.3E-11 8.1E-8 
Chemokine activity 13 3.8E-7 5.8E-4 
Cytokine activity 20 8.7E-5 1.3E-1 
Double-stranded RNA binding 11 1.4E-4 2.2E-1 
TAP1 binding 4 2.5E-4 3.8E-1 
2'-5'-oligoadenylate synthetase activity 4 2.5E-4 3.8E-1 
CXCR chemokine receptor binding 5 2.8E-4 4.2E-1 
Cytokine receptor activity 8 4.9E-4 7.5E-1 
Identical protein binding 50 5.6E-4 8.6E-1 
DNA replication origin binding 5 6.8E-4 1.0E0 
Growth factor activity 17 8.3E-4 1.3E0 
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DNA clamp loader activity 4 3.1E-3 4.7E0 
TAP2 binding 3 4.7E-3 7.0E0 
Peptide antigen-transporting atpase activity 3 4.7E-3 7.0E0 
Tumor necrosis factor receptor binding 6 5.5E-3 8.1E0 
Single-stranded DNA-dependent atpase activity 4 6.3E-3 9.2E0 
Signal transducer activity 17 8.3E-3 1.2E1 
Protein self-association 7 9.8E-3 1.4E1 
Ubiquitin protein ligase binding 21 1.2E-2 1.7E1 
Transcription factor activity, RNA polymerase II 
core promoter proximal region sequence-specific 
binding 
5 1.2E-2 1.7E1 
DNA helicase activity 5 1.4E-2 2.0E1 
C3HC4-type RING finger domain binding 3 2.2E-2 2.9E1 
Virus receptor activity 8 2.2E-2 2.9E1 
4 iron, 4 sulfur cluster binding 6 2.6E-2 3.3E1 
Single-stranded RNA binding 6 2.8E-2 3.5E1 
Receptor activity 16 2.9E-2 3.7E1 
Zinc ion binding 61 3.0E-2 3.7E1 
ATP-dependent DNA helicase activity 5 3.8E-2 4.5E1 
SUMO binding 3 3.8E-2 4.5E1 
K63-linked polyubiquitin binding 4 3.9E-2 4.5E1 
Actin filament binding 11 4.0E-2 4.7E1 
Ligase activity 18 4.5E-2 5.1E1 
Enzyme binding 21 4.8E-2 5.3E1 
 
Functions analysis enrichment result at 20 hours incubation of IT4var37 with 
HBMEC/TNF. 
Enriched functions of up and down regulated genes are listed in the table and separated into 
3 GO term categories (biological process, molecular function and cellular component). Size, 
number of expressed genes associated with the term. FDR, False discovery rate.  
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Appendix12: 
 
Screening for mycoplasma infection in IT4var14 parasite and HDMEC. 
Lane M, Promega pGEM® DNA Markers (Cat.# G1741); lane 1, IT4var14 parasite; lane 2, 
HDMEC; lane 3, HDMEC growth media; lane 4, Parasite growth media; lane 5, -ve control; 
lane 6, +ve control. 
 
M         1         2         3         4         5         6
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Appendix13: 
Ensemble Gene ID Gene Name Description Coordinates 
FPKM 
PRBC 0h 
FPKM 
PRBC 2h 
Log2 Fold 
Change P-value FDR 
ENSG00000138061 CYP1B1 cytochrome P450 family 1 subfamily B member 1 chr2:37923186-38239590 0.0559435 4.70835 6.39511 0.00035 0.0450679 
ENSG00000182568 SATB1 SATB homeobox chr3:17157161-18920401 0.190542 6.24003 5.03337 5e-05 0.01043 
ENSG00000171246 NPTX1 neuronal pentraxin 1 chr17:80467147-80477843 0.645323 20.8499 5.01388 5e-05 0.01043 
ENSG00000137834 SMAD6 SMAD family member 6 chr15:66702227-66782848 1.75016 56.0449 5.00102 5e-05 0.01043 
ENSG00000140465 CYP1A1 cytochrome P450 family 1 subfamily A member 1 chr15:74719541-74725610 6.51256 206.834 4.98911 5e-05 0.01043 
ENSG00000171604 CXXC5 CXXC finger protein 5 chr5:139647298-139683882 3.15975 55.2379 4.12778 5e-05 0.01043 
ENSG00000063438 AHRR aryl-hydrocarbon receptor repressor chr5:271620-438291 0.411271 4.77446 3.53718 5e-05 0.01043 
ENSG00000107731 UNC5B unc-5 netrin receptor B chr10:71212569-71302864 1.68203 18.9589 3.49461 5e-05 0.01043 
ENSG00000118200 CAMSAP2 
calmodulin regulated 
spectrin associated protein 
family member 2 
chr1:200739557-200860704 2.56607 28.216 3.45888 0.0001 0.0182982 
ENSG00000165795 NDRG2 NDRG family member 2 chr14:21016762-21104722 0.609393 5.81043 3.2532 5e-05 0.01043 
ENSG00000185480 PARPBP PARP1 binding protein chr12:102120184-102480645 7.47861 0.471243 -3.98823 5e-05 0.01043 
ENSG00000135365 PHF21A PHD finger protein 21A chr11:45929322-46121178 24.5969 2.40407 -3.35493 5e-05 0.01043 
ENSG00000265972 TXNIP thioredoxin interacting protein chr1:145992434-145996600 70.4704 7.51412 -3.22934 5e-05 0.01043 
ENSG00000131089 ARHGEF9 Cdc42 guanine nucleotide exchange factor 9p chrX:63634966-63809274 12.0347 1.33333 -3.17409 0.0004 0.0485116 
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ENSG00000232810 TNF tumor necrosis factor chr6:31575566-31578336 25.7731 3.72734 -2.78965 0.0002 0.0311343 
ENSG00000148926 ADM adrenomedullin chr11:10304679-10307397 285.044 44.673 -2.67371 5e-05 0.01043 
ENSG00000165507 C10orf10 chromosome 10 open reading frame 10 chr10:44811023-44995891 108.482 18.8563 -2.52434 5e-05 0.01043 
ENSG00000164400 CSF2 colony stimulating factor 2 chr5:132073789-132076170 133.908 24.209 -2.46762 5e-05 0.01043 
ENSG00000185499 MUC1 mucin 1, cell surface associated chr1:155169407-155192916 6.13405 1.29673 -2.24196 0.0001 0.0182982 
ENSG00000188536 HBA2 hemoglobin subunit alpha 2 chr16:172846-173710 465.773 119.592 -1.9615 5e-05 0.01043 
 
A full description of top ten up and down regulated genes in HDMEC/TNF interacted with IT4var14 parasite at 2 hours. 
The table presents the ensemble gene ID of the top ten up and down regulated genes, gene name, location of the gene in the genome, Fragments Per Kilobase 
of exon per Million fragments mapped (FPKM) at 0 and 2 hours, log2 fold change, P-value and FDR value of each gene involve in this study. PRBC indicates 
the P. falciparum infected erythrocyte. 
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Appendix14: 
Ensemble Gene ID Gene Name Description Coordinates 
FPKM 
PRBC 0h 
FPKM 
PRBC 6h 
Log2 Fold 
Change P-value FDR 
ENSG00000135678 CPM carboxypeptidase M chr12:68808171-68971570 0.0537127 5.77092 6.74739 5e-05 0.011 
ENSG00000140465 CYP1A1 cytochrome P450 family 1 subfamily A member 1 chr15:74719541-74725610 6.69851 412.925 5.94589 5e-05 0.011 
ENSG00000171246 NPTX1 neuronal pentraxin 1 chr17:80467147-80477843 0.664586 24.5275 5.2058 5e-05 0.011 
ENSG00000082014 SMARCD3 
SWI/SNF related, matrix 
associated, actin 
dependent regulator of 
chromatin, subfamily d, 
member 3 
chr7:151232488-151277896 0.232953 4.98085 4.41828 5e-05 0.011 
ENSG00000079102 RUNX1T1 RUNX1 translocation partner 1 chr8:91954966-92103286 0.449452 5.45003 3.60003 5e-05 0.011 
ENSG00000115257 PCSK4 proprotein convertase subtilisin/kexin type 4 chr19:1481427-1497927 1.47031 10.1969 2.79393 0.00035 0.0463974 
ENSG00000128513 POT1 protection of telomeres 1 chr7:124822385-125379321 4.04539 17.6908 2.12864 5e-05 0.011 
ENSG00000087903 RFX2 regulatory factor X2 chr19:5978402-6199572 1.89238 7.75019 2.03403 5e-05 0.011 
ENSG00000025434 NR1H3 
nuclear receptor 
subfamily 1 group H 
member 3 
chr11:47239301-47269032 4.47314 15.1365 1.75868 0.0003 0.04136 
ENSG00000179403 VWA1 von Willebrand factor A domain containing 1 chr1:1434860-1442882 26.1843 84.5726 1.69149 0.0001 0.0181404 
ENSG00000116151 MORN1 MORN repeat containing 1 chr1:2321252-2391707 10.4087 0.773552 -3.75014 0.0003 0.04136 
ENSG00000251247 ZNF345 zinc finger protein 345 chr19:36797517-36916291 5.86974 0.494505 -3.56924 5e-05 0.011 
ENSG00000116106 EPHA4 EPH receptor A4 chr2:221418026-221574454 6.88857 0.698906 -3.30103 5e-05 0.011 
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ENSG00000164400 CSF2 colony stimulating factor 2 chr5:132073789-132076170 138.834 14.6357 -3.2458 5e-05 0.011 
ENSG00000105699 LSR lipolysis stimulated lipoprotein receptor chr19:35248329-35267964 6.28833 0.730187 -3.10634 0.0002 0.0318154 
ENSG00000163121 NEURL3 neuralized E3 ubiquitin protein ligase 3 chr2:96497642-96508109 44.5928 6.63587 -2.74845 5e-05 0.011 
ENSG00000122970 IFT81 intraflagellar transport 81 chr12:110124334-110218797 14.913 2.37758 -2.64901 0.0002 0.0318154 
ENSG00000127533 F2RL3 F2R like thrombin/trypsin receptor 3 chr19:16888859-16892606 8.84846 1.414 -2.64565 0.00035 0.0463974 
ENSG00000066651 TRMT11 tRNA methyltransferase 11 homolog chr6:125986429-126039276 14.0548 2.24743 -2.64471 0.0002 0.0318154 
ENSG00000186827 TNFRSF4 TNF receptor superfamily member 4 chr1:1211325-1214138 256.968 46.2719 -2.47338 5e-05 0.011 
 
A full description of top ten up and down regulated genes in HDMEC/TNF interacted with IT4var14 parasite at 6 hours. 
The table presents the ensemble gene ID of the top ten up and down regulated genes, gene name, location of the gene in the genome, Fragments Per Kilobase 
of exon per Million fragments mapped (FPKM) at 0 and 6 hours, log2 fold change, P-value and FDR value of each gene involve in this study. PRBC indicates 
the P. falciparum infected erythrocyte. 
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Appendix15: 
Ensemble Gene ID Gene Name Description Coordinates 
FPKM 
PRBC 0h 
FPKM 
PRBC 20h 
Log2 Fold 
Change P-value FDR 
ENSG00000140465 CYP1A1 cytochrome P450 family 1 subfamily A member 1 chr15:74719541-74725610 3.76103 46.2772 3.6211 5e-05 0.00818138 
ENSG00000171864 PRND prion protein 2 chr20:4721909-4728460 0.0571954 0.622117 3.44322 0.00015 0.0176118 
ENSG00000162777 DENND2D 
DENN domain containing 
2D chr1:111187173-111243440 0.0805743 0.595492 2.88569 0.0002 0.021817 
ENSG00000162692 VCAM1 vascular cell adhesion molecule 1 chr1:100719741-100739045 0.533853 3.25258 2.60707 5e-05 0.00818138 
ENSG00000115009 CCL20 C-C motif chemokine ligand 20 chr2:227813841-227817564 0.234889 1.40141 2.57683 0.0004 0.0339912 
ENSG00000265972 TXNIP thioredoxin interacting protein chr1:145992434-145996600 11.1227 66.2085 2.57351 5e-05 0.00818138 
ENSG00000114812 VIPR1 vasoactive intestinal peptide receptor 1 chr3:42489298-42537573 0.0766432 0.450533 2.5554 5e-05 0.00818138 
ENSG00000006210 CX3CL1 C-X3-C motif chemokine ligand 1 chr16:57372457-57385048 0.206721 1.14051 2.46392 5e-05 0.00818138 
ENSG00000100767 PAPLN papilin, proteoglycan-like sulfated glycoprotein chr14:73237496-73274640 1.79858 9.7613 2.44021 5e-05 0.00818138 
ENSG00000272636 DOC2B double C2 domain beta chr17:142788-181636 0.173891 0.906035 2.38138 5e-05 0.00818138 
ENSG00000183691 NOG noggin chr17:56593698-56595590 5.49245 0.134192 -5.35508 5e-05 0.00818138 
ENSG00000115738 ID2 inhibitor of DNA binding 2 chr2:8666635-8684453 58.1397 4.92853 -3.56029 5e-05 0.00818138 
ENSG00000188536 HBA2 hemoglobin subunit alpha 2 chr16:172846-173710 29.3289 4.74045 -2.62923 5e-05 0.00818138 
ENSG00000198673 FAM19A2 
family with sequence 
similarity 19 (chemokine 
(C-C motif)-like), 
member A2 
chr12:61708258-62417431 0.576024 0.0976469 -2.56048 0.0006 0.0433268 
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ENSG00000244734 HBB hemoglobin subunit beta chr11:5225463-5229395 51.6099 9.63441 -2.42138 5e-05 0.00818138 
ENSG00000125968 ID1 inhibitor of DNA binding 1 chr20:31605282-31606515 534.501 107.681 -2.31143 5e-05 0.00818138 
ENSG00000135547 HEY2 
hes related family bHLH 
transcription factor with 
YRPW motif 2 
chr6:125578557-125761269 4.14179 0.864693 -2.25999 5e-05 0.00818138 
ENSG00000099860 GADD45B 
growth arrest and DNA 
damage inducible beta chr19:2476121-2478259 91.8943 20.5668 -2.15966 5e-05 0.00818138 
ENSG00000165899 OTOGL otogelin like chr12:80209452-80379090 0.63461 0.14639 -2.11605 0.00035 0.0311176 
ENSG00000168874 ATOH8 atonal bHLH transcription factor 8 chr2:85751343-85788066 29.1582 6.75063 -2.11081 5e-05 0.00818138 
 
A full description of top ten up and down regulated genes in HDMEC/TNF interacted with IT4var14 parasite at 20 hours. 
The table presents the ensemble gene ID of the top ten up and down regulated genes, gene name, location of the gene in the genome, Fragments Per Kilobase 
of exon per Million fragments mapped (FPKM) at 0 and 20 hours, log2 fold change, P-value and FDR value of each gene involve in this study. PRBC 
indicates the P. falciparum infected erythrocyte. 
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Appendix16: 
Biological Process – Up Regulated Genes: 
Go term 
Size P-value FDR 
Response to hydrogen peroxide 4 3.4E 4.8E-2 
Oxygen transport 3 1.5E-4 2.2E-1 
Positive regulation of apoptotic process  5 4.7E-4 6.6E-1 
Regulation of cell proliferation 4 1.5E-3 2.1E0 
Positive regulation of smooth muscle cell 
proliferation 3 2.5E-3 3.5E0 
Response to wounding 3 2.8E-3 3.8E0 
Positive regulation of gene expression 4 4.1E-3 5.6E0 
Positive regulation of transcription from RNA 
polymerase II promoter 6 6.3E-3 8.5E0 
Negative regulation of cell division  2 8.7E-3 1.2E1 
Cellular response to phorbol 13-acetate 12-
myristate  2 8.7E-3 1.2E1 
Positive regulation of podosome assembly  2 1.2E-2 1.6E1 
Negative regulation of cell proliferation 4 1.3E-2 1.6E1 
Negative regulation of glucose import  2 1.4E-2 1.8E1 
Response to lipopolysaccharide  3 1.8E-2 2.2E1 
Negative regulation of apoptotic process 4 1.8E-2 2.3E1 
Protein phosphorylation 4 1.8E-2 2.3E1 
Monocyte differentiation  2 2.1E-2 2.6E1 
Blood coagulation 3 2.2E-2 2.7E1 
Negative regulation of transcription, DNA-
templated 4 2.3E-2 2.8E1 
Hydrogen peroxide catabolic process  2 2.5E-2 3.0E1 
Transcription from RNA polymerase II promoter 4 2.5E-2 3.0E1 
Positive regulation of transcription, DNA-
templated  4 2.5E-2 3.0E1 
Positive regulation of gtpase activity  4 3.2E-2 3.7E1 
Apoptotic process  4 3.2E-2 3.7E1 
Positive regulation of cell death  2 3.6E-2 4.0E1 
Cellular response to fibroblast growth factor 
stimulus 2 3.7E-2 4.1E1 
Cellular response to epidermal growth factor 
stimulus 2 4.0E-2 4.4E1 
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MAPK cascade  3 4.2E-2 4.5E1 
Negative regulation of extrinsic apoptotic 
signaling pathway in absence of ligand  2 4.5E-2 4.8E1 
Positive regulation of cysteine-type endopeptidase 
activity involved in apoptotic process  2 4.9E-2 5.1E1 
Regulation of mitotic cell cycle 2 4.9E-2 5.1E1 
 
Biological Process – Down Regulated Genes: 
Go term 
Size P-value FDR 
Negative regulation of transcription from RNA 
polymerase II promoter  11 5.2E-6 7.6E-3 
Angiogenesis  6 1.8E-4 2.6E-1 
Transcription, DNA-templated  14 4.0E-4 5.9E-1 
Positive regulation of transcription, DNA-
templated  7 1.3E-3 1.9E0 
Transforming growth factor beta receptor 
signaling pathway  4 1.4E-3 2.0E0 
Negative regulation of Notch signaling pathway 
involved in somitogenesis  2 4.8E-3 6.8E0 
Negative regulation of transcription, DNA-
templated  6 6.3E-3 8.9E0 
Regulation of transcription, DNA-templated  10 7.7E-3 1.1E1 
Positive regulation of transcription from RNA 
polymerase II promoter  8 7.8E-3 1.1E1 
Negative regulation of sequence-specific DNA 
binding transcription factor activity  3 9.0E-3 1.2E1 
Positive regulation of smooth muscle cell 
proliferation  3 9.0E-3 1.2E1 
Enucleate erythrocyte differentiation  2 1.2E-2 1.6E1 
Negative regulation of cell proliferation  5 1.4E-2 1.9E1 
Tube formation  2 1.9E-2 2.4E1 
Omega-hydroxylase P450 pathway  2 2.1E-2 2.7E1 
Notch signaling involved in heart development  2 2.1E-2 2.7E1 
Pulmonary valve morphogenesis  2 2.4E-2 3.0E1 
Epithelial to mesenchymal transition involved in 
endocardial cushion formation  2 3.1E-2 3.7E1 
Positive regulation of apoptotic process  4 3.4E-2 4.0E1 
Blood vessel morphogenesis 2 4.0E-2 4.5E1 
Epoxygenase P450 pathway  2 4.2E-2 4.7E1 
Negative regulation of gene expression  3 4.2E-2 4.7E1 
Positive regulation of pri-mirna transcription from 
RNA polymerase II promoter 2 4.7E-2 5.0E1 
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Cellular Component – Up Regulated Genes: 
Go term 
Size P-value FDR 
Cytosol 12 1.1E-3 1.1E0 
Haptoglobin-hemoglobin complex 2 5.0E-3 4.8E0 
Extracellular region 7 1.3E-2 1.2E1 
Hemoglobin complex 2 1.5E-2 1.4E1 
Endocytic vesicle lumen 2 2.0E-2 1.8E1 
Cytoplasm 12 4.0E-2 3.3E1 
Cytosol 12 1.1E-3 1.1E0 
Haptoglobin-hemoglobin complex	 2 5.0E-3 4.8E0 
 
Cellular Component – Down Regulated Genes: 
Go term 
Size P-value FDR 
Cytoplasm 22 1.3E-3 1.4E0 
Nucleus 21 5.5E-3 5.8E0 
Organelle membrane 3 1.6E-2 1.6E1 
 
Molecular Function – Up Regulated Genes: 
Go term 
Size P-value FDR 
Protein binding 21 4.8E-4 5.1E-1 
RNA polymerase II core promoter proximal 
region sequence-specific DNA binding 5 1.2E-3 1.3E0 
Transcriptional activator activity, RNA 
polymerase II core promoter proximal region 
sequence-specific binding 
4 3.9E-3 4.0E0 
Haptoglobin binding 2 4.1E-3 4.2E0 
Oxygen transporter activity 2 1.9E-2 1.8E1 
Peroxidase activity 2 3.0E-2 2.7E1 
Protein complex binding 3 3.2E-2 2.9E1 
Transcription factor activity, sequence-specific 
DNA binding	 5 3.9E-2 3.4E1 
Protein binding 21 4.8E-4 5.1E-1 
 
Molecular Function – Up Regulated Genes: 
Go term 
Size P-value FDR 
Protein binding 32 1.5E-4 1.8E-1 
Protein dimerization activity 5 3.5E-4 4.1E-1 
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Transcription factor activity, sequence-specific 
DNA binding 9 1.1E-3 1.3E0 
RNA polymerase II regulatory region sequence-
specific DNA binding 5 1.2E-3 1.4E0 
Protein homodimerization activity 7 5.4E-3 6.2E0 
Identical protein binding 7 6.1E-3 6.9E0 
DNA binding 10 1.0E-2 1.2E1 
Transcription factor binding	 4 2.6E-2 2.6E1 
Sequence-specific DNA binding 5 2.8E-2 2.9E1 
Oxidoreductase activity, acting on paired donors, 
with incorporation or reduction of molecular 
oxygen, reduced flavin or flavoprotein as one 
donor, and incorporation of one atom of oxygen 
2 3.3E-2 3.3E1 
Heme binding 3 3.8E-2 3.6E1 
RNA polymerase II core promoter proximal 
region sequence-specific DNA binding 4 4.5E-2 4.2E1 
Activating transcription factor binding 2 4.8E-2 4.4E1 
 
Functions analysis enrichment result at 2 hours incubation of IT4var14 with 
HDMEC/TNF. 
Enriched functions of up and down regulated genes are listed in the table and separated into 
3 GO term categories (biological process, molecular function and cellular component). Size, 
number of expressed genes associated with the term. FDR, False discovery rate.  
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Appendix17: 
Biological Process – Up Regulated Genes: 
Go term	 Size	 P-value	 FDR	
Cellular lipid metabolic process	 2 3.1E-2 3.1E1 
 
Biological Process – Down Regulated Genes: 
Go term 
Size P-value FDR 
Signal transduction 15 1.2E-5 1.8E-2 
Inflammatory response 9 2.6E-5 3.8E-2 
Chemotaxis 6 4.4E-5 6.4E-2 
Immune response 9 5.5E-5 8.0E-2 
Chemokine-mediated signaling pathway 5 7.9E-5 1.1E-1 
Blood coagulation 5 2.9E-3 4.1E0 
Positive regulation of interferon-beta production 3 3.4E-3 4.8E0 
Positive regulation of protein kinase activity 3 1.0E-2 1.3E1 
Peptidyl-tyrosine phosphorylation 4 1.3E-2 1.7E1 
Negative regulation of ERK1 and ERK2 cascade 3 1.5E-2 1.9E1 
Response to lipopolysaccharide 4  1.6E-2 2.0E1 
Cell chemotaxis 3 1.9E-2 2.4E1 
Positive regulation of interleukin-12 biosynthetic 
process 2 1.9E-2 2.4E1 
Toll-like receptor 2 signaling pathway 2 1.9E-2 2.4E1 
Protein heterooligomerization 3 2.0E-2 2.5E1 
Positive regulation of inflammatory response 3 2.3E-2 2.9E1 
Response to molecule of bacterial origin 2 2.9E-2 3.4E1 
Cellular response to lipoteichoic acid 2 2.9E-2 3.4E1 
Cell proliferation 5 3.0E-2 3.5E1 
Oxygen transport 2 4.7E-2 5.0E1 
Positive regulation of macrophage derived foam cell 
differentiation 2 5.0E-2 5.2E1 
 
Cellular Component – Down Regulated Genes: 
Go term 
Size P-value FDR 
Plasma membrane 24 4.4E-4 5.1E-1 
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Cell surface 7 4.3E-3 4.9E0 
Membrane 14 7.6E-3 8.4E0 
Perinuclear region of cytoplasm 7 8.2E-3 9.1E0 
Haptoglobin-hemoglobin complex 2 1.1E-2 1.2E1 
Extracellular region 11 1.4E-2 1.5E1 
Integral component of plasma membrane 10 1.8E-2 1.9E1 
Hemoglobin complex 2 3.4E-2 3.3E1 
Extracellular space 9 3.6E-2 3.4E1 
Endocytic vesicle lumen 2 4.5E-2 4.1E1 
 
Molecular Function – Down Regulated Genes: 
Go term 
Size P-value FDR 
Chemokine activity 4 5.1E-4 6.1E-1 
Identical protein binding 9 2.5E-3 2.9E0 
Haptoglobin binding 2 9.6E-3 1.1E1 
Receptor binding 5 2.6E-2 2.7E1 
CXCR chemokine receptor binding 2 2.8E-2 2.9E1 
Oxygen transporter activity 2 4.4E-2 4.2E1 
 
Functions analysis enrichment result at 6 hours incubation of IT4var14 with 
HDMEC/TNF. 
Enriched functions of up and down regulated genes are listed in the table and separated into 
3 GO term categories (biological process, molecular function and cellular component). Size, 
number of expressed genes associated with the term. FDR, False discovery rate.  
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Appendix18: 
Biological Process – Up Regulated Genes: 
Go term 
Size P-value FDR 
Receptor internalization 3 6.7E-3 9.4E0 
Negative regulation of branching involved in 
ureteric bud morphogenesis 2 1.1E-2 1.5E1 
Steroid hormone mediated signaling pathway 3 1.2E-2 1.6E1 
Negative regulation of interferon-gamma-mediated 
signaling pathway 2 1.4E-2 1.9E1 
Positive regulation of endothelial cell proliferation 3 1.7E-2 2.2E1 
Negative regulation of cholesterol storage 2 1.7E-2 2.2E1 
Cellular response to insulin stimulus 3 2.0E-2 2.6E1 
Positive regulation of phagocytosis, engulfment 2 2.3E-2 2.9E1 
Response to lipid 2 2.3E-2 2.9E1 
Secondary heart field specification 2 2.3E-2 2.9E1 
Positive regulation of lipoprotein lipase activity 2 2.8E-2 3.4E1 
Negative regulation of macrophage derived foam 
cell differentiation 2 3.7E-2 4.2E1 
Negative regulation of substrate adhesion-dependent 
cell spreading 2 3.7E-2 4.2E1 
Cell adhesion 5 4.2E-2 4.7E1 
Apoptotic cell clearance 2 4.2E-2 4.7E1 
Lipoprotein transport 2 4.2E-2 4.7E1 
Cell surface receptor signaling pathway 4 4.3E-2 4.8E1 
Anterior/posterior axis specification 2 4.8E-2 5.1E1 
Monocyte differentiation 2 4.8E-2 5.1E1 
Response to iron ion 2 5.0E-2 5.3E1 
Response to vitamin A 2 5.0E-2 5.3E1 
 
Biological Process – Down Regulated Genes: 
Go term 
Size P-value FDR 
Inflammatory response 16 5.9E-9 9.2E-6 
Immune response 16 2.4E-8 3.7E-5 
Lipopolysaccharide-mediated signaling pathway 6 1.1E-6 1.8E-3 
Positive regulation of NF-kappab transcription 
factor activity 9 1.2E-6 1.8E-3 
251 
Chemokine-mediated signaling pathway 7 3.8E-6 5.9E-3 
Chemotaxis 8 7.7E-6 1.2E-2 
Response to molecule of bacterial origin 4 1.6E-5 2.5E-2 
Cell chemotaxis 6 4.0E-5 6.3E-2 
Protein heterooligomerization 6 4.7E-5 7.3E-2 
Response to lipopolysaccharide 8 5.2E-5 8.2E-2 
Positive regulation of inflammatory response 6 7.0E-5 1.1E-1 
Apoptotic process 13 1.2E-4 1.9E-1 
Positive regulation of I-kappab kinase/NF-kappab 
signaling 7 3.8E-4 5.9E-1 
I-kappab kinase/NF-kappab signaling 5 4.3E-4 6.7E-1 
Cellular response to lipopolysaccharide 6 5.5E-4 8.5E-1 
Regulation of tumor necrosis factor-mediated 
signaling pathway 4 7.2E-4 1.1E0 
Interferon-gamma-mediated signaling pathway 5 8.2E-4 1.3E0 
Positive regulation of gene expression 8 9.1E-4 1.4E0 
Negative regulation of viral genome replication 4 1.7E-3 2.6E0 
Positive regulation of macrophage chemotaxis 3 1.8E-3 2.8E0 
Oxygen transport 3 3.4E-3 5.2E0 
Cellular response to tumor necrosis factor 5 4.1E-3 6.2E0 
Positive regulation of chemokine production 3 4.4E-3 6.7E0 
Tumor necrosis factor-mediated signaling 
pathway 5 5.2E-3 7.9E0 
T cell proliferation 3 5.5E-3 8.3E0 
Hydrogen peroxide catabolic process 3 6.1E-3 9.1E0 
Regulation of inflammatory response 4 6.1E-3 9.2E0 
Positive regulation of neutrophil chemotaxis 3 7.4E-3 1.1E1 
Leukocyte cell-cell adhesion 3 9.5E-3 1.4E1 
Nucleotide-binding oligomerization domain 
containing signaling pathway 3 9.5E-3 1.4E1 
Positive regulation of interferon-beta production 3 1.1E-2 1.6E1 
Nucleotide-binding oligomerization domain 
containing 1 signaling pathway 2 1.2E-2 1.7E1 
Positive regulation of cell death 3 1.3E-2 1.8E1 
Myd88-dependent toll-like receptor signaling 
pathway 3 1.6E-2 2.2E1 
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Defense response to virus 5 1.6E-2 2.3E1 
Aging 5 1.6E-2 2.3E1 
Response to exogenous dsrna 3 1.7E-2 2.4E1 
Signal transduction 14 1.9E-2 2.6E1 
Cell adhesion 8 1.9E-2 2.6E1 
Positive regulation of ERK1 and ERK2 cascade 5 2.0E-2 2.7E1 
Negative regulation of extrinsic apoptotic 
signaling pathway in absence of ligand 3 2.0E-2 2.7E1 
Protein homooligomerization 5 2.1E-2 2.8E1 
Regulation of cell proliferation 5 2.4E-2 3.2E1 
Positive regulation of cell adhesion 3 2.7E-2 3.4E1 
Positive regulation of nitric oxide biosynthetic 
process 3 2.7E-2 3.4E1 
Response to virus 4 2.7E-2 3.5E1 
Bicarbonate transport 3 2.8E-2 3.6E1 
Extracellular matrix organization 5 2.9E-2 3.7E1 
Positive regulation of interleukin-6 production 3 2.9E-2 3.7E1 
Nucleotide-binding oligomerization domain 
containing 2 signaling pathway 2 2.9E-2 3.7E1 
JNK cascade 3 3.4E-2 4.2E1 
Toll-like receptor 2 signaling pathway 2 3.5E-2 4.3E1 
Positive regulation of interleukin-12 biosynthetic 
process 2 3.5E-2 4.3E1 
Response to hydrogen peroxide 3 3.6E-2 4.4E1 
Cellular response to interferon-gamma 3 4.5E-2 5.1E1 
Negative regulation of ERK1 and ERK2 cascade 3 4.6E-2 5.2E1 
Negative regulation of lipid storage 2 4.6E-2 5.2E1 
Neutrophil activation 2 4.6E-2 5.2E1 
Cellular response to organic cyclic compound 3 4.7E-2 5.3E1 
Positive regulation of T cell proliferation 3 4.9E-2 5.4E1 
 
Cellular Component – Up Regulated Genes: 
Go term 
Size P-value FDR 
Receptor complex 4 4.3E-3 4.6E0 
Perinuclear region of cytoplasm 7 5.0E-3 5.4E0 
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Nuclear chromatin 4 1.3E-2 1.4E1 
Dendritic spine 3 2.7E-2 2.6E1 
Cell junction 5 3.0E-2 2.9E1 
Apical plasma membrane 4 3.9E-2 3.5E1 
 
Cellular Component – Down Regulated Genes: 
Go term 
Size P-value FDR 
Extracellular space 21 4.2E-5 5.0E-2 
Haptoglobin-hemoglobin complex 3 1.8E-4 2.2E-1 
Cytosol 33 7.3E-4 8.7E-1 
Plasma membrane 38 9.7E-4 1.1E0 
Hemoglobin complex 3 1.9E-3 2.3E0 
Cell surface 10 3.2E-3 3.7E0 
Endocytic vesicle lumen 3 3.5E-3 4.0E0 
Extracellular region 18 7.1E-3 8.1E0 
Membrane 22 8.5E-3 9.7E0 
Perinuclear region of cytoplasm 9 2.2E-2 2.3E1 
Protein complex 7 2.7E-2 2.8E1 
Early endosome 5 3.9E-2 3.7E1 
Golgi apparatus 10 5.0E-2 4.6E1 
Cytoplasm 38 5.0E-2 4.6E1 
 
Molecular Function – Up Regulated Genes: 
Go term 
Size P-value FDR 
Chromatin binding 6 4.5E-3 5.3E0 
Lipoprotein particle binding 2 1.4E-2 1.5E1 
High-density lipoprotein particle binding 2 2.2E-2 2.4E1 
Low-density lipoprotein receptor activity 2 3.6E-2 3.5E1 
 
Molecular Function – Down Regulated Genes: 
Go term 
Size P-value FDR 
Chemokine activity 6 8.8E-6 1.1E-2 
Haptoglobin binding 3 9.8E-5 1.3E-1 
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Cytokine activity 7 5.3E-4 6.9E-1 
CXCR chemokine receptor binding 3 1.1E-3 1.5E0 
Identical protein binding 13 1.2E-3 1.5E0 
Oxygen transporter activity 3 2.8E-3 3.6E0 
Peroxidase activity 3 7.0E-3 8.7E0 
Protein binding 63 1.2E-2 1.4E1 
Tumor necrosis factor receptor binding 3 1.2E-2 1.4E1 
Oxygen binding 3 3.0E-2 3.2E1 
 
Functions analysis enrichment result at 20 hours incubation of IT4var14 with 
HDMEC/TNF. 
Enriched functions of up and down regulated genes are listed in the table and separated into 
3 GO term categories (biological process, molecular function and cellular component). Size, 
number of expressed genes associated with the term. FDR, False discovery rate. 
